Page last updated: 2024-12-05

terbutaline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Terbutaline: A selective beta-2 adrenergic agonist used as a bronchodilator and tocolytic. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

terbutaline : A member of the class of phenylethanolamines that is catechol substituted at position 5 by a 2-(tert-butylamino)-1-hydroxyethyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5403
CHEMBL ID1760
CHEBI ID9449
SCHEMBL ID4391
MeSH IDM0021177

Synonyms (117)

Synonym
BRD-A50157456-065-02-4
gtpl560
KBIO1_000078
DIVK1C_000078
5-{2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl}benzene-1,3-diol
5-[2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diol
bricyn
terbutalin
1,3-benzenediol, 5-(2-((1,1-dimethylethyl)amino)-1-hydroxyethyl)-
terbutaline [inn:ban]
bricaril
brican
5-(2-((1,1-dimethylethyl)amino)-1-hydroxyethyl)-1,3-benzenediol
brn 2370513
einecs 245-385-8
terbutalinum [inn-latin]
terbutalino [inn-spanish]
terbutalina [dcit]
bricar
benzyl alcohol, alpha-((t-butylamino)methyl)-3,5-dihydroxy-
brethine
SPECTRUM_001030
SPECTRUM5_001262
PRESTWICK3_000391
BSPBIO_002066
(+-)-5-(2-((1,1-dimethylethyl)amino)-1-hydroxyethyl)-1,3-benzenediol
(+-)-terbutaline
1,3-benzenediol, 5-(2-((1,1-dimethylethyl)amino)-1-hydroxyethyl)-, (+-)-
LOPAC0_001126
PDSP2_000157
OPREA1_823972
PRESTWICK2_000391
IDI1_000078
BSPBIO_000601
PDSP1_000158
BPBIO1_000663
5-[2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diol, 5
terbutaline,(+/-)
bdbm25770
AB00053548
23031-25-6
C07129
terbutaline
DB00871
KBIO3_001566
KBIO2_001510
KBIO2_006646
KBIOSS_001510
KBIO2_004078
KBIOGR_001539
PRESTWICK1_000391
SPBIO_002522
SPBIO_001453
NINDS_000078
PRESTWICK0_000391
SPECTRUM3_000593
SPECTRUM4_000870
SPECTRUM2_001327
NCGC00089821-02
NCGC00016010-06
L000594
asthmasian (tn)
terbutaline (inn)
D08570
chebi:9449 ,
CHEMBL1760
asthmasian
5-[2-(tert-butylamino)-1-oxidanyl-ethyl]benzene-1,3-diol
A816514
CCG-205201
NCGC00016010-03
NCGC00016010-04
terbutalinum
n8onu3l3pg ,
unii-n8onu3l3pg
terbutalina
terbutalino
AKOS015889885
5-[2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl]-1,3-benzenediol
terbutaline [inn]
terbutaline [who-dd]
terbutaline [mi]
5-[(1rs)-2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diol
bambuterol hydrochloride impurity a [epimpurity]
(rs)-5-(2-(tert-butylamino)-1-hydroxyethyl)benzene-1,3-diol
terbutaline [vandf]
1,3-benzenediol, 5-[2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl]-
SCHEMBL4391
1-(3',5'-dihydroxyphenyl)-2-(t-butylamino)-ethanol
bricanyl (salt/mix)
benzyl alcohol, .alpha.-((t-butylamino)methyl)-3,5-dihydroxy-
5-[2-(tert-butylamino)-1-hydroxyethyl]-1,3-benzenediol #
brethaire (salt/mix)
terbutaline sulfate (salt/mix)
5-(2-(tert-butylamino)-1-hydroxyethyl)benzene-1,3-diol
AB00053548_15
DTXSID7021310 ,
SR-01000000174-2
sr-01000000174
46719-29-3
J-014950
SBI-0051094.P004
FT-0674864
Q424340
23031-25-6 (free base)
1164563-86-3
BRD-A50157456-065-12-3
SDCCGSBI-0051094.P005
NCGC00016010-16
aerodur; brican; bricar
terbutaline 1000 microg/ml in acetonitrile
EN300-151467
CS-0013822
HY-B0802A
r03cc03
r03ac03
dtxcid001310

Research Excerpts

Overview

Terbutaline is a fast-acting beta(2)-adrenergic agonist used in the treatment of obstructive pulmonary diseases. It may mediate its effects via direct beta2-receptor stimulation, baroreceptor-mediated increases in sympathetic tone, or via presynaptic beta 2-stimulation.

ExcerptReferenceRelevance
"Terbutaline sulphate (TS) is a selective short-acting β"( The interaction of a β2 adrenoceptor agonist drug with biomimetic cell membrane models: The case of terbutaline sulphate.
Andrade, S; Loureiro, JA; Oliveira, N; Pereira, MC; Ramalho, MJ, 2021
)
2.28
"Terbutaline is a β-agonist that used as growth promoters to improved carcass chemical composition of chicks without residues. "( Effects of Terbutaline on Growth Performance, Carcass Quality, Some Biochemical Parameters and its Residues in Broiler Chicken.
El-Shenawy, AM; Fadl, SE; Nassef, E; Sakr, OA; Salem, NE; Zaki, RH, 2019
)
2.35
"Terbutaline is a β"( Enantioselective resolution of Rac-terbutaline and evaluation of optically pure R-terbutaline hydrochloride as an efficient anti-asthmatic drug.
Beng, H; Jayachandra, R; Li, J; Tan, W; Wu, J; Zhang, H, 2018
)
2.2
"Terbutaline is a prohibited drug except for athletes with a therapeutic use exemption certificate; terbutaline's effects on endurance performance are relatively unknown. "( The Effects of Inhaled Terbutaline on 3-km Running Time-Trial Performance.
Chester, NJ; Dickinson, JW; Loosemore, M; Molphy, J; Whyte, G, 2019
)
2.27
"Terbutaline is a β-2 agonist available in oral dosage form."( Oral terbutaline in replacement for intravenous dopamine in a patient with end-stage heart failure.
Cheng, JW; Miles, A; Shulan, A, 2013
)
1.63
"Terbutaline is a fast-acting beta(2)-adrenergic agonist used in the treatment of obstructive pulmonary diseases. "( Terbutaline sulfoconjugate: characterization and urinary excretion monitored by LC/ESI-MS/MS.
Guddat, S; Gütschow, M; Kohler, M; Orlovius, AK; Parr, MK; Schänzer, W; Thevis, M, 2009
)
3.24
"Terbutaline is a beta2-adrenergic agonist that may mediate its effects via direct beta2-receptor stimulation, baroreceptor-mediated increases in sympathetic tone, or via presynaptic beta2-stimulation."( Terbutaline for chronotropic support in heart transplantation.
Coons, JC; Kormos, R; Schonder, K; Shullo, M, 2004
)
2.49
"Terbutaline is a beta-adrenergic receptor antagonist that acts as a bronchodilator in the treatment of asthma and chronic bronchitis. "( Simple determination of terbutaline in dog plasma by column-switching liquid chromatography.
Zhang, Y; Zhang, ZR, 2004
)
2.07
"Terbutaline is a selective beta 2 agonist used predominantly in the treatment of asthma. "( Cardiovascular and metabolic effects of terbutaline.
Bradley, D; Dean, S; Gibson, R; Kendall, MJ; Worthington, DJ, 1982
)
1.97
"Terbutaline (T) is a beta-adrenergic compound which is commonly employed as a tocolytic agent in preterm labor. "( The effects of terbutaline on acid base, serum electrolytes, and glucose homeostasis during the management of preterm labor.
Cotton, DB; Goldstein, DA; Lipson, LG; Strassner, HT, 1981
)
2.06
"Terbutaline is a widely used, selective beta 2-adrenergic agonist whose penetration into brain has not been demonstrated in laboratory animals. "( Tissue distribution of 3H-terbutaline in rabbits.
Basmadjian, GP; Hsu, CH; Robinson, CP, 1994
)
2.03
"Terbutaline is a safe bronchodilator drug when administered orally in 2.5-mg doses for children with chronic asthma in this range of ages and weights, with minimal cardiovascular side effects and effective bronchodilation."( Safety and effectiveness of terbutaline in children with chronic asthma.
Gavani, UD; Hyde, JS; Khurana, S; Manaligod, LM, 1979
)
1.28
"Terbutaline is a vasodilator, a sympathomimetic beta2-receptor stimulator."( Preventive effect of a vasodilator on the occurrence of decompression sickness in rabbits.
Balldin, U; Linér, M, 1978
)
0.98
"Terbutaline is a beta-sympathomimetic agent that has gained wide use in obstetrics as a tocolytic agent. "( Long-term subcutaneous terbutaline tocolysis: report of possible neonatal toxicity.
Loughead, JL; Thorkelsson, T, 1991
)
2.03
"Terbutaline is a beta 2-agonist and administered as the racemic mixture. "( Pharmacokinetics of the enantiomers of terbutaline after repeated oral dosing with racemic terbutaline.
Borgström, L; Liu, CX; Walhagen, A, 1989
)
1.99
"Terbutaline seems to be a coronary vasodilator in dogs."( Beta 2-mediated changes in central haemodynamics, coronary circulation and myocardial metabolism in canine.
Diamant, B; Hansen, PB; Hjelms, E; Steiness, E; Waldorff, S, 1988
)
1

Effects

Terbutaline has a direct effect on the fetal heart apart from the effect of uterine relaxation. It is rarely associated with clinically significant cardiac arrhythmias when used to treat preterm labor.

ExcerptReferenceRelevance
"Terbutaline has a direct effect on the fetal heart apart from the effect of uterine relaxation."( Terbutaline: effects on the fetal heart at term.
Abdelhak, Y; Roque, H; Young, BK, 2011
)
2.53
"Terbutaline have been reported to have anti-inflammatory activity. "( Pharmacological exploration of anti-arthritic potential of terbutaline through in-vitro and in-vivo experimental models.
Abbas Bukhari, SN; Akram, M; Alamgeer, -; Alotaibi, NH; Irfan, HM; Jabbar, Z; Khan, AQ; Munir, MU; Rasul Niazi, Z; Sarwar, M, 2022
)
2.41
"Terbutaline has been used as a foetal resuscitation measure to improve the intrapartum foetal heart rate abnormalities and neonatal outcome for suspected foetal compromise. "( Terbutaline for acute tocolysis prior to emergency caesarean delivery for suspected foetal compromise.
Azny, MY; Gayathiri, M; Sakinah, A; Zahar, AZ, 2023
)
3.8
"Terbutaline has a direct effect on the fetal heart apart from the effect of uterine relaxation."( Terbutaline: effects on the fetal heart at term.
Abdelhak, Y; Roque, H; Young, BK, 2011
)
2.53
"Terbutaline has been shown to accelerate the rate of alveolar fluid clearance and augment surfactant secretion."( Therapeutic role of terbutaline in a rat whole-lung lavage model.
Bai, C; Chen, Z; Jiang, J; Li, S; Song, Y; Wang, X; Wu, X, 2011
)
1.41
"Terbutaline has direct effects on the cardiac conduction system, but when used to treat preterm labor it is rarely associated with clinically significant cardiac arrhythmias. "( Atrial fibrillation in pregnancy associated with oral terbutaline.
Carson, MP; Fisher, AJ; Scorza, WE, 2002
)
2.01
"Terbutaline has been determined in milk and plasma from 4 nursing mothers treated with Bricanyl tablets (2.5 or 5 mg, 3 times daily) because of obstructive lung disease. "( Transfer of terbutaline into breast milk.
Boréus, LO; de Château, P; Lindberg, C; Lindström, B; Lönnerholm, G; Nyberg, L, 1984
)
2.09
"Terbutaline has been used in obstetrics to treat premature labor. "( Terbutaline-induced changes in ovine, fetal and maternal hemodynamics, and fetal electroencephalogram.
Ayromlooi, J; Desiderio, DM; Tobias, M, 1981
)
3.15
"Terbutaline has little effect on the restrictive ventilatory deficit after CABG but does improve the efficiency of oxygenation in the early postoperative period."( Terbutaline improves efficiency of oxygenation after coronary artery bypass surgery.
Saunders, NR; Waller, DA, 1996
)
3.18
"Terbutaline has also been reported to raise HDL cholesterol."( Nonpharmacologic and pharmacologic alteration of high-density lipoprotein cholesterol: therapeutic approaches to prevention of atherosclerosis.
Glueck, CJ, 1985
)
0.99
"Terbutaline sulfate has been selected as a suitable compound for evaluation of this inhaler."( Turbuhaler: a new powder inhaler for administration of drugs to the airways.
Wetterlin, K, 1988
)
1

Actions

Terbutaline failed to increase lung fluid absorption in rats given the specific alpha-ENaC siRNA-generating plasmid (pSi-4) Terbutaline can increase gene expression of VEGF in rat astrocytes after induction by NE and burn serum.

ExcerptReferenceRelevance
"Terbutaline failed to increase lung fluid absorption in rats given the specific alpha-ENaC siRNA-generating plasmid (pSi-4)."( RNA interference for alpha-ENaC inhibits rat lung fluid absorption in vivo.
Folkesson, HG; Li, T, 2006
)
1.06
"Terbutaline resulted in lower median contraction frequency per 10 minutes (2.9 [25-75 percentile, 1.7- 3.3] vs 4 [25-75 percentile, 2.5- 5]; P < .002) and reduced tachysystole (1.8% vs 18.9%; P = .003)."( Randomized comparison of intravenous terbutaline vs nitroglycerin for acute intrapartum fetal resuscitation.
Caughey, AB; Druzin, ML; El-Sayed, YY; Pullen, KM; Riley, ET; Taylor, L; Waller, SA, 2007
)
1.33
"Terbutaline can increase gene expression of VEGF in rat astrocytes after induction by NE and burn serum."( [The influence of terbutaline on VEGF gene expression in rat astrocytes after norepinephrine and burn serum induction].
Wang, YM; Yang, ZC, 2007
)
2.12
"(+)-terbutaline did not inhibit the effects of (-)-terbutaline in these tissues."( Steric aspects of agonism and antagonism at beta-adrenoceptors: experiments with the enantiomers of terbutaline and pindolol.
Jeppsson, AB; Johansson, U; Waldeck, B, 1984
)
0.96
"terbutaline because of bronchoconstriction (dosage not documented)."( [Acute theophylline intoxication as differential diagnosis of pneumothorax in an asthma patient].
Schaarschmidt, S; Standl, T, 1997
)
1.02
"Terbutaline induced an increase in serum lactate concentration but did not influence the lactate response to exercise."( Influence of a beta2-agonist on physical performance at low temperature in elite athletes.
Gavhed, D; Holmér, I; Jorfelt, L; Larsson, K; Larsson, L; Ohlsén, P, 1997
)
1.02
"Terbutaline did not increase the amiloride-sensitive Na+ conductance."( Adrenergic stimulation of Na+ transport across alveolar epithelial cells involves activation of apical Cl- channels.
Ingbar, DH; Jiang, X; O'Grady, SM, 1998
)
1.02
"Terbutaline evoked an increase in the forskolin response but no desensitization of receptor-mediated responses."( Are developing beta-adrenoceptors able to desensitize? Acute and chronic effects of beta-agonists in neonatal heart and liver.
Auman, JT; Seidler, FJ; Slotkin, TA; Tate, CA, 2002
)
1.04
"Terbutaline did not produce a significant effect upon blood gases or blood pH."( Effects of terbutaline, a synthetic beta adrenoceptor agonist, on in vivo erythropoietin production.
Fisher, JW; Gross, DM, 1978
)
1.37
"Terbutaline caused an increase in heart rate, respiration rate and minute volume."( [Broncholytic therapy--beta 2 stimulation and vagolysis from an animal experimental viewpoint].
Stepanek, J, 1978
)
0.98
"The terbutaline-induced increase was the same in the upper and lower pelvis."( Effects of dobutamine and terbutaline on adenylate cyclase activity and cyclic AMP content in the renal pelvis of rabbits.
Kondo, S; Morita, T; Tashima, Y, 1992
)
1.06
"Terbutaline caused an increase in VA/Q inequality in patients having PaO2 values greater than 60 mm Hg which resulted in a moderate fall in the PaO2."( Ventilation-perfusion distributions and central hemodynamics in chronic obstructive pulmonary disease. Effects of terbutaline administration.
Andersen, JB; Eliasen, K; Heslet, L; Qvist, J; Ringsted, CV, 1989
)
1.21
"Terbutaline caused a 23% increase in PEF and a 37% increase in FEV1 at five minutes, and a 40% and 58% increase at 15 minutes."( Subcutaneous adrenaline versus terbutaline in the treatment of acute severe asthma.
Clarke, SW; Millar, AB; Pavia, D; Spiteri, MA, 1988
)
1.28

Treatment

Treatment with terbutaline, a Na/K-ATPase-stimulating drug, resulted in attack-free periods of approximately 9 months, after which the attacks reoccurred. Pretreatment with Terbutaline reduced the fall induced by dry-air challenge in Taw by 37% and the subsequent rise in Rcs by 87%.

ExcerptReferenceRelevance
"Terbutaline treatment reduced the number of osteogenic cells."( Mechanical loading alleviated the inhibition of β2-adrenergic receptor agonist terbutaline on bone regeneration.
Bai, H; Lin, M; Liu, C; Liu, Y; Wang, Z; Xiao, C; Zhang, J, 2021
)
1.57
"Terbutaline treatment of the rats with ALI resulted in significant differences in PaO2, oxygenation index, and EVLW from those in ALI group without treatment. "( [Role of epithelial sodium channel alpha subunit in terbutaline-induced transient enhancement of pulmonary edema clearance in adult rats with acute lung injury].
He, L; Huang, DX; Li, TP, 2009
)
2.05
"Terbutaline treatment did not affect alpha-, beta-, or gamma-ENaC mRNA or alpha-ENaC protein steady-state levels, but increased total cellular levels and rate of synthesis of alpha(1)-Na(+)-K(+)-ATPase protein in FDLE in the absence of any change in alpha(1)-Na(+)-K(+)-ATPase mRNA."( Long-term terbutaline exposure stimulates alpha1-Na+-K+-ATPase expression at posttranscriptional level in rat fetal distal lung epithelial cells.
Duan, W; Gandhi, S; O'Brodovich, H; Otulakowski, G; Rahman, MS; Sarangapani, A, 2010
)
1.48
"In terbutaline-treated rats with ARDS, the EVLW content were lower than that of non-treated rats, but still higher than that of the control rats."( [Alveolar fluid clearance and changes of alveolar type II cell cAMP and cGMP levels in rats with oleic acid-induced acute respiratory distress syndrome].
He, L; Li, TP; Zhu, LH, 2008
)
0.86
"Terbutaline-treated women, however, were significantly more likely to have a serum glucose level in excess of 140 mg/dl than were women treated with ritodrine (13 of 26 versus 6 of 29, p less than 0.05)."( A double-blind study comparing ritodrine and terbutaline in the treatment of preterm labor.
Ashmead, G; Caritis, SN; Heddinger, LA; Toig, G, 1984
)
1.25
"Both terbutaline treatments resulted in a significant increase in forced expiratory volume in one second, as compared with placebo (P less than 0.001), but treatment with the tube-spacer aerosol produced significantly more improvement than did treatment with the conventional aerosol (P less than 0.01)."( Aerosol treatment of bronchoconstriction in children, with or without a tube spacer.
Pedersen, S, 1983
)
0.72
"Terbutaline treatment of CREAE rats lowered the splenocyte receptor number to normal values."( Beta-adrenergic agonists suppress chronic/relapsing experimental allergic encephalomyelitis (CREAE) in Lewis rats.
Arnason, BG; Chelmicka-Schorr, E; Kim, DH; Muthyala, S; Wiegmann, K, 1995
)
1.01
"Terbutaline pretreatment significantly decreased feeding elicited by PYY in a dose-dependent fashion."( Suppression of peptide YY-induced hyperphagia by terbutaline.
Hagan, MM; Moss, DE, 1993
)
1.26
"Terbutaline treatment was associated with significantly higher rates of anomalies than in controls at all dosages used, whereas ritodrine induced significantly more anomalies at or above doses of 4.6 x 10(-9) mol per embryo. "( Cardiovascular teratogenicity of terbutaline and ritodrine in the chick embryo.
Kolesari, GL; Kuhlmann, RS; Lawrence, JM; Lenselink, DR, 1994
)
2.01
"Terbutaline pretreatment desensitized the vascular response to isoproterenol, resulting in a fourfold increase in the dose of isoproterenol required to produce 10% vasodilation (geometric mean after terbutaline, 100.8 ng/min; without terbutaline, 26.7 ng/min; p < 0.001)."( Long-term exposure to beta 2-receptor agonist specifically desensitizes beta-receptor-mediated venodilation.
Deegan, R; Stein, M; Wood, AJ, 1993
)
1.01
"The terbutaline-treated group in contrast to the magnesium sulphate-treated group had reduced uterine activity as measured by Montevideo units (p < 0.002)."( Acute tocolysis for fetal distress: terbutaline versus magnesium sulphate.
Chauhan, SP; Cleveland, RS; Dockery, JR; Magann, EF; Martin, JN; Morrison, JC, 1993
)
1.04
"Terbutaline treatment elicited marked attenuation (approximately 75% reductions) of isoprenaline-induced cyclic AMP accumulation in the alveolar macrophages."( Beta 2-agonist treatment reduces beta 2-sensitivity in alveolar macrophages despite corticosteroid treatment.
Hjemdahl, P; Larsson, K; Zetterlund, A, 1996
)
1.02
"2. Terbutaline treatment caused a significant reduction in isoprenaline (1 nM-10 microM)-induced increases in lymphocyte cyclic AMP content; the maximal increase was 14 +/- 3 pmol/10(6) cells before and 7 +/- 2 pmol/10(6) cells (n = 9, P < 0.05) after terbutaline treatment."( Chronic terbutaline treatment desensitizes beta-adrenergic inhibition of lymphocyte activation in healthy volunteers.
Brodde, OE; Poller, U; Werner, C, 1997
)
1.25
"Oral terbutaline treatment decreases beta-adrenoceptor sensitivity in alveolar macrophages in vivo."( beta2-Adrenoceptor desensitization in human alveolar macrophages induced by inhaled terbutaline in vivo is not counteracted by budesonide.
Hjemdahl, P; Larsson, K; Zetterlund, A, 2001
)
0.99
"Terbutaline treatment decreased beta-receptor number and isoproterenol-stimulated cyclic adenosine monophosphate (cAMP) generation in natural killer cells, helper T cells, and suppressor/cytotoxic T cells but not in B cells."( A new method for isolation of human lymphocyte subsets reveals differential regulation of beta-adrenergic receptors by terbutaline treatment.
Fowler, P; Maisel, AS; Michel, MC; Motulsky, HJ; Rearden, A, 1989
)
1.21
"Terbutaline, used in the treatment of premature labor and asthma, crosses the placenta and can stimulate beta 2-adrenergic receptors in the fetus. "( Prenatal terbutaline exposure in the rat: selective effects on development of noradrenergic projections to cerebellum.
Baker, FE; Dobbins, SS; Eylers, JP; Lappi, SE; Seidler, FJ; Slotkin, TA,
)
1.99
"Terbutaline pretreatment did not prevent the pulmonary hypertension that characteristically occurs after endotoxin injection, nor did it decrease the initial fall in platelet count, leukocyte count, arterial oxygen tension (PaO2), or respiratory compliance (t = 30)."( Influence of terbutaline on endotoxin-induced lung injury.
Christenson, JT; Sigurdsson, GH, 1988
)
1.37
"Terbutaline treatment suppressed plasma and urinary levels of epinephrine significantly without any effect on norepinephrine."( Influence of slow-release terbutaline on the circadian variation of catecholamines, histamine, and lung function in nonallergic patients with partly reversible airflow obstruction.
Keyzer, JJ; Koëter, GH; Meurs, H; Postma, DS, 1986
)
1.29
"Terbutaline-treated animals developed arrhythmias during more treatment cycles (50%) and at lower drug concentrations, whereas hexaprenaline-treated animals developed arrhythmias at higher drug concentrations, with an overall arrhythmia frequency of 14%."( A comparison of the relative toxicities of beta-sympathomimetic tocolytic agents.
Hankins, GD; Hauth, JC, 1985
)
0.99
"24h treatment with terbutaline stimulated these currents in normoxia and hypoxia, although stimulation was less in the latter."( Beta2-adrenergic stimulation blunts inhibition of epithelial ion transport by hypoxia of rat alveolar epithelial cells.
Baloglu, E; Bärtsch, P; Ke, A; Loeh, B; Mairbäurl, H, 2010
)
0.68
"Treatment with terbutaline in the Pa-instilled group significantly increased basal AFC compared with the saline and Pa group, (respectively 22.3 ± 1.3% versus 12.5 ± 4.7%, p < 0.001)."( Beta-adrenergic modulation of lung fluid balance in acute P aeruginosa pneumonia in rats.
Guery, B; Kipnis, E; Kipris, E; Robriquet, L, 2011
)
0.71
"Treatment with terbutaline was continued for 13 days and was well tolerated."( Terbutaline for chronotropic support in heart transplantation.
Coons, JC; Kormos, R; Schonder, K; Shullo, M, 2004
)
2.11
"Pretreatment with terbutaline was found to attenuate both the wheal and the flare reactions to allergen throughout the observation period of 150 min but only the effect on the wheal response reached statistical significance (P less than 0.01)."( Effect in man of oral terbutaline on cutaneous reactions induced by allergen and cold stimulation.
Grönneberg, R; Hägermark, O; Strandberg, K, 1980
)
0.9
"Pretreatment with terbutaline did produce small but nonsignificant increases in aerobic fractional utilization (percent peak VO2 on drug: 65.9%, 72.6%, and 76.7% vs."( Beta 2-agonists and running economy in prepubertal boys.
Aitchison, TC; Paton, JY; Thomson, KJ; Unnithan, VB, 1994
)
0.61
"Treatment with terbutaline CR alone or the combination was preferred by as many patients as was treatment with ipratropium alone."( Terbutaline controlled-release tablets and ipratropium aerosol in nocturnal asthma.
Elo, J; Mansury, L; Tammivaara, R, 1993
)
2.07
"Treatment with terbutaline eliminated this change in group T at 6 hrs after extubation."( Terbutaline improves efficiency of oxygenation after coronary artery bypass surgery.
Saunders, NR; Waller, DA, 1996
)
2.08
"Pretreatment with terbutaline, aminophylline or DBcAMP prevented the increases in both PAP and lung weight (P <0.001)."( Pulmonary edema induced by phorbol myristate acetate is attenuated by compounds that increase intracellular cAMP.
Chang, ML; Chen, HI; Hsu, K; Wang, D; Wu, CP, 1996
)
0.62
"Pretreatment with terbutaline and surfactant significantly limited the increase of lung resistance to +36 and +34%, respectively."( Aerosolized surfactant inhibits acetylcholine-induced airway obstruction in rats.
Fabel, H; Heinrich, U; Hohlfeld, J; Hoymann, HG; Molthan, J, 1997
)
0.62
"Treatment with terbutaline, a Na/K-ATPase-stimulating drug, resulted in attack-free periods of approximately 9 months, after which the attacks reoccurred."( Multiple anomalies, hypokalaemic paralysis and partial symptomatic relief by terbutaline.
Andersen, PE; Djurhuus, MS; Jensen, BM; Klitgaard, NA; Schrøder, HD, 1998
)
0.87
"Pretreatment with terbutaline (100 micrograms/kg) reduced the fall induced by dry-air challenge in Taw by 37% and the subsequent rise in Rcs by 87%."( Terbutaline acts at multiple sites to inhibit bronchoconstriction induced by dry air in canine peripheral airways.
Chen, HI; Chou, CL; Freed, AN; Hsu, K; Wang, D, 1992
)
2.05
"Treatment with terbutaline in Turbuhaler was preferred by a majority of children and parents."( Comparison of Bricanyl Turbuhaler and Berotec dry powder inhaler.
Ribeiro, LB; Wirén, JE, 1990
)
0.62
"Thus treatment with terbutaline for 1 day did not result in any rebound increase in bronchial responsiveness."( Rebound increase in bronchial responsiveness after treatment with inhaled terbutaline.
Britton, JR; Higgins, BG; Knox, AJ; Tattersfield, AE; Vathenen, AS, 1988
)
0.82
"Treatment with terbutaline and magnesium sulfate was unsuccessful in alleviating the uterine hypertonus, necessitating cesarean section."( Methylergonovine-induced hypertonus in term pregnancy. A case report.
Carpenter, RJ; Moise, KJ, 1988
)
0.61

Toxicity

Continuous subcutaneous terbutaline infusion was associated with an extremely low incidence of serious adverse events. Terbutaline was found to be safe for use in this patient group in doses ranging between 1 and 5 microg/kg/min.

ExcerptReferenceRelevance
" No adverse effects (including tachyphylaxis and tremor) were observed for either drug during a three-month period."( Safety and effectiveness of terbutaline in children with chronic asthma.
Gavani, UD; Hyde, JS; Khurana, S; Manaligod, LM, 1979
)
0.55
" No toxic effects of the drug have been found."( The therapeutic value of oral long-term treatment with terbutaline (Bricanyl) in asthma. A follow-up study of its efficacy and side effects.
Formgren, H, 1975
)
0.5
" We conclude that frequent administration of high doses of nebulized terbutaline is safe in the management of acute severe childhood asthma even in the setting of prolonged administration to the hospitalized child."( Safety of frequent high dose nebulized terbutaline in children with acute severe asthma.
Katz, R; Kelly, HW; McWilliams, BC; Murphy, S, 1990
)
0.78
" The primary objective was to evaluate safety (pulse rate, blood pressure, adverse events, hematology, and clinical chemistry)."( One-year safety study with bambuterol once daily and terbutaline three times daily in 2-12-year-old children with asthma. The Bambuterol Multicentre Study Group.
Kuusela, AL; Marenk, M; Olsson, H; Persson, B; Sandahl, G; Valovirta, E; Zarkovic, JP, 2000
)
0.56
" Maternal side effects, particularly cardiovascular adverse events (8."( Effectiveness and safety of the oxytocin antagonist atosiban versus beta-adrenergic agonists in the treatment of preterm labour. The Worldwide Atosiban versus Beta-agonists Study Group.
, 2001
)
0.31
" No serious adverse events were noted."( Efficacy and safety of Ascoril in the management of cough--National Study Group report.
Ainapure, SS; Desai, A; Korde, K, 2001
)
0.31
" Oxis Turbuhaler (90 microg) was at least as safe and well tolerated as terbutaline (10 mg) [DOSAGE ERROR CORRECTED] in patients with acute bronchoconstriction."( Safety of formoterol Turbuhaler at cumulative dose of 90 microg in patients with acute bronchial obstruction.
Böszörményi Nagy, G; Brander, R; Larsso, P; Malolepszy, J; Selroos, O, 2001
)
0.54
" Adverse events, serum potassium levels, electrocardiogram, vital signs and lung function were assessed monthly; peak expiratory flow and severe asthma exacerbations were recorded daily."( Safety of formoterol by Turbuhaler as reliever medication compared with terbutaline in moderate asthma.
Böszörményi, NG; Ind, PW; Pietinalho, A; Selroos, O; Shiner, RJ; Soliman, S; Villasante, C, 2002
)
0.55
" Disruption of alpha(2)AR expression and function may therefore contribute to adverse effects that have been noted in the offspring of pregnant women treated with terbutaline."( Beta-adrenoceptor modulation of transiently overexpressed alpha 2-adrenoceptors in brain and peripheral tissues: cellular mechanisms underlying the developmental toxicity of terbutaline.
Kreider, ML; Seidler, FJ; Slotkin, TA, 2004
)
0.71
"The purpose of this study was to determine the frequency of serious adverse events in patients receiving continuous subcutaneous terbutaline after arrested preterm labor."( The occurrence of adverse events in women receiving continuous subcutaneous terbutaline therapy.
Elliott, JP; Istwan, NB; Rhea, D; Stanziano, G, 2004
)
0.76
" Electronic patient records were reviewed for patient tolerance of medication and serious adverse events."( The occurrence of adverse events in women receiving continuous subcutaneous terbutaline therapy.
Elliott, JP; Istwan, NB; Rhea, D; Stanziano, G, 2004
)
0.55
" Severe adverse events were identified on 12 patients either during treatment with continuous subcutaneous terbutaline (n=4), or after discontinuation of outpatient treatment (n=8)."( The occurrence of adverse events in women receiving continuous subcutaneous terbutaline therapy.
Elliott, JP; Istwan, NB; Rhea, D; Stanziano, G, 2004
)
0.77
"Continuous subcutaneous terbutaline infusion was associated with an extremely low incidence of serious adverse events."( The occurrence of adverse events in women receiving continuous subcutaneous terbutaline therapy.
Elliott, JP; Istwan, NB; Rhea, D; Stanziano, G, 2004
)
0.86
"Terbutaline was found to be safe for use in this patient group in doses ranging between 1 and 5 microg/kg/min."( Safety of intravenous terbutaline in acute severe asthma: a retrospective study.
Kambalapalli, M; Nichani, S; Upadhyayula, S, 2005
)
2.09
"Tulobuterol tape is a newly formulated, effective and safe medication for the treatment of asthma."( [The efficacy and safety of tulobuterol tape in mild and moderate persistent asthma patients].
Cao, ZL; Chen, BY; Chen, X; He, J; He, QY; Lin, JT; Su, N; Xiao, Y; Yan, XX; Yang, M, 2007
)
0.34
" Secondary outcomes were the efficacy to delay delivery > or =48 hours and 7 days, the adverse events and the birth outcomes."( Safety and efficacy of oral nifedipine versus terbutaline injection in preterm labor.
Laohapojanart, N; Ratanajamit, C; Soorapan, S; Wacharaprechanont, T, 2007
)
0.6
"The aim of this review is to assess the risk of fatal and non-fatal serious adverse events in trials that randomised patients with chronic asthma to regular formoterol versus placebo or regular short-acting beta(2)-agonists."( Regular treatment with formoterol for chronic asthma: serious adverse events.
Cates, CJ; Cates, MJ, 2012
)
0.38
" We sought unpublished data on mortality and serious adverse events."( Regular treatment with formoterol for chronic asthma: serious adverse events.
Cates, CJ; Cates, MJ, 2012
)
0.38
" Non-fatal serious adverse event data could be obtained for all participants from published studies comparing formoterol and placebo but only 80% of those comparing formoterol with salbutamol or terbutaline."( Regular treatment with formoterol for chronic asthma: serious adverse events.
Cates, CJ; Cates, MJ, 2012
)
0.57
"In comparison with placebo, we have found an increased risk of serious adverse events with regular formoterol, and this does not appear to be abolished in patients taking inhaled corticosteroids."( Regular treatment with formoterol for chronic asthma: serious adverse events.
Cates, CJ; Cates, MJ, 2012
)
0.38
"Aggravation of asthmatic response (asthmatic attack, 2 cases) and adverse events (tremor, 1 case) due to a switch from a brand-name tulobuterol tape to a generic tape were recently reported."( [Questionnaire survey on the change of asthmatic response, adverse events and product usability due to drug switching between name-brand and generic tulobuterol tapes].
Hori, S; Izumi, T; Miki, A; Satoh, H; Sawada, Y, 2012
)
0.38
" The two groups were compared with respect to symptom scores of cough, wheeze, respiratory rate, wheezing sound, three depression sign and peak expiratory flow, as well as adverse events."( [Efficacy and safety of tulobuterol patch versus oral salbutamol sulfate in children with mild or moderate acute attack of bronchial asthma: a comparative study].
Bao, YX; Lin, Q; Liu, QH, 2013
)
0.39
" One child developed hand trembling in the salbutamol group, while no adverse event occurred in the tulobuterol group."( [Efficacy and safety of tulobuterol patch versus oral salbutamol sulfate in children with mild or moderate acute attack of bronchial asthma: a comparative study].
Bao, YX; Lin, Q; Liu, QH, 2013
)
0.39
" In women in preterm labour, we compared the impact of terbutaline versus nifedipine on inhibition of uterine contractions, preterm birth, neonatal sepsis, intracranial haemorrhage or necrotizing enterocolitis, death or admission to a neonatal intensive care unit and maternal adverse reactions."( Nifedipine versus terbutaline, tocolytic effectiveness and maternal and neonatal adverse effects: a randomized, controlled pilot trial.
Guyatt, G; Lopes, LC; Padovani, TR, 2015
)
1
"The results indicate that overall, terbutaline infusion was well tolerated without irreversible adverse effects of the treatment."( Safety of Terbutaline for Treatment of Acute Severe Pediatric Asthma.
Doymaz, S; Schneider, J, 2018
)
1.16
" In the present study, safe and effective ionic liquids for transdermal absorption were obtained as salts generated by a neutralization reaction between highly biocompatible aliphatic carboxylic acids (octanoic acid or isostearic acid) and aliphatic amines (diisopropanolamine or triisopropanolamine) (Medrx Co."( The molecular assembly of the ionic liquid/aliphatic carboxylic acid/aliphatic amine as effective and safety transdermal permeation enhancers.
Kubota, K; Shibata, A; Yamaguchi, T, 2016
)
0.43
" However, this side effect may be complicated by a tachypnea compensating for metabolic acidosis and should be known to avoid unnecessary therapeutic escalation."( [Hyperlactatemia induced by inhaled β2 agonists: An underrecognized side effect. Report of two cases].
David, C; Pouchot, J; Ranque, B, 2019
)
0.51
" Adverse events (AEs), serious AEs (SAEs), discontinuations due to AEs (DAEs), and study-defined asthma-related discontinuations from corresponding treatment groups in both studies were pooled."( Safety of As-Needed Budesonide-Formoterol in Mild Asthma: Data from the Two Phase III SYGMA Studies.
Alagappan, VKT; Barnes, PJ; Bateman, ED; Emerath, U; FitzGerald, JM; Ivanov, S; Jansen, G; Lamarca, R; Larsdotter, U; O'Byrne, PM; Puu, M; Reddel, HK; Surmont, F; Zheng, J, 2021
)
0.62
"Perioperative respiratory adverse events are common in children."( Effect of Tulobuterol Patch Versus Placebo on the Occurrence of Respiratory Adverse Events in Children Undergoing Tonsillectomies: A Randomized Controlled Trial.
Jang, YE; Ji, SH; Kang, P; Kim, EH; Kim, HS; Kim, JK; Kim, JT; Lee, JH; Lee, SH; Park, JB; Park, YH, 2023
)
0.91
" The primary outcome was the occurrence of any perioperative respiratory adverse events: oxygen desaturation <95%, airway obstruction, laryngospasm, bronchospasm, severe coughing, or stridor."( Effect of Tulobuterol Patch Versus Placebo on the Occurrence of Respiratory Adverse Events in Children Undergoing Tonsillectomies: A Randomized Controlled Trial.
Jang, YE; Ji, SH; Kang, P; Kim, EH; Kim, HS; Kim, JK; Kim, JT; Lee, JH; Lee, SH; Park, JB; Park, YH, 2023
)
0.91
" The incidence of any perioperative respiratory adverse event was lower with tulobuterol (n = 13/88; 14."( Effect of Tulobuterol Patch Versus Placebo on the Occurrence of Respiratory Adverse Events in Children Undergoing Tonsillectomies: A Randomized Controlled Trial.
Jang, YE; Ji, SH; Kang, P; Kim, EH; Kim, HS; Kim, JK; Kim, JT; Lee, JH; Lee, SH; Park, JB; Park, YH, 2023
)
0.91
"In preschool children undergoing tonsillectomy, the preoperative application of a tulobuterol patch could decrease the occurrence of perioperative respiratory adverse events."( Effect of Tulobuterol Patch Versus Placebo on the Occurrence of Respiratory Adverse Events in Children Undergoing Tonsillectomies: A Randomized Controlled Trial.
Jang, YE; Ji, SH; Kang, P; Kim, EH; Kim, HS; Kim, JK; Kim, JT; Lee, JH; Lee, SH; Park, JB; Park, YH, 2023
)
0.91
"Scoping review with the objective of describing the adverse effects related to the administration of norepinephrine through short peripheral venous access and the characteristics of drug administration in patients hospitalized in ICU, surgery, and emergency services."( Adverse effects related with norepinephrine through short peripheral venous access: Scoping review.
Arteaga-Noriega, A; Bedoya, OA; García-Uribe, J; Gutiérrez-Vargas, J; Lopera-Jaramillo, D,
)
0.13
"The main adverse effect was extravasation, no additional complications occurred, phentolamine and terbutaline seem to be useful, and its availability is a necessity."( Adverse effects related with norepinephrine through short peripheral venous access: Scoping review.
Arteaga-Noriega, A; Bedoya, OA; García-Uribe, J; Gutiérrez-Vargas, J; Lopera-Jaramillo, D,
)
0.35

Pharmacokinetics

The pharmacokinetics of orally administered bambuterol were investigated in healthy adult subjects. Regular use of terbutaline did not influence the pharmacokinetic data in a significant way.

ExcerptReferenceRelevance
" Regular use of terbutaline did not influence the pharmacokinetic data in a significant way."( Pharmacokinetics of terbutaline after subcutaneous administration.
Lamont, H; Leferink, JG; Maes, RA; Pouwels, R; van der Straeten, M; Wagemaker-Engels, I, 1979
)
0.93
" Patients with renal failure but not asthmatics show changed pharmacokinetic profiles."( Pharmacokinetic/pharmacodynamic characteristics of the beta-2-agonists terbutaline, salbutamol and fenoterol.
Hochhaus, G; Möllmann, H, 1992
)
0.52
" In order to reach the desired plasma concentrations of terbutaline immediately, a pharmacokinetic simulation was done."( Effects of a constant dose rate of terbutaline on circadian peak expiratory flow, heart rate and systolic arterial pressure in patients with asthma exacerbation.
Arnaud, A; Bruguerolle, B; Lagier, F; Leonardelli, M; Orlando, JP; Philip-Joet, F; Pierson, F; Reynaud, M; Vervloet, D, 1992
)
0.81
" By using pharmacokinetic pharmacodynamic modeling the pharmacodynamics of racemic metoprolol and the active S-isomer, were quantitated in EMs and PMs in terms of IC50 values, representing metoprolol plasma concentrations resulting in half-maximum receptor occupancy."( Debrisoquine phenotype and the pharmacokinetics and beta-2 receptor pharmacodynamics of metoprolol and its enantiomers.
Jonkers, RE; Koopmans, RP; Portier, EJ; van Boxtel, CJ, 1991
)
0.28
" The isolated vagus nerve-trachea tube preparation of the guinea-pig is well suited for the concommitant study of pharmacodynamic and pharmacokinetic properties of bronchodilator drugs."( Pharmacodynamic and pharmacokinetic aspects on the transport of bronchodilator drugs through the tracheal epithelium of the guinea-pig.
Jeppsson, AB; Roos, C; Waldeck, B; Widmark, E, 1989
)
0.28
" The differences in CL were reflected in values of the elimination half-life and MRT."( Pharmacokinetic evaluation in man of terbutaline given as separate enantiomers and as the racemate.
Borgström, L; Jönsson, S; Lindberg, C; Nyberg, L; Paulson, J, 1989
)
0.55
"01) increased half-life (8."( The effects of a beta-2 selective adrenergic agonist and a beta-nonselective antagonist on theophylline clearance.
Bertino, JS; Goldberg, A; Lombardi, TP; Middleton, E; Slaughter, RL, 1987
)
0.27
"The pharmacokinetic mechanism of the theophylline-terbutaline interaction has been studied."( Increased theophylline clearance in asthmatic patients due to terbutaline.
Garty, M; Ilfeld, DN; Mazar, A; Paul-Keslin, L; Rosenfeld, JB; Spitzer, S, 1989
)
0.77
" Essentially the same ke0 was found for FEv1, Raw, and sGaw, indicating that the concerning receptors are "localized" in the same pharmacokinetic compartment."( Pharmacokinetic-pharmacodynamic modeling of terbutaline bronchodilation in asthma.
Braat, MC; Oosterhuis, B; Roos, CM; Van Boxtel, CJ; Wemer, J, 1986
)
0.53
"Plasma levels and elimination half-life of tulobuterol, a new beta-adrenergic agonist, were determined in ten healthy male volunteers after repeated dosing with 2 mg, twice daily, for seven days."( Pharmacokinetics of the bronchodilator tulobuterol in man after repeated oral doses.
Chasseaud, LF; Wood, SG, 1986
)
0.27
"The basal model-independent pharmacokinetic parameters body clearance (CL), renal clearance (CLR), mean residence time (MRT), and volume of distribution in steady state (Vss) were calculated from concentrations of terbutaline in plasma and amounts in urine after intravenous administration of the drug in 19 healthy men."( Pharmacokinetics of terbutaline after parenteral administration.
Fagerström, PO, 1984
)
0.78
" The pharmacokinetic parameters are therefore preferably calculated by a non-compartmental method."( Pharmacokinetic parameters of terbutaline in healthy man. An overview.
Nyberg, L, 1984
)
0.56
" The growing use of the drug has increased the need of pharmacokinetic information to design and optimize therapy."( Pharmacokinetics of terbutaline therapy.
Andersson, KE; Nyberg, L, 1984
)
0.59
" Thus, although there are differences in routes of metabolism, the selectivity of action within the airways when the drugs are inhaled is to a large part dependent on pharmacokinetic and metabolic factors."( Pharmacokinetic studies with inhaled drugs.
Davies, DS, 1982
)
0.26
"Simultaneous administration of terbutaline and theophylline to guinea pigs did not cause significant alterations of the pharmacokinetic properties of any of the drugs."( Pharmacokinetics of terbutaline and theophylline in guinea pigs when administered simultaneously.
Madsen, SM; Ribel, U, 1981
)
0.87
"21 ng/mL, Tmax was 14."( Pharmacokinetics and pharmacodynamics of the tulobuterol patch, HN-078, in childhood asthma.
Akimoto, K; Ebisawa, M; Iikura, Y; Ishizu, H; Kabayama, H; Miura, K; Sakaguchi, N; Tsubaki, T; Uchiyama, H; Yagi, K, 1995
)
0.29
"A comparison has been made of pulmonary deposition of terbutaline sulphate from a pressurized metered dose inhaler (pMDI), measured in 8 healthy male subjects by gamma scintigraphy and by a pharmacokinetic (charcoal-block) method, involving drug recovery in urine."( Comparison of gamma scintigraphy and a pharmacokinetic technique for assessing pulmonary deposition of terbutaline sulphate delivered by pressurized metered dose inhaler.
Borgström, L; Hooper, G; Källén, A; Newman, S; Steed, K, 1995
)
0.75
" Thus, the pharmacokinetic properties of bambuterol make it suitable for oral once-daily dosage."( Pharmacokinetics of bambuterol in healthy subjects.
Jönsson, S; Kennedy, BM; Nilsson, M; Nyberg, L; Rosenborg, J; Weibull, E, 1998
)
0.3
"The pharmacokinetic parameters in the present study were grossly similar to those found in a study of bambuterol in subjects with normal plasma cholinesterase activity (N)."( Pharmacokinetics of bambuterol in subjects homozygous for the atypical gene for plasma cholinesterase.
Bang, U; Nyberg, L; Rosenborg, J; Viby-Mogensen, J, 1998
)
0.3
"The pharmacokinetics of orally administered bambuterol were investigated in healthy adult subjects, with particular regard to time to steady state, pharmacokinetic linearity, intraindividual variability for the parent drug and its active beta2-adrenergic metabolite terbutaline and bioequivalence between tablet and solution."( Pharmacokinetics of bambuterol during oral administration of plain tablets and solution to healthy adults.
Larsson, P; Nyberg, L; Rosenborg, J, 2000
)
0.49
" Mean terminal half-life of terbutaline was 22 h and steady-state was reached within one week of bambuterol treatment."( Pharmacokinetics of bambuterol during oral administration of plain tablets and solution to healthy adults.
Larsson, P; Nyberg, L; Rosenborg, J, 2000
)
0.6
"To determine pharmacokinetics of terbutaline in healthy horses and to relate serum terbutaline concentrations with the drug's pharmacodynamic effects."( Pharmacokinetics and pharmacodynamics of terbutaline in healthy horses.
Appelgren, LE; Ingvast-Larsson, JC; Johansson, JM; Törneke, MK, 2000
)
0.85
" Pharmacokinetic analysis indicated that absorption of bambuterol was slow and multi-phasic and that slow biotransformation to terbutaline occurred both presystemically and systemically."( Clinical-pharmacokinetic aspects of prolonged effect duration as illustrated by beta2-agonists.
Rosenburg, J, 2002
)
0.52
" After an oral administration of 10 mg bambuterol hydrochloride to 18 healthy Chinese volunteers the main pharmacokinetic parameters of bambuterol were as follows: Tmax was (2."( [Determination of bambuterol in human plasma by liquid chromatography-electrospray tandem mass spectrometry: application to pharmacokinetic study].
Chen, XY; Xu, HY; Yang, HY; Zhang, YF; Zhong, DF, 2001
)
0.31
"The method is shown to be accurate, robust and convenient, and suitable for pharmacokinetic studies of bambuterol."( [Determination of bambuterol in human plasma by liquid chromatography-electrospray tandem mass spectrometry: application to pharmacokinetic study].
Chen, XY; Xu, HY; Yang, HY; Zhang, YF; Zhong, DF, 2001
)
0.31
" A comparison is also presented between several methods based on animal pharmacokinetic data, using the same set of proprietary compounds, and it lends further support for the use of this method, as opposed to methods that require the gathering of pharmacokinetic data in laboratory animals."( Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY, 2004
)
0.32
"5 mg/kg, the mean peak serum concentration, residence time, and half-life were 708."( Terbutaline pharmacokinetics in cows: preliminary data.
Boileau, MJ; Clarke, CR; Maxwell, LK; Streeter, RN; Washburn, KE, 2007
)
1.78
" Serum concentrations were analysed over a period of 6 h and pharmacokinetic key variables for each drug were calculated."( Pharmacokinetics of intraperitoneally instilled aminophylline, terbutaline and tobramycin in pigs.
Aadahl, P; Aasarød, K; Asheim, P; Spigset, O; Uggen, PE; Walstad, RA; Zahlsen, K, 2008
)
0.59
"The pharmacokinetic properties after intraperitoneal administration differed among the three drugs, but the results are encouraging and provide a basis for further investigation in humans."( Pharmacokinetics of intraperitoneally instilled aminophylline, terbutaline and tobramycin in pigs.
Aadahl, P; Aasarød, K; Asheim, P; Spigset, O; Uggen, PE; Walstad, RA; Zahlsen, K, 2008
)
0.59
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" Hence, this system can be particularly useful for obtaining a detailed pharmacokinetic characterization of inhaled compounds in drug discovery/development."( Short inhalation exposures of the isolated and perfused rat lung to respirable dry particle aerosols; the detailed pharmacokinetics of budesonide, formoterol, and terbutaline.
Andersson, P; Blomgren, A; Eirefelt, SJ; Ewing, P; Gerde, P; Ryrfeldt, A, 2008
)
0.54
" The purpose of this study is to determine the pharmacokinetic properties of terbutaline in patients with severe renal impairment as defined by a glomerular filtration rate (GFR) below 30 mL/min."( Pharmacokinetics of terbutaline in chronic kidney disease.
Bastiansen, A; Eggert, S; Pedersen, E, 2013
)
0.94
" The concentration of terbutaline in the blood and in the urine was used to calculate pharmacokinetic parameters."( Pharmacokinetics of terbutaline in chronic kidney disease.
Bastiansen, A; Eggert, S; Pedersen, E, 2013
)
1.03
" The validated method has been successfully applied to the human pharmacokinetic study of R-bambuterol involving 10 healthy volunteers."( A sensitive LC-MS/MS method for simultaneous determination of R-bambuterol and its active metabolite R-terbutaline in human plasma and urine with application to a clinical pharmacokinetic study.
Cheng, Q; Liu, S; Tan, W; Xu, L; Zhao, T; Zhou, T, 2014
)
0.62
" After single intravenous administration, no significant differences were observed between the two drugs in pharmacokinetic data."( Comparative pharmacokinetics and bile transformation of R-enantiomer and racemic bambuterol after single-dose intravenous, oral administration in rats and beagle dogs.
Chen, JD; Guan, S; He, MY; Hu, CY; Huang, LJ; Tan, W; Tang, YX; Yang, YY, 2015
)
0.42
" For the first time, the validated method was successfully applied to an enantioselective pharmacokinetic study of rac-bambuterol in 8 healthy volunteers."( Chiral analysis of bambuterol, its intermediate and active drug in human plasma by liquid chromatography-tandem mass spectrometry: Application to a pharmacokinetic study.
He, M; Liu, S; Qu, S; Tan, W; Xu, B; Xu, L; Zeng, J; Zhao, T; Zhou, T, 2015
)
0.42
" The validated method has been successfully applied to a pharmacokinetic study of three doses of tulobuterol patch in rats for the first time."( Determination of tulobuterol in rat plasma using a liquid chromatography-tandem mass spectrometry method and its application to a pharmacokinetic study of tulobuterol patch.
Bi, K; Fang, L; Han, X; Hui, M; Ji, L; Li, Q; Liu, R, 2016
)
0.43

Compound-Compound Interactions

The study aimed to investigate the clinical value of N-acetylcysteine (NAC) combined with terbutaline sulfate in the treatment of COPD in elderly people. The uterine effects of Terbutaline alone or in combination with rolipram were tested in vivo.

ExcerptReferenceRelevance
" We conclude that terbutaline given alone counteracts the loss of plasma volume during septicaemia and, when combined with a chemotherapeutic and dexamethasone, significantly improves long term survival."( Septic shock in rats treated with terbutaline alone and in combination with chemotherapeutics, dexamethasone, and infusion of 3% albumin.
Dawidson, I; Ottosson, J; Persson, T; Svensjö, E, 1992
)
0.9
" The study showed improved bronchodilation when PEP was combined with inhalation of beta 2-agonist compared with beta 2-agonist alone."( Treatment of bronchial asthma with terbutaline inhaled by conespacer combined with positive expiratory pressure mask.
Dahl, R; Frischknecht-Christensen, E; Nørregaard, O, 1991
)
0.56
"We describe a successful, prolonged, inhibition of preterm labor using nifedipine combined with terbutaline in a patient undergoing complicated obstetrical problems."( The management of preterm labor with the calcium channel-blocking agent nifedipine combined with the beta-mimetic terbutaline.
Friedman, PA; Frigoletto, FD; Kaul, AF; Osathanondh, R; Safon, LE, 1985
)
0.7
"5 mg) combined with 280 mg anhydrous theophylline orally in the randomized, double-blind, cross-over study in eight asthmatics."( Effects of oral theophylline combined with oral and inhaled beta-2-adrenostimulants in asthmatics.
Svedmyr, K, 1982
)
0.26
"The haemodynamic response to two xanthines, enprofylline and theophylline, was studied in 6 healthy male volunteers at rest, during exercise and in combination with the beta 2-agonist, terbutaline."( Cardiovascular effects of two different xanthines in healthy subjects. Studies at rest, during exercise and in combination with a beta-agonist, terbutaline.
Conradson, TB, 1984
)
0.66
"The additional effect of N-acetylcysteine in combination with inhaled terbutaline was studied in a controlled randomized double-blind cross-over study of one week periods in 22 patients with stable reversible chronic obstructive pulmonary disease."( Effects of inhaled N-acetylcysteine in combination with terbutaline.
Melin, S; Nemcek, K; Stiksa, G, 1984
)
0.75
" The results indicate that theophylline alone has only a moderate acute bronchodilating effect at recommended plasma concentrations but gives a good effect when combined with inhaled beta 2-adrenostimulants."( Bioavailability of theophylline from three different tablets in asthmatic patients and their bronchodilating effects in combination with terbutaline inhalation.
Mellstrand, T; Svedmyr, K; Svedmyr, N, 1982
)
0.47
" The effects of inhaling terbutaline in combination with mannitol on MCC were investigated in nine healthy (aged 19+/-1 yrs) and 11 mild (aged 21+/-4 yrs) asthmatic subjects."( Effects of terbutaline in combination with mannitol on mucociliary clearance.
Anderson, SD; Chan, HK; Daviskas, E; Eberl, S; Seale, JP; Young, IH, 2002
)
1.01
" The uterine effects of terbutaline alone or in combination with rolipram were tested in vivo."( Uterus-relaxing effect of β2-agonists in combination with phosphodiesterase inhibitors: studies on pregnant rat in vivo and on pregnant human myometrium in vitro.
Ducza, E; Falkay, G; Gáspár, R; Hajagos-Tóth, J; Klukovits, A; Kormányos, Z; Seres, AB; Verli, J, 2013
)
0.7
" Herein, by using terbutaline mouse McAb as a model, a novel label-free strategy based on on-line microdialysis (MD) sampling combined with flow injection chemiluminescent detection was designed for measuring antibody affinity to hapten in a homogeneous system."( A label-free strategy for measuring the affinity between monoclonal antibody and hapten using microdialysis sampling combined with chemiluminescent detection.
Fu, Z; He, Y; Ouyang, H; Wang, L; Wang, P; Xiong, J; Yue, H; Zhou, Y, 2017
)
0.79
" Our study aimed to investigate the clinical value of N-acetylcysteine (NAC) combined with terbutaline sulfate in the treatment of COPD in elderly people, and its effect on the apoptosis/anti-apoptosis mechanism."( Clinical value of N-acetylcysteine combined with terbutaline sulfate in elderly patients with chronic obstructive pulmonary disease and its effect on apoptosis/anti-apoptosis mechanism.
Lin, J; Sun, Y; Xie, M; Zhang, L; Zhou, Q, 2020
)
1.03

Bioavailability

The aim of the study was to determine the relative lung and systemic bioavailability of terbutaline. The addition of ter butaline to the repeated administration of theophylline lowered the relative bioavailability by approximately 11%.

ExcerptReferenceRelevance
"A recently proposed bioavailability estimation procedure, the "semisimultaneous" method, in which the test and reference dose administrations are separated by a short time interval and total concentrations are analyzed, was compared with the stable isotope method for precision and accuracy."( A comparison between the semisimultaneous and the stable isotope techniques for bioavailability estimation of terbutaline in humans.
Borgström, L; Bredberg, U; Karlsson, MO, 1992
)
0.5
" The oral contribution to the overall systemic bioavailability after inhalation, when charcoal was coadministered, could thus be neglected."( A method for determination of the absolute pulmonary bioavailability of inhaled drugs: terbutaline.
Borgström, L; Nilsson, M, 1990
)
0.5
"The study aimed at finding the absolute bioavailability of terbutaline of a newly developed CR-granulate."( Absolute bioavailability of terbutaline from a CR-granulate in asthmatic children.
Borgström, L; Fuglsang, G; Hertz, B; Holm, EB,
)
0.67
" The bioavailability of (+/-)T was similar to that of (-)T."( Pharmacokinetic evaluation in man of terbutaline given as separate enantiomers and as the racemate.
Borgström, L; Jönsson, S; Lindberg, C; Nyberg, L; Paulson, J, 1989
)
0.55
" The addition of terbutaline to the repeated administration of theophylline lowered the relative bioavailability of theophylline by approximately 11% during the night interval."( Theophylline-terbutaline, a steady state study on possible pharmacokinetic interactions with special reference to chronopharmacokinetic aspects.
Borgström, L; de Noord, OE; Jonkman, JH; van der Boon, WJ, 1988
)
0.98
" Deuterium-labeled terbutaline can be used, intravenously or orally, as an absolute reference in bioavailability studies on terbutaline."( Comparative pharmacokinetics of unlabeled and deuterium-labeled terbutaline: demonstration of a small isotope effect.
Borgström, L; Jönsson, S; Lindberg, C; Svensson, K, 1988
)
0.84
" This creates a range in the extent of bioavailability of 7-26%, the decrease of the percentages being due to a high first-pass metabolism."( Pharmacokinetic parameters of terbutaline in healthy man. An overview.
Nyberg, L, 1984
)
0.56
"The bioavailability of three different theophylline tablets (microcrystallinic theophylline, Theolair, Nuelin, 3M Riker), choline theophyllinate as a new film-coated tablet (Teovent, Ferrosan, Sweden) and theophyllaminopropanol (Oxyphylline, Draco, Sweden) was investigated in eight adult asthmatics and a randomized, double-blind, cross-over study."( Bioavailability of theophylline from three different tablets in asthmatic patients and their bronchodilating effects in combination with terbutaline inhalation.
Mellstrand, T; Svedmyr, K; Svedmyr, N, 1982
)
0.47
" The absolute bioavailability is calculated at 10%."( Pharmacokinetics of terbutaline, a beta 2-sympathomimetic, in healthy volunteers and asthmatic patients.
Kreukniet, J; Leferink, JG; Maes, RA; van den Berg, W; Wagemaker-Engels, I, 1982
)
0.59
"To study the pharmacokinetics and bioavailability of the prodrug bambuterol and its bronchodilator moiety terbutaline in healthy subjects."( Pharmacokinetics of bambuterol in healthy subjects.
Jönsson, S; Kennedy, BM; Nilsson, M; Nyberg, L; Rosenborg, J; Weibull, E, 1998
)
0.51
" Generated terbutaline had a bioavailability of 36% (28-46) after intravenous and 10."( Pharmacokinetics of bambuterol in healthy subjects.
Jönsson, S; Kennedy, BM; Nilsson, M; Nyberg, L; Rosenborg, J; Weibull, E, 1998
)
0.69
"For inhaled formulations of a drug substance, the balance between desired local activity and undesired systemic activity can be expressed with an L:T ratio, where L stands for the local bioavailability and T stands for the total systemic bioavailability."( Local versus total systemic bioavailability as a means to compare different inhaled formulations of the same substance.
Borgström, L, 1998
)
0.3
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
" Bioavailability following oral administration was < 1%."( Pharmacokinetics and pharmacodynamics of terbutaline in healthy horses.
Appelgren, LE; Ingvast-Larsson, JC; Johansson, JM; Törneke, MK, 2000
)
0.57
" The steady-state concentration of TS was relatively consistent and the bioavailability was approximately 50% higher in pH 5 formulations than pH 10."( Evaluation of carboxymethyl guar films for the formulation of transdermal therapeutic systems.
Hiremath, SR; Narasimha Murthy, S; Paranjothy, KL, 2004
)
0.32
" The proposed method enables the unambiguous identification and quantification of tulobuterol for pharmacokinetic, bioavailability or bioequivalence studies."( High-performance liquid chromatography electrospray ionization mass spectrometry determination of tulobuterol in rabbit's plasma.
Gong, G; Jiao, H; Liang, J; Tian, Y; Xu, F; Zhang, Z, 2005
)
0.33
"The impact of intestinal conjugative metabolism on oral bioavailability was assessed by sequential and simultaneous analyses of the reported data in humans."( Differentiation of organ availability by sequential and simultaneous analyses: intestinal conjugative metabolism impacts on intestinal availability in humans.
Hayashi, M; Kawashima, K; Mizuma, T; Sakaguchi, S; Sakai, S, 2005
)
0.33
" Plasma concentrations found with terbutaline and metoprolol are presented showing that terbutaline has its best uptake in the upper small intestine, whereas metoprolol shows the same bioavailability along the whole gut."( A convenient method for local drug administration at predefined sites in the entire gastrointestinal tract: experiences from 13 phase I studies.
Abrahamsson, B; Borgå, O; Månsson, W; Nyberg, L; Seidegård, J, 2007
)
0.62
" These "in combo" PAMPA data were used to predict the human absolute bioavailability of the ampholytes."( The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
Avdeef, A; Sun, N; Tam, KY; Tsinman, O, 2010
)
0.36
" The relative lung and systemic bioavailability of terbutaline from Bricanyl Turbuhaler when used by healthy subjects and COPD patients were determined after one and two inhalations at slow and fast inhalation flows using a novel urinary terbutaline pharmacokinetic method."( Emitted dose and lung deposition of inhaled terbutaline from Turbuhaler at different conditions.
Abdelrahim, ME, 2010
)
0.87
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
"The aim of the study was to determine the relative lung and systemic bioavailability of terbutaline."( Relative bioavailability of terbutaline to the lung following inhalation, using urinary excretion.
Abdelrahim, ME; Assi, KH; Chrystyn, H, 2011
)
0.89
" This urinary pharmacokinetic method to identity relative lung and systemic bioavailability between two nebuliser systems was easy to perform and is a useful and simple in vivo method to compare different nebulisers in patients receiving non-invasive ventilation."( The relative lung and systemic bioavailability of terbutaline following nebulisation in non-invasively ventilated patients.
Abdelrahim, ME; Chrystyn, H; Plant, PK, 2011
)
0.62
" The film formula of choice gave a significantly faster drug absorption rate and recorded a relative bioavailability of 204."( Fast-dissolving sublingual films of terbutaline sulfate: formulation and in vitro/in vivo evaluation.
El-Milligi, MF; Ibrahim, HK; Mohamed, MI; Sayed, S, 2013
)
0.66
" The bioavailability of R-enantiomer and racemate were comparative and relatively high in beagle dogs."( Comparative pharmacokinetics and bile transformation of R-enantiomer and racemic bambuterol after single-dose intravenous, oral administration in rats and beagle dogs.
Chen, JD; Guan, S; He, MY; Hu, CY; Huang, LJ; Tan, W; Tang, YX; Yang, YY, 2015
)
0.42
"The present work aimed to improve the bioavailability of terbutaline sulphate (TS) and to prolong its nasal residence time for the treatment of asthma."( Novel lipid-polymer hybrid nanoparticles incorporated in thermosensitive in situ gel for intranasal delivery of terbutaline sulphate.
Mohamed, S; Nasr, M; Refai, H; Salama, A, 2020
)
1.01

Dosage Studied

Inhaled terbutaline in the dosage given did not cause hypoxia in patients with severe chronic airflow obstruction. Nebulizer and Nebuhaler use was associated with a rise in SaO2 related to increased ventilation whilst breathing through a mouthpiece.

ExcerptRelevanceReference
" The importance of commencing clinical evaluation of bronchodilators with a dose-response test is stressed."( Cumulative dose-response curves for early evaluation of bronchodilator drugs.
Larsson, S; Svedmyr, N, 1978
)
0.26
" The receptors were tested by infusion of increasing doses of isoprenaline, so that dose-response curves for isoprenaline were recorded."( Lack of bronchial beta adrenoceptor resistance in asthmatics during long-term treatment with terbutaline.
Larsson, S; Svedmyr, N; Thiringer, G, 1977
)
0.48
" These were reduced by terbutaline (1 and 10 nmol) which produced a significant shift in the histamine dose-response lines to lower absorbance values."( Beta-adrenoceptor mediated inhibition by terbutaline of histamine effects on vascular permeability.
O'Donnell, SR; Persson, CG, 1978
)
0.83
"4 microgram/ml after two weeks of continuous dosing with the combination drug."( A comparison of a theophylline-ephedrine combination with terbutaline.
Alcala, JC; Bush, RK; Lee, TP; Smith, AM; Welling, PG, 1978
)
0.5
"50 mg terbutaline aerosol used on a regular dosage schedule over a six-week period."( Aerosolized terbutaline sulfate--an evalution of efficacy and side effects in patients with reversible airway disease.
Allegra, J; Gillin, M; Trautlein, J, 1977
)
1.12
" No significant side effects were encountered with this dosage and route of administration."( A comparison of the bronchodilator effects of the same amounts of terbutaline aerosol given as a single or in divided doses.
Dulfano, MJ; Glass, P; McPhillips, JJ, 1977
)
0.49
"25 mg/puff) when administered as metered aerosol in a dosage of one puff followed by two puffs 30 min later produced the same maximum improvement of ventilatory function."( Hexoprenaline and terbutaline administered by inhalation. A comparison between two beta2-adrenoreceptor agonists with respect to effect on bronchial obstruction, heart rate, blood pressure and muscle tremor.
Hörnblad, Y; Leideman, T; Ripe, E, 1978
)
0.59
" Dose-response curves were compared for terbutaline from a metered-dose aerosol, and pressure nebulized with and without intermittent positive pressure breathing (IPPB)."( Aerosolized terbutaline in asthmatics. Comparison of dosage strength, schedule, and method of administration.
Nelson, HS; Petty, WE; Weber, RW, 1979
)
0.91
" Sublingual isoproterenol (Isuprel) has been effective in a few cases but the every-two-hour dosage schedule is inconvenient on a long-term basis."( Primary pulmonary hypertension. Responses to indomethacin, terbutaline, and isoproterenol.
Person, B; Proctor, RJ, 1979
)
0.5
" In the dosage used an increase in maternal and fetal heart rate was observed, more frequently in the patients receiving salbutamol compared with those receiving terbutaline."( The effect of salbutamol and terbutaline in the management of premature labour.
Rydén, G, 1977
)
0.74
" Reproduceable responses sufficient for calculating dose-response curves, could be obtained up to 30 h after death."( Physiological and pharmacological studies on isolated human bronchial preparations.
Berlin, E; Boe, J; Thulesius, O, 1978
)
0.26
"A dose-response study of terbutaline nebulizer solution has been performed in nine convalescent asthmatic patients."( Terbutaline sulphate nebulizer solution: a dose-response study.
Birrell, DJ; Clarke, CW; May, CS, 1978
)
2
" Overall analysis of results did not indicate a definite dose-response dependency within the aerosol and oral routes at the tested dosages, whereas the incidence of side effects was clearly dose-dependent."( The bronchodilator effects of terbutaline: route of administration and patterns of response.
Dulfano, MJ; Glass, P, 1976
)
0.54
" Dose-response curves for both drugs for FEV, heart rate, blood pressure, and tremor were recorded."( Comparison of intravenous ibuterol (KWD 2058), a new bronchodilator, and terbutaline.
Larsson, S; Svedmyr, N, 1977
)
0.49
" For all parameters studied the four compounds produced similar maximal responses and dose-response curves were close to parallel."( Comparison of the effects of (--)-isoprenaline, orciprenaline terbutaline, and Me506 on heart rate, soleus muscle contractility and pulmonary resistance of anaesthetized cats.
Malta, E; Raper, C,
)
0.37
"Changes in bath temperature caused changes in the adrenergic responsiveness of rabbit iris dilator muscle as indicated by shifts in dose-response curves along the log axis and changes in maximum responses."( Role of neuronal and extraneuronal factors in temperature mediated responsiveness of adrenoceptors.
Ahlquist, RP; Matheny, JL, 1976
)
0.26
" The dose-response curves obtained during infusions of beta-adrenergic-stimulating drugs are linearly related to the dose given and are highly reproducible."( Evaluation of skeletal muscle tremor due to bronchodilator agents.
Svedmyr, N; Thiringer, G, 1975
)
0.25
"Complete in vitro dose-response curves for (see article) -isoproterenol (isoprenaline) sulfate showed no functional defects in bronchial muscular beta-adrenergic receptors in three patients with chronic intrinsic asthma, as compared to 60 patients with normal pulmonary function."( Development of "resistance" in beta-adrenergic receptors of asthmatic patients.
Larsson, SA; Svedmyr, NL; Thiringer, GK, 1976
)
0.26
" Tachycardia is a side effect which limits dosage in a few patients only."( Comparison of infused and inhaled terbutaline in patients with asthma.
Svedmyr, N; Thiringer, G, 1976
)
0.53
" Compared with those of normal rats, dose-response curves in cirrhotic rats indicated significantly decreased reactivity in arterial pressure and heart rate."( Hemodynamic effects of terbutaline, a beta 2-adrenoceptor agonist, in conscious rats with secondary biliary cirrhosis.
Braillon, A; Gaudin, C; Hadengue, A; Lebrec, D; Poo, JL, 1992
)
0.59
" beta 1-PAA was demonstrated with carteolol by dose-related increases in resting heart rate and systolic blood pressure, and a plateau in the dose-response curve for attenuation of exercise tachycardia."( Evaluation of in vivo partial beta 1/beta 2-agonist activity: a dose-ranging study with carteolol.
Lipworth, BJ; McDevitt, DG; Wheeldon, NM, 1992
)
0.28
"Between 26 and 32 weeks' gestation, a single dosage of indomethacin or terbutaline increases fetal breathing movements by 103% and 78%, respectively."( The effect of tocolytic agents (indomethacin and terbutaline) on fetal breathing and body movements: a prospective, randomized, double-blind, placebo-controlled clinical trial.
Cotton, DB; Dorman, KF; Hallak, M; Lira, N; Moise, K; Smith, EO, 1992
)
0.77
"Reversed-phase high-performance liquid chromatography (RP-HPLC), isotachophoresis (ITP) and capillary zone electrophoresis (CZE) were applied to the determination of salbutamol, terbutaline sulphate and fenoterol hydrobromide in commercially available pharmaceutical dosage forms."( Comparison of isotachophoresis, capillary zone electrophoresis and high-performance liquid chromatography for the determination of salbutamol, terbutaline sulphate and fenoterol hydrobromide in pharmaceutical dosage forms.
Ackermans, MT; Beckers, JL; Everaerts, FM; Seelen, IG, 1992
)
0.68
" The above data suggest terbutaline inhalation therapy at the dosage noted will have early onset of action and better early clinical improvement than the traditional epinephrine injection regimen."( [A comparative study of epinephrine injection and beta 2-agonist inhalation in the treatment of childhood asthma].
Liao, MH; Ting, CK,
)
0.44
" During the high dosing the secretion rate of parotid saliva decreased and the concentrations of its total protein, amylase, hexosamine and the ratio of hexosamine/total protein were lowered."( Saliva composition in asthmatic patients after treatment with two dose levels of a beta 2-adrenoceptor agonist.
Ericson, T; Möller, C; Ryberg, M, 1990
)
0.28
"Our study investigated the differential effects of continuous or unequal day-night terbutaline dosing on circadian bronchial patency, heart rate, and arterial pressure in severe acute asthma."( Unequal day-night terbutaline i.v. dosing in acute severe asthma: effect on nocturnal bronchial patency, heart rate, and arterial pressure.
Arnaud, A; Bruguerolle, B; Lagier, F; Leonardelli, M; Orlando, JP; Philip-Joet, F; Pierson, F; Reynaud, M; Vervloet, D, 1991
)
0.84
" To determine the effects of high dose terbutaline on the possible development of tolerance we have examined the influence on dose-response of regular nebulised terbutaline."( Regular nebulised terbutaline in chronic obstructive airways disease: dose-response studies fail to detect tolerance.
Pearson, SB; Teale, C, 1991
)
0.88
" The dose-response curves for these agonists were shifted slightly to the right when the amplitude of the twitch was increased up to twice its original size."( Dissociation constants and relative efficacies estimated from the functional antagonism of beta-adrenoceptor agonists on transmural stimulation in rat vas deferens.
Diaz-Toledo, A; Jurkiewicz, A, 1990
)
0.28
" This study emphasizes the need for individual dosing of inhaled bronchodilators."( The bronchodilator response from increasing doses of terbutaline inhaled from a multi-dose powder inhaler (Turbuhaler).
Persson, G; Wirén, JE, 1990
)
0.53
" The CR-formulation is easily swallowed and can be dosed twice daily."( Absolute bioavailability of terbutaline from a CR-granulate in asthmatic children.
Borgström, L; Fuglsang, G; Hertz, B; Holm, EB,
)
0.43
" Dose-response curves were constructed both for the autonomic agonists and the histamine-releasing agents."( Characterization of purified dog mastocytoma cells. Autonomic membrane receptors and pharmacologic modulation of histamine release.
Barnes, PJ; Gold, WM; Phillips, MJ, 1985
)
0.27
" Methacholine dose-response curves (10(-11) to 10(-7) mol iv) obtained at the conclusion of the experiments were similar among capsaicin, phosphoramidon, and control groups."( Tachykinins mediate bronchoconstriction elicited by isocapnic hyperpnea in guinea pigs.
Drazen, JM; Hernandez, C; Leff, AR; Ray, DW; Solway, J, 1989
)
0.28
" The dose-response curve for 0-10% CO2 was S-shaped."( Regulation of lung surfactant secretion by intracellular pH.
Chander, A, 1989
)
0.28
" Eight patients with extrinsic and 10 patients with intrinsic asthma deprived of oral bronchodilator treatment and corticosteroids for at least a week, and in a clinically stable condition, 10 patients with extrinsic rhinitis and on no treatment, as well as age and sex matched healthy control subjects showed almost identical dose-response relations for the inhibitory effect of intradermally injected terbutaline (0."( Equivalent inhibition by terbutaline of anti-human IgE skin responses in atopic and non-atopic subjects.
Grönneberg, R; Stålenheim, G; Strandberg, K; Zetterström, O, 1985
)
0.74
" Equipotent doses of terbutaline were selected from the comparison of separate cumulative dose-response curves for MDI and NEB."( Comparison of outpatient nebulized vs metered dose inhaler terbutaline in chronic airflow obstruction.
Copland, JM; McDonald, CF; Mestitz, H, 1989
)
0.84
" The pharmacokinetics of the two enantiomers of terbutaline, (+)T and (-)T, and the racemate (+/-)T, have been evaluated after single intravenous and oral dosage to six healthy volunteers."( Pharmacokinetic evaluation in man of terbutaline given as separate enantiomers and as the racemate.
Borgström, L; Jönsson, S; Lindberg, C; Nyberg, L; Paulson, J, 1989
)
0.81
"Thirteen children with asthma were treated with cumulative doses of terbutaline delivered as a pressurized aerosol and from a new multidose powder inhaler (Turbuhaler) in a randomized cross-over dose-response study."( Comparison of a new multidose powder inhaler with a pressurized aerosol in children with asthma.
Fuglsang, G; Pedersen, S, 1989
)
0.51
" Monotherapy with theophylline and terbutaline in a relatively low dosage achieved a good lung function improvement without severe side effects, as compared to placebo."( Combination therapy of theophylline and terbutaline as sustained-release preparations in patients with asthmatic bronchitis.
Fokkens, JK; Hamelink, MJ; Kreukniet, J; Maes, RA; van der Vet, AP; van Drost, RH, 1987
)
0.82
"In a group of ten patients with chronic asthmatic bronchitis, a good improvement of the lung function was achieved by a sustained-release terbutaline preparation (Bricanyl Retard) in a dosage of 5 mg twice daily."( Terbutaline sustained-release treatment during one week 5 mg b.i.d. compared to one week placebo: terbutaline plasma levels, c-AMP plasma levels, lung function and tremor measurement.
Drost, RH; Fokkens, JK; Hamelink, ML; Kreukniet, J; Maes, RA; van der Vet, AP, 1987
)
1.92
" The elevation of ODC caused by adrenergic stimulation was cyclic AMP-dependent, as evidenced by: direct measurement of cyclic AMP levels after isoproterenol administration; comparisons of the dose-response curve for stimulation of cyclic AMP with that of ODC; examination of the time course of effect on the two variables; stimulation of ODC by administration of cyclic AMP analogs; demonstration of identical kinetic mechanisms for ODC stimulation by dibutyryl-cyclic AMP and isoproterenol; and potentiation of the actions of isoproterenol on both cyclic AMP and ODC by RO-201724, a specific inhibitor of phosphodiesterase."( Beta-2 adrenergic control of ornithine decarboxylase activity in brain regions of the developing rat.
Morris, G; Slotkin, TA, 1985
)
0.27
" When chronic symptoms necessitate maintenance treatment, the frequency of dosing may become a deciding factor in the selection of a bronchodilator."( Tulobuterol in the management of obstructive airways disease in adults.
Patel, KR, 1985
)
0.27
" Biotransformations are determined by environmental or genetic factors and by the associated therapy and can change dramatically from one patient to another (interindividual variability) or for the same patient by multiple dosing (intra-individual variability)."( [Metabolism of beta-adrenergic substances. Therapeutic implications].
Brès, J; Bressolle, F; Clauzel, AM; Pistre, MC; Rachmat, H,
)
0.13
" The slow-release tablets were preferred by 15 of 18 children and their families when the effects, side effects and dosage were evaluated."( Terbutaline slow-release tablets in children with asthma. A comparison with t.i.d. beta 2-agonist therapy.
Croner, S; Gustafsson, M; Kjellman, NI; Säwedal, L, 1986
)
1.71
" The tulobuterol dosages were 30 and 40 mcg/kg twice daily; the terbutaline dosage was 75 mcg/kg three times daily."( Tulobuterol in childhood asthma: single dose ranging and repeated oral dose comparative studies.
Javier, MA; Noche, ML, 1986
)
0.51
" The isoproterenol-induced potentiation of the [3H]prostaglandin D2 binding gave a bell-shaped dose-response relationship (maximum response at 3 X 10(-8) M) in a stereospecific manner."( Beta 2-adrenergic regulation of prostaglandin D2 receptor in rabbit platelets.
Hanasaki, K; Ichikawa, A; Ikeda, M; Mizuno, Y; Shimonishi, M; Tomita, K; Yoshimura, S, 1987
)
0.27
" Dose-response curves were plotted upon the inhalation of salbutamol in two-week intervals in patients treated with betamimetics."( Development of drug tachyphylaxis in asthmatic patients treated with beta-adrenergic drugs.
Böszörményi-Nagy, G; Debreczeni, LA; Herjavecz, I; Szeitz, A, 1987
)
0.27
" Twice daily doses (50 mg/kg body wt) of the non-selective beta-adrenergic agonist, isoproterenol, for six days, increased Ca-ATPase specific activity of parotid gland by 17 per cent but that of submandibular gland was the same as controls; with dobutamine, the same dosage caused a 53 per cent decrease in submandibular activity and a 31 per cent decrease in parotid."( Ca-ATPase activity in salivary glands of rats treated with reserpine, isoproterenol, terbutaline or dobutamine.
Cheung, H; Schneyer, CA, 1987
)
0.5
" Initial findings from studies of unequal (morning versus evening) BID dosing schedules--more theophylline or terbutaline before bed-time than arising--reveal a better therapeutic advantage relative to equal BID dosing schedules for those patients with predominantly nocturnal symptoms."( Chronobiology and asthma. II. Body-time-dependent differences in the kinetics and effects of bronchodilator medications.
McGovern, JP; Reinberg, A; Scott, PH; Smolensky, MH, 1987
)
0.48
" The animals were sacrificed 20 hrs after the last drug dosage and the lung membrane homogenates were prepared for 3H-dihydroalprenolol (3H-DHA) binding in vitro."( Concomitant glucocorticoid treatment prevents the development of beta-adrenoceptor desensitization in the guinea pig lung.
Salonen, RO, 1985
)
0.27
", increase in cell size but not cell number was observed; moreover, the same dosage effected an increase in DNA of parotid but not submandibular gland."( Growth of rat salivary glands after terbutaline or dobutamine.
Schneyer, CA, 1986
)
0.55
" Inhaled terbutaline in the dosage given did not cause hypoxia in patients with severe chronic airflow obstruction, but nebulizer and Nebuhaler use was associated with a rise in SaO2 related to increased ventilation whilst breathing through a mouthpiece."( Changes in blood gas levels after nebuhaler and nebulizer administration of terbutaline in severe chronic airway obstruction.
Chadwick, GA; Cookson, WO; Higgins, RM,
)
0.78
" Pretreatment of exercise-induced asthma is most efficient by inhaled beta 2-agonist; orally dosed beta 2-agonist is not as efficient as inhaled beta 2-agonist in the pretreatment of exercise-induced asthma."( Exercise and the asthmatic.
Bundgaard, A,
)
0.13
" To investigate whether a shift in localization of the bronchodilator effect occurs when terbutaline is inhaled repeatedly, dose-response curves with terbutaline were performed for parameters derived from MEFV curves when breathing air and for density dependence of expiratory airflow."( Effects of terbutaline and atenolol on large and small airways in asthmatic patients.
Folgering, HT; Lammers, JW; Müller, ME; van Herwaarden, CL, 1988
)
0.89
" Total daily drug dosage remained exceptionally low (less than 3 mg/24 hours)."( Use of the subcutaneous terbutaline pump for long-term tocolysis.
Gill, P; Katz, M; Kitzmiller, JL; Lam, F; Smith, M, 1988
)
0.58
" It can be concluded that no dosage adjustment is necessary when terbutaline and theophylline are given together."( Theophylline-terbutaline, a steady state study on possible pharmacokinetic interactions with special reference to chronopharmacokinetic aspects.
Borgström, L; de Noord, OE; Jonkman, JH; van der Boon, WJ, 1988
)
0.88
" Terbutaline in the chosen dosage slightly decreased diastolic blood pressure and did not increase heart rate."( Beta-adrenoceptor stimulating and blocking agents in essential hypertension: single and combined therapy with terbutaline and metoprolol.
Gotzen, R; Meyer-Sabellek, W; Röcker, L; Schulte, KL; Thiede, HM, 1987
)
1.4
" For each agent tested in this study, dose-response curves were established."( Micturition in the unanesthetized rat: spinal vs. peripheral pharmacology of the adrenergic system.
Durant, PA; Lucas, PC; Yaksh, TL, 1988
)
0.27
" An oral 50 gm, 1-hour glucose challenge test was done 48 hours after terbutaline dosing began."( Carbohydrate intolerance in patients receiving oral tocolytics.
Angel, JL; Knuppel, RA; Morales, WJ; O'Brien, WF; Sims, CJ, 1988
)
0.51
"A liquid chromatographic method with electrochemical detection has been developed for the determination of terbutaline sulfate in dosage forms."( Determination of terbutaline sulfate in dosage forms by liquid chromatography with electrochemical detection.
Childress, WL,
)
0.68
"A colorimetric method is proposed for determination of terbutaline sulfate, orciprenaline sulfate, and their dosage forms."( Colorimetric determination of terbutaline sulfate and orciprenaline sulfate via nitrosation and difference spectrophotometry.
Abdel Latef, HE; Aboul Khier, AA; el-Sadek, ME,
)
0.67
" Responses were dose-related by both methods and the log dose-response lines were parallel."( A dose-response study of inhaled terbutaline administered via Nebuhaler or nebuliser to asthmatic children.
Blackhall, MI; O'Donnell, SR, 1987
)
0.55
" Tocolytic dosage was adjusted to maintain mean uterine contraction frequency of less than 4/hr."( Detection of preterm labor by ambulatory monitoring of uterine activity for the management of oral tocolysis.
Gill, PJ; Katz, M; Newman, RB, 1986
)
0.27
" Then after a further 3 wk of dosing 3 times a day of the second medication (10 patients received each medication), they were challenged once more 16 h after the last dose."( Comparison of tremor responses to orally administered albuterol and terbutaline.
Druz, WS; Jenne, JW; Shaughnessy, TK; Starkey, PW; Valcarenghi, G; Yu, C, 1986
)
0.51
"Plasma levels and elimination half-life of tulobuterol, a new beta-adrenergic agonist, were determined in ten healthy male volunteers after repeated dosing with 2 mg, twice daily, for seven days."( Pharmacokinetics of the bronchodilator tulobuterol in man after repeated oral doses.
Chasseaud, LF; Wood, SG, 1986
)
0.27
" The dosing was repeated after delivery."( Pharmacokinetics of terbutaline during pregnancy.
Grahnén, A; Lindberg, B; Lindström, B; Lönnerholm, G; Lyrenäs, S, 1986
)
0.59
" In this single blind placebo controlled study in six healthy male volunteers, we have compared the effects of chronic dosing with either oral terbutaline (5 mg three times daily for two weeks) or placebo on a number of these responses produced by an intravenous infusion of terbutaline (6 micrograms per kilogram over 1 hour)."( Downgrading of biochemical and cardiovascular responses to an intravenous infusion of terbutaline following chronic treatment with oral terbutaline.
Kendall, MJ; Smith, SR, 1986
)
0.7
" These findings imply possible therapeutic advantages of oral albuterol and terbutaline with respect to dosing frequency, while the more rapid onset of oral metaproterenol suggests that it may have an advantage when used on an as-needed basis."( Comparison of the acute cardiopulmonary effects of oral albuterol, metaproterenol, and terbutaline in asthmatics.
Biedermann, AA; Chu, TJ; Wolfe, JD; Yamate, M, 1985
)
0.72
" The dose-response curves of terbutaline on isolated tracheae of actively sensitized guinea pigs were significantly shifted to the right in comparison with control trachea (ED50 11."( Mechanical and biochemical alterations in guinea-pig tracheae caused by sensitisation.
Beier, W; Feddersen, C; Kaukel, E; Koppermann, G; Schrum, C, 1984
)
0.56
" After the terbutaline dose-response curve was determined, terbutaline was inhaled three times in increasing doses."( Pafenolol, a highly selective beta 1-adrenoceptor-antagonist, in asthmatic patients: interaction with terbutaline.
Löfdahl, CG; Marlin, GE; Svedmyr, N, 1983
)
0.87
" Using three beta-adrenoceptor agonists: terbutaline (beta 2), dobutamine (beta 1), and isoprenaline and monitoring atenolol's antagonism of the agonist effects on heart rate, airway elastance and soleus muscle tension, parallel shifts in dose-response curves for each agonist were observed on each parameter."( The determination of beta-adrenoceptor antagonist cardioselectivity "in vivo": atenolol in anaesthetized cats.
Kiyingi, KS; Temple, DM, 1983
)
0.53
" Preincubation with cocaine, 10(-5) M, shifted the inhibitory dose-response curves of Iso and Orc to the left, 16."( Mechanism of action of isoprenaline, isoxuprine, terbutaline and orciprenaline on gravid human isolated myometrium. Influence of the neuronal uptake process.
Calixto, JB; Simas, CM, 1984
)
0.52
" Terbutaline (TER) (10, 20, or 40 microgram/kg intravenously) shifted dose dependently the airways MeCh dose-response curves to the right, with minor stimulation of the heart."( Actions of theophylline, terbutaline, and ipratropium bromide alone and in combinations on the methacholine induced bronchoconstriction in rats.
Edholm, LE; Mattila, MJ; Salonen, RO, 1982
)
1.48
" 3) The action of c-AMP related substances on the circulatory systems was manifested as the dose-response of beta 1 action to the maternal blood pressure, maternal and fetal heart rate."( [Beta 1-, beta 2-effects of ritrodine and terbutaline in the treatment of preterm labor (author's transl)].
Chimura, T; Inoue, K; Mitsui, T, 1981
)
0.53
" Inhaled beta-2-agonists were found to give better protection against EIA than intramuscular dosed beta-2-agonists."( Exercise-induced asthma - laboratory observations.
Bundgaard, A, 1983
)
0.27
" The rate of this chemical reaction for the three drugs correlated with the amount of the tetrahydroquinolines formed by incubation with the soluble fraction and in orally dosed rats."( The formaldehyde-donating activity of N5,N10-methylene tetrahydrofolic acid in xenobiotic biotransformation.
Kucharczyk, N; Sofia, RD; Wong, KK; Yang, JT, 1984
)
0.27
" When the dosage of dobutamine was increased to 200 micrograms ."( Effects of adrenergic agonists on electrolyte transport in perfused salivary duct of rat.
Jirakulsomchok, D; Schneyer, CA, 1984
)
0.27
" A dose-response study with inhaled terbutaline in six patients before and after 4 weeks of nebulizer treatment showed no evidence of a decline in response."( Home nebulizers in severe chronic asthma.
Davies, D; Macfarlane, J; McGivern, DV; Revill, S; Sechiari, A; Ward, M, 1984
)
0.54
" From these studies it is concluded that the main advantage with the SR tablets is the twice-daily dosage regimen."( Pharmacokinetics of terbutaline given in slow-release tablets.
Kennedy, BM; Nyberg, L, 1984
)
0.59
"The erythrocyte: plasma concentration ratio of terbutaline was measured in 3 healthy volunteers during and after a steady-state dosing interval."( Pharmacokinetic implications of slow equilibration of terbutaline between plasma and erythrocytes.
Borgå, O; Lindberg, C, 1984
)
0.77
"9) were observed at the beginning and end of the dosage interval."( Transfer of terbutaline into breast milk.
Boréus, LO; de Château, P; Lindberg, C; Lindström, B; Lönnerholm, G; Nyberg, L, 1984
)
0.65
" These results indicate that intravenous terbutaline infusion, at the dosage employed, produces beneficial hemodynamic effects without a deterioration of myocardial metabolism in patients with heart failure due to coronary artery disease."( Myocardial metabolic effects of intravenous terbutaline in patients with severe heart failure due to coronary artery disease.
Chow, MS; Lee, PK; Tse, TF; Wang, RY; Yu, DY,
)
0.66
" This study indicates that the bronchodilating effect of terbutaline administered via the spacer is dose-dependent at the first inhalation, and that succeeding inhalations show no dose-response effects."( Cumulative dose response study comparing clinical effects of two doses of terbutaline sulphate administered via a 750 ml spacer to asthmatic patients.
Franck, K; Laursen, LC; Munch, EP; Taudorf, E; Weeke, B, 1984
)
0.74
" Mg++ rich medium shifted the dose-response curve of terbutaline to the left and the pre-incubation with Mg++ increased the inhibitory effect of terbutaline on the tonic part of K-contracture."( [The pattern of spontaneous contraction and the effects of Mg++ and terbutaline on pregnant human myometrium].
Ikeda, M; Kawarabayashi, T; Nakano, H; Sugimori, H, 1984
)
0.75
"125 mg given intramuscularly, while this dosage elicited maximal bronchodilator effect."( Cardiovascular effects of intramuscular or inhaled terbutaline in asthmatics.
Buch, J; Bundgaard, A, 1984
)
0.52
" Both atenolol and metoprolol lowered resting heart rate and FEV1 significantly and produced a down- and rightward shift of the dose-response curves to infused terbutaline."( Cardioselectivity of atenolol and metoprolol. A study in asthmatic patients.
Löfdahl, CG; Svedmyr, N, 1981
)
0.46
" Fenoterol used at the dosage of 100 micrograms per puff (half the standard commercially available dose of 200 micrograms per puff) caused significantly more cardiac effects than terbutaline, as measured by the magnitude and duration of increases in heart rate, and the incidence of reported palpitations."( A comparative double-blind study of the bronchodilator effects and side effects of inhaled fenoterol and terbutaline administered in equipotent doses.
Costello, JF; Frame, MH; Gray, BJ, 1982
)
0.67
" After terbutaline inhalation there was a highly significant shift in the RHE dose-response curves to the right and a trend towards a linear increase in PD10RHE with increasing doses of terbutaline."( Inhibition of the bronchial response to respiratory heat exchange by increasing doses of terbutaline sulphate.
Hargreave, FE; Morris, M; O'Byrne, PM; Roberts, R, 1982
)
0.94
" Cumulative dose-response curves showed that further improvement occurred after each inhalation during TI but that there was significant improvement only after the first inhalation during TII."( Aerosolized terbutaline in asthmatics: development of subsensitivity with long-term administration.
Nelson, HS; Smith, JA; Weber, RW, 1982
)
0.64
"A low dosage combination of terbutaline plus guanethidine was applied topically to the eyes of rabbits with experimentally induced ocular hypertension, markedly lowering intraocular pressure."( Intraocular-pressure-lowering effect of low-dosage combination of guanethidine and terbutaline in rabbit.
Bellucci, R; Bonomi, L; Gamba, GC; Massa, F; Perfetti, S, 1983
)
0.78
"A sustained release preparation of terbutaline sulphate has been formulated (Bricanyl depot tablets) in order to extend the duration and accordingly change the dosage regimen to twice a day."( Terbutaline depot tablets in asthma. A clinical evaluation.
Bundgaard, A; Fagerström, PO; Taudorf, E; Weeke, B; Weeke, E, 1981
)
1.98
" All patients improved objectively and subjectively on these higher dosage regimens during both day and night."( High-dose inhaled terbutaline in the management of chronic severe asthma: comparison of wet nebulisation and tube-spacer delivery.
Cochrane, GM; Nowell, RV; Prior, JG, 1982
)
0.6
" Our findings suggest that the two effects have different dose-response relationships, with higher doses of adrenergic agonists needed to prevent EIA than to maintain bronchodilation."( Bronchodilation and inhibition of induced asthma by adrenergic agonists.
Beasley, PP; Eggleston, PA, 1981
)
0.26
" On the last day of each period a cumulative dose-response experiment with terbutaline in the doses 50, 100, 250 and 500 micrograms (cumulative dose 900 micrograms) was performed."( Influence of budesonide on the response to inhaled terbutaline in children with mild asthma.
Agertoft, L; Fuglsang, G; Pedersen, S; Vikre-Jørgensen, J, 1995
)
0.77
" The Cmax for evening vs morning dosing was 17."( Bambuterol in the treatment of asthma. A placebo-controlled comparison of once-daily morning vs evening administration.
D'Alonzo, GE; Feldman, S; Gnosspelius, Y; Karlsson, K; Smolensky, MH, 1995
)
0.29
"0% at a dosage of 1 nmol/kg)."( The effects of formoterol, a long-acting beta 2-adrenoceptor agonist, on mucociliary activity.
Khan, R; Lindberg, S; Runer, T, 1995
)
0.29
"Changes in beta 2-adrenoceptor function by chronic dosing of beta 2-mimetics and the possible influence of a single dose of prednisone have been studied as changes over time in the concentration-effect relationship of the beta 2-adrenoceptor agonist terbutaline."( Pharmacodynamic modelling of the drug-induced downregulation of a beta 2-adrenoceptor mediated response and lack of restoration of receptor function after a single high dose of prednisone.
Braat, MC; Jonkers, RE; Koopmans, RP; van Boxtel, CJ, 1995
)
0.47
" When selecting a 15-min pretreatment interval with equieffective anti-WFR doses from the first dose-response experiments (i."( Effects of local treatment with salmeterol and terbutaline on anti-IgE-induced wheal, flare, and late induration in human skin.
Grönneberg, R; Raud, J, 1996
)
0.55
"A transdermal dosage form of terbutaline may be useful to prevent nocturnal wheezing by providing prolonged duration of action."( Terbutaline transdermal delivery: preformulation studies and limitations of in-vitro predictive parameters.
Kasina, R; Mandal, T; Puranajoti, P; Tenjarla, S, 1996
)
2.03
" Dose-response effects of terbutaline were examined in adult type II cells."( Actin depolymerization is developmentally regulated in rat type II cells exposed to terbutaline.
Bhandari, V; Kresch, MJ; Lu, H; Pachter, J, 1997
)
0.82
" Bronchoconstrictor and bronchodilator responsiveness were assessed with cumulative dose-response curves, using histamine and terbutaline, respectively."( Lack of correlation between bronchoconstrictor response and bronchodilator response in a population-based study.
de Gooijer, A; Douma, WR; Koëter, GH; Postma, DS; Rijcken, B; Schouten, JP; Weiss, ST, 1997
)
0.5
"To study the dose-response effects of intravenous terbutaline on the cardiovascular and respiratory autonomic nervous regulation."( The dose-response effects of terbutaline on the variability, approximate entropy and fractal dimension of heart rate and blood pressure.
Jartti, TT; Kaila, TJ; Kuusela, TA; Tahvanainen, KU; Välimäki, IA, 1998
)
0.84
" The accuracy of dosing and the technically perfect use of devices are extremely important, especially when drugs with potential systemic side effects are administered."( Inhalation devices in childhood asthma.
Gács, E; Göndöcs, R; Jákly, A; Uhereczky, G, 1998
)
0.3
"Tachyphylaxis to bronchoprotection against methacholine challenge develops after 2 weeks of therapy with formoterol, a long-acting beta(2)-agonist, at all three dosage regimens that were tested."( Effects of treatment with formoterol on bronchoprotection against methacholine.
Aiken, T; Baker, R; Devlin, M; Hendrick, D; Lipworth, B; Tan, S, 1998
)
0.3
"The aim of this study was to investigate whether regular treatment with inhaled salmeterol modifies the dose-response curve to the inhaled short-acting beta2-agonist terbutaline or affects the concentration of nitric oxide (NO) in exhaled air of children with asthma."( Effect of salmeterol treatment on nitric oxide level in exhaled air and dose-response to terbutaline in children with mild asthma.
Agertoft, L; Fuglsang, G; Pedersen, S; Vikre-Jørgensen, J, 1998
)
0.72
" This method was applied, without any interferences from the excipients, to determine the drug in a tablet dosage form."( Determination of terbutaline based on oxidation by voltammetry.
Biryol, I; Ozkan, SA; Sentürk, Z; Uslu, B; Yilmaz, N, 1998
)
0.64
" The patients were randomly given subcutaneous epinephrine, 10 micrograms/kg (n = 28) or subcutaneous terbutaline at the same dosage (n = 26)."( [Comparison of the effect of subcutaneous injection of adrenaline and terbutaline in asthma crisis in infants].
Khaldi, F; Salem, N, 1998
)
0.75
" Opaque glucose base tablets were given at 4-hour intervals in the sulindac treatment arm to mimic the dosing interval in the terbutaline arm of the study."( A randomized double-blind study comparing the fetal effects of sulindac to terbutaline during the management of preterm labor.
Belfort, M; Dorman, K; Kramer, WB; Mayes, M; Moise, KJ; Saade, GR, 1999
)
0.74
" Airway relaxant dose-response curves were constructed to measure isometric tension after administration of terbutaline (concentration range, 10(-8) to 10(-4) M), diltiazem (concentration range, 3 x 10(-7) to 1 x 10(-4) M), and aminophylline (concentration range, 10(-7) to 10(-4) M)."( Differential bronchodilatory effects of terbutaline, diltiazem, and aminophylline in canine intraparenchymal airways.
Akhtar, S; Bosnjak, Z; Cheng, EY; Kampine, JP; Mazzeo, AJ, 1999
)
0.78
"To investigate dose proportionality, dosing frequency, and ethnic aspects of the pharmacokinetics of bambuterol in asthmatic children, and to discuss the relationship with previous observations in adults."( Pharmacokinetics of bambuterol during oral administration to asthmatic children.
Ahlström, H; Alvero, J; Alvero, R; Espos, R; Fajutrao, L; Herrera, J; Kjellman, B; Kubista, J; Laxmyr, L; Leviste, C; Meyer, P; Nyberg, L; Oldaeus, G; Olsson, H; Rosenborg, J; Siricururat, A; Vichyanond, P; Weibull, E; Wettrell, G; Wong, E, 1999
)
0.3
" Peak plasma concentrations and dosing interval area under curve (AUC) of bambuterol and the active metabolite terbutaline were assessed at steady state."( Pharmacokinetics of bambuterol during oral administration to asthmatic children.
Ahlström, H; Alvero, J; Alvero, R; Espos, R; Fajutrao, L; Herrera, J; Kjellman, B; Kubista, J; Laxmyr, L; Leviste, C; Meyer, P; Nyberg, L; Oldaeus, G; Olsson, H; Rosenborg, J; Siricururat, A; Vichyanond, P; Weibull, E; Wettrell, G; Wong, E, 1999
)
0.51
" Twice-daily dosing (2 x AUC(0,12 h)) could not be shown to differ from once-daily dosing (AUC(0,24 h)) in the preschool Caucasians."( Pharmacokinetics of bambuterol during oral administration to asthmatic children.
Ahlström, H; Alvero, J; Alvero, R; Espos, R; Fajutrao, L; Herrera, J; Kjellman, B; Kubista, J; Laxmyr, L; Leviste, C; Meyer, P; Nyberg, L; Oldaeus, G; Olsson, H; Rosenborg, J; Siricururat, A; Vichyanond, P; Weibull, E; Wettrell, G; Wong, E, 1999
)
0.3
" Dose-response curves were compared using an analysis of covariance."( Tolerance to beta-agonists during acute bronchoconstriction.
Aldridge, RE; Cowan, JO; Flannery, EM; Hancox, RJ; Herbison, GP; McLachlan, CR; Taylor, DR; Town, GI, 1999
)
0.3
" These data provide a potential mechanism to explain the paradoxical increase in asthma morbidity and mortality associated with the chronic use of scheduled dosing of short-acting beta-adrenergic agonists."( Beta-adrenergic modulation of human type-1/type-2 cytokine balance.
Agarwal, SK; Marshall, GD, 2000
)
0.31
" In five asthmatics a cumulative dose-response curve for terbutaline pMDI was obtained."( Influence of low temperature on bronchodilatation induced by terbutaline administered by metered dose or dry powder inhalers in asthmatics.
Ciscar, MA; Juan, G; Marín, J; Martí-Bonmatí, E; Morcillo, EJ; Ramón, M,
)
0.62
" The beta(2)AR polymorphism significantly affected the dose-response curves for terbutaline-induced inotropic and chronotropic responses: compared with WT individuals, subjects with the Thr164Ile receptor had substantial blunting in maximal increases in heart rate (WT, 29."( Blunted cardiac responses to receptor activation in subjects with Thr164Ile beta(2)-adrenoceptors.
Brodde, OE; Büscher, R; Dhein, S; Insel, PA; Radke, J; Tellkamp, R, 2001
)
0.54
" It has been applied to the determination of (S)-(+)-terbutaline and (R)-(-)-terbutaline in urine from a healthy volunteer dosed with racemic terbutaline sulfate."( Determination of terbutaline enantiomers in human urine by coupled achiral-chiral high-performance liquid chromatography with fluorescence detection.
Kim, HJ; Kim, JH; Kim, KH; Shin, SD, 2001
)
0.9
" Terbutaline concentration-effect relationships were studied before and after one week of dosing of terbutaline, with or without theophylline."( Prevention by theophylline of beta-2-receptor down regulation in healthy subjects.
Derks, MG; Koopmans, RP; Oosterhoff, E; Van Boxtel, CJ,
)
1.04
" Usually, oral dosage forms of beta 2-agonists have been used, but side effects such as palpitation and tremor have been reported because of excessive serum levels around Tmax."( [Development of transdermal formulation of tulobuterol for the treatment of bronchial asthma].
Kato, H; Nagata, O; Nakano, Y; Suzuki, T; Yamazaki, M, 2002
)
0.31
"There is a lack of information concerning analysis of terbutaline sulfate and quantification of its related substances particularly in the liquid dosage forms."( Determination of terbutaline sulfate and its degradation products in pharmaceutical formulations using LC.
Al-Omari, MM; Badwan, AA; Daraghmeh, N; Jaber, AM; Sara, Z, 2002
)
0.9
" Dose proportionality for terbutaline makes dosing with bambuterol predictable."( Clinical-pharmacokinetic aspects of prolonged effect duration as illustrated by beta2-agonists.
Rosenburg, J, 2002
)
0.61
" Because of its short biological half life and dosing schedule, a long acting TBS formulation is required to improve patient compliance."( Formulation and in vitro/in vivo evaluation of terbutaline sulphate incorporated in PLGA (25/75) and L-PLA microspheres.
Ercan, MT; Hincal, AA; Kas, HS; Sahin, S; Sargon, M; Selek, H,
)
0.39
" It has been applied to the determination of (S)-(+)terbutaline and (R)-(-)-terbutaline in urine from healthy volunteer dosed with racemic terbutaline sulfate."( Determination of terbutaline enantiomers in human urine by capillary electrophoresis using hydroxypropyl-beta-cyclodextrin as a chiral selector.
Jeun, EY; Kang, JS; Kim, HJ; Kim, KH; Mar, W; Seo, SH; Youm, JR, 2003
)
0.91
" From the results and observations of this work, it may be concluded that the mini-model air suspension coating instrument designed, may be a useful piece of equipment for preparing coated multiparticulate dosage forms in small quantities for sustained drug delivery, especially in research works."( Pellet coating by air suspension technique using a mini-model coating unit.
Ganesan, M; Jayakumar, M; Pal, TK, 2003
)
0.32
" Because the patient remained bradycardic on postoperative day 11 (HR 64 beats/min; mean 75), terbutaline was titrated to a dosage of 5 mg every 8 hours."( Terbutaline for chronotropic support in heart transplantation.
Coons, JC; Kormos, R; Schonder, K; Shullo, M, 2004
)
1.99
" The goal of this study is to evaluate the utility of weight-based subcutaneous terbutaline dosing to reduce plasma potassium concentrations in a group of subjects with chronic kidney disease (CKD) requiring hemodialysis."( Subcutaneous terbutaline use in CKD to reduce potassium concentrations.
Cronin, D; Kraus, MA; Mueller, BA; Sowinski, KM, 2005
)
0.92
" Long-term terbutaline treatment also desensitized venous Thr164Ile beta2-AR; after terbutaline treatment, dose-response curves for terbutaline-induced venodilation were superimposable in WT and Thr164Ile beta2-AR subjects."( Human beta2-adrenergic receptor gene haplotypes and venodilation in vivo.
Brodde, OE; Bruck, H; Heusch, G; Leineweber, K; Park, J; Philipp, T; Weber, M, 2005
)
0.72
" We carried out a dose-response analysis where rats were given 0-200 microg/kg body wt pSi-4, and alpha-ENaC mRNA and protein expressions were analyzed."( RNA interference for alpha-ENaC inhibits rat lung fluid absorption in vivo.
Folkesson, HG; Li, T, 2006
)
0.33
" We theorized that this lack of demonstrable benefit resulted from variations in dosing and titration, rather than the drug per se, and that intensive care unit (ICU) LOS would be shortened by the administration of terbutaline according to a protocol incorporating a quantitative assessment of severity of illness."( Protocol-based titration of intravenous terbutaline decreases length of stay in pediatric status asthmaticus.
Carroll, CL; Schramm, CM, 2006
)
0.79
"Transdermal beta 2-agonist tulobuterol showed an improvement in FEV1, FVC and IC after dosing compared with those at baseline."( Comparison of bronchodilatory properties of transdermal and inhaled long-acting beta 2-agonists.
Akamatsu, K; Hirano, T; Ichikawa, T; Ichinose, M; Matsunaga, K; Minakata, Y; Nakanishi, M; Sugiura, H; Ueshima, K; Yamagata, T; Yanagisawa, S, 2008
)
0.35
" At 10(-7) M of ST-91, the antagonism was characterized by a rightward shift of isoproterenol dose-response curve (A50=6."( alpha2B-adrenoceptor agonist ST-91 antagonizes beta2-adrenoceptor-mediated relaxation in rat mesenteric artery rings.
Gyires, K; Kató, E; Lipták, L; Mátyus, P; Rónai, AZ; Shujaa, N, 2008
)
0.35
" Dose-response curves were constructed for NE with and without the addition of the alpha-adrenergic antagonist prazosin, EPI (after 20%-30% preconstruction with the thromboxane analog U46619) with and without the addition of the beta-adrenergic antagonist propranolol, and NE in the presence of 10(-8) M EPI."( The effect of maternal catecholamines on the caliber of gravid uterine microvessels.
Segal, S; Wang, SY, 2008
)
0.35
" However, the preferred type of beta-adrenergic receptor agonist and dosage are unclear."( Acute tocolysis for uterine activity reduction in term labor: a review.
de Heus, R; Derks, JB; Mulder, EJ; Visser, GH, 2008
)
0.35
" The clinical condition scores, frequency of attacks and dosage of Terbutaline inhaled were scored and recorded on the first day of hospitalization (before treatment) and after treatment."( Effect of ligustrazine injection on levels of interleukin-4 and interferon-gamma in patients with bronchial asthma.
Che, XW; Wang, H; Wang, W; Zhang, Y, 2008
)
0.58
" The results from this study provide data that can be used for the preparative process monitoring of terbutaline hemisulphate, an important beta(2) agonist drug in various dosage forms and its interaction with excipients and other components."( Vibrational spectroscopic study of terbutaline hemisulphate.
Ali, HR; Edwards, HG; Kendrick, J; Scowen, IJ, 2009
)
0.85
" Our findings suggested that the initial dosage of theophylline should be adjusted according to the gender of pediatric patients and particularly in the case of infants."( Effect of gender on theophylline clearance in the asthmatic acute phase in Japanese pediatric patients.
Igarashi, T; Iwakawa, S, 2009
)
0.35
"Two simple, rapid, accurate and precise methods have been developed for simultaneous estimation of Montelukast sodium and Bambuterol hydrochloride from tablet dosage form."( Simultaneous estimation of Montelukast sodium and Bambuterol hydrochloride in tablets by spectrophotometry.
Kothapalli, LP; Nanda, RK; Pangarkar, VB; Pawar, AA; Thomas, AB,
)
0.13
"10 U kg(-1) inhaled human insulin was administered on each dosing day with or without prior administration of the bronchodilator terbutaline (in random order)."( The effect of terbutaline on the absorption of pulmonary administered insulin in subjects with asthma.
Köhler, G; Korsatko, S; Olschewski, H; Petersen, AH; Pieber, TR; Råstam, J; Sparre, T; Wollmer, P; Wutte, A, 2010
)
0.93
" Specifically, the results show that FGF10 haploinsufficiency affects lung function measures providing a model for a dosage sensitive effect of FGF10 in the development of COPD."( Fibroblast growth factor 10 haploinsufficiency causes chronic obstructive pulmonary disease.
Badhai, J; Bergendal, B; Blomstrand, P; Brange, CS; Brunmark, C; Dahl, N; Håkansson, HF; Klar, J, 2011
)
0.37
"Spectrophotometric and stability-indicating HPLC procedures are described for determination of terbutaline sulfate in bulk powder and dosage form."( Spectrophotometric and stability-indicating high-performance liquid chromatographic determinations of terbutaline sulfate.
Elmasry, MS; Hashem, HA; Hassan, WE; Jira, T; Tründelberg, C,
)
0.57
" Terbutaline is a β-2 agonist available in oral dosage form."( Oral terbutaline in replacement for intravenous dopamine in a patient with end-stage heart failure.
Cheng, JW; Miles, A; Shulan, A, 2013
)
1.81
" However, more research is needed to determine if dosage adjustment is warranted in patients with CKD."( Pharmacokinetics of terbutaline in chronic kidney disease.
Bastiansen, A; Eggert, S; Pedersen, E, 2013
)
0.71
" The main outcome was EIB 24 h after the last dosing of study medication."( Combination of budesonide/formoterol on demand improves asthma control by reducing exercise-induced bronchoconstriction.
Bjermer, L; Carlsen, KH; Dahlén, B; Ekström, T; Hedlin, G; Jørgensen, L; Larsson, K; Lazarinis, N; Pullerits, T, 2014
)
0.4
" After oral dosing of R-bambuterol, the AUCs of R-enantiomer presented linear correlation."( Comparative pharmacokinetics and bile transformation of R-enantiomer and racemic bambuterol after single-dose intravenous, oral administration in rats and beagle dogs.
Chen, JD; Guan, S; He, MY; Hu, CY; Huang, LJ; Tan, W; Tang, YX; Yang, YY, 2015
)
0.42
" The proposed method has been successfully applied to the analysis of BH in pharmaceutical dosage forms without interference from other dosage form additives and the results have been statistically compared with pharmacopeial method."( Application of a new spectrophotometric method manipulating ratio spectra for determination of bambuterol hydrochloride in the presence of its degradation product terbutaline.
Lamie, NT, 2015
)
0.61
" Bambuterol is a prodrug of β2-agonist commonly used for the treatment of asthma and chronic obstructive pulmonary disease (COPD) with the advantage of once daily dosing and favorable side effect profile."( The Lipid-lowering Effects of R-bambuterol in Healthy Chinese Volunteers: A Randomized Phase I Clinical Study.
Bu, S; Cheng, Q; Quan, L; Tan, W; Xu, H; Ye, Y; Zeng, J; Zhou, T; Zhu, L; Zou, C, 2015
)
0.42
" The proposed method is simple, accurate, reproducible and applied successfully to analyze three compounds in pure as well dosage form."( RP-HPLC-UV method development and validation for simultaneous determination of terbutaline sulphate, ambroxol HCl and guaifenesin in pure and dosage forms.
Itagimatha, N; Manjunatha, DH, 2019
)
0.74
"A novel, simple and sensitive spectrofluorimetric approach for determination of terbutaline sulphate (TER) and its prodrug bambuterol (BAM) in their pure and pharmaceutical dosage forms was developed."( Micelle-enhanced spectrofluorimetric method for the rapid determination of bronchodilator terbutaline and its prodrug bambuterol: application for content uniformity test.
Mohamed, AA; Mohamed, SK; Nour-Eldeen, DA; Omar, MA, 2022
)
1.17
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (7)

RoleDescription
beta-adrenergic agonistAn agent that selectively binds to and activates beta-adrenergic receptors.
EC 3.1.1.7 (acetylcholinesterase) inhibitorAn EC 3.1.1.* (carboxylic ester hydrolase) inhibitor that interferes with the action of enzyme acetylcholinesterase (EC 3.1.1.7), which helps breaking down of acetylcholine into choline and acetic acid.
anti-asthmatic drugA drug used to treat asthma.
bronchodilator agentAn agent that causes an increase in the expansion of a bronchus or bronchial tubes.
sympathomimetic agentA drug that mimics the effects of stimulating postganglionic adrenergic sympathetic nerves. Included in this class are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters.
tocolytic agentAny compound used to suppress premature labour and immature birth by suppressing uterine contractions.
hypoglycemic agentA drug which lowers the blood glucose level.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
phenylethanolaminesAn ethanolamine compound having a phenyl (substituted or unsubstituted) group on the carbon bearing the hydroxy substituent.
resorcinolsAny benzenediol in which the two hydroxy groups are meta to one another.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (15)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glp-1 receptor, partialHomo sapiens (human)Potency0.16360.01846.806014.1254AID624148
thioredoxin reductaseRattus norvegicus (Norway rat)Potency0.22390.100020.879379.4328AID588453
GLS proteinHomo sapiens (human)Potency7.94330.35487.935539.8107AID624146
arylsulfatase AHomo sapiens (human)Potency37.93301.069113.955137.9330AID720538
beta-2 adrenergic receptorHomo sapiens (human)Potency10.32250.00586.026332.6427AID485366
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency0.75690.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)134.00000.11007.190310.0000AID1443980; AID1473738
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Beta-2 adrenergic receptorHomo sapiens (human)EC50 (µMol)3.16230.00000.311110.0000AID606103
Beta-2 adrenergic receptorHomo sapiens (human)Kd68.42710.00000.62888.9130AID1798580; AID426242; AID770362
Beta-1 adrenergic receptorHomo sapiens (human)Kd101.38520.00010.803910.0000AID1798580
Beta-3 adrenergic receptorHomo sapiens (human)Kd101.38520.00010.76318.9130AID1798580
Beta-adrenergic receptor kinase 1Homo sapiens (human)Kd7.40000.17005.579122.4940AID1799821
Beta-2 adrenergic receptor Bos taurus (cattle)Kd3.98000.00061.47759.1200AID40694
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Beta-2 adrenergic receptor Bos taurus (cattle)Concentration1,000,000.00001.00005.500010.0000AID40688
Beta-2 adrenergic receptor Bos taurus (cattle)KD app4.48000.03701.17744.4800AID40687
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (100)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
diet induced thermogenesisBeta-2 adrenergic receptorHomo sapiens (human)
regulation of sodium ion transportBeta-2 adrenergic receptorHomo sapiens (human)
transcription by RNA polymerase IIBeta-2 adrenergic receptorHomo sapiens (human)
receptor-mediated endocytosisBeta-2 adrenergic receptorHomo sapiens (human)
smooth muscle contractionBeta-2 adrenergic receptorHomo sapiens (human)
cell surface receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
activation of transmembrane receptor protein tyrosine kinase activityBeta-2 adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
endosome to lysosome transportBeta-2 adrenergic receptorHomo sapiens (human)
response to coldBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of protein kinase A signalingBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of bone mineralizationBeta-2 adrenergic receptorHomo sapiens (human)
heat generationBeta-2 adrenergic receptorHomo sapiens (human)
negative regulation of multicellular organism growthBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeBeta-2 adrenergic receptorHomo sapiens (human)
bone resorptionBeta-2 adrenergic receptorHomo sapiens (human)
negative regulation of G protein-coupled receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIBeta-2 adrenergic receptorHomo sapiens (human)
negative regulation of smooth muscle contractionBeta-2 adrenergic receptorHomo sapiens (human)
brown fat cell differentiationBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of mini excitatory postsynaptic potentialBeta-2 adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of autophagosome maturationBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of lipophagyBeta-2 adrenergic receptorHomo sapiens (human)
cellular response to amyloid-betaBeta-2 adrenergic receptorHomo sapiens (human)
response to psychosocial stressBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of cAMP-dependent protein kinase activityBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of AMPA receptor activityBeta-2 adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressureBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of heart rate by epinephrine-norepinephrineBeta-1 adrenergic receptorHomo sapiens (human)
positive regulation of the force of heart contraction by epinephrine-norepinephrineBeta-1 adrenergic receptorHomo sapiens (human)
diet induced thermogenesisBeta-1 adrenergic receptorHomo sapiens (human)
response to coldBeta-1 adrenergic receptorHomo sapiens (human)
heat generationBeta-1 adrenergic receptorHomo sapiens (human)
negative regulation of multicellular organism growthBeta-1 adrenergic receptorHomo sapiens (human)
fear responseBeta-1 adrenergic receptorHomo sapiens (human)
regulation of circadian sleep/wake cycle, sleepBeta-1 adrenergic receptorHomo sapiens (human)
brown fat cell differentiationBeta-1 adrenergic receptorHomo sapiens (human)
regulation of postsynaptic membrane potentialBeta-1 adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-1 adrenergic receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisBeta-1 adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressureBeta-1 adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeBeta-1 adrenergic receptorHomo sapiens (human)
receptor-mediated endocytosisBeta-3 adrenergic receptorHomo sapiens (human)
negative regulation of G protein-coupled receptor signaling pathwayBeta-3 adrenergic receptorHomo sapiens (human)
diet induced thermogenesisBeta-3 adrenergic receptorHomo sapiens (human)
carbohydrate metabolic processBeta-3 adrenergic receptorHomo sapiens (human)
generation of precursor metabolites and energyBeta-3 adrenergic receptorHomo sapiens (human)
energy reserve metabolic processBeta-3 adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerBeta-3 adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayBeta-3 adrenergic receptorHomo sapiens (human)
response to coldBeta-3 adrenergic receptorHomo sapiens (human)
heat generationBeta-3 adrenergic receptorHomo sapiens (human)
negative regulation of multicellular organism growthBeta-3 adrenergic receptorHomo sapiens (human)
eating behaviorBeta-3 adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeBeta-3 adrenergic receptorHomo sapiens (human)
brown fat cell differentiationBeta-3 adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-3 adrenergic receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisBeta-3 adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressureBeta-3 adrenergic receptorHomo sapiens (human)
desensitization of G protein-coupled receptor signaling pathwayBeta-adrenergic receptor kinase 1Homo sapiens (human)
negative regulation of the force of heart contraction by chemical signalBeta-adrenergic receptor kinase 1Homo sapiens (human)
G protein-coupled receptor signaling pathwayBeta-adrenergic receptor kinase 1Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayBeta-adrenergic receptor kinase 1Homo sapiens (human)
tachykinin receptor signaling pathwayBeta-adrenergic receptor kinase 1Homo sapiens (human)
heart developmentBeta-adrenergic receptor kinase 1Homo sapiens (human)
peptidyl-serine phosphorylationBeta-adrenergic receptor kinase 1Homo sapiens (human)
viral genome replicationBeta-adrenergic receptor kinase 1Homo sapiens (human)
receptor internalizationBeta-adrenergic receptor kinase 1Homo sapiens (human)
positive regulation of catecholamine secretionBeta-adrenergic receptor kinase 1Homo sapiens (human)
negative regulation of striated muscle contractionBeta-adrenergic receptor kinase 1Homo sapiens (human)
symbiont entry into host cellBeta-adrenergic receptor kinase 1Homo sapiens (human)
cardiac muscle contractionBeta-adrenergic receptor kinase 1Homo sapiens (human)
negative regulation of relaxation of smooth muscleBeta-adrenergic receptor kinase 1Homo sapiens (human)
regulation of the force of heart contractionBeta-adrenergic receptor kinase 1Homo sapiens (human)
protein phosphorylationBeta-adrenergic receptor kinase 1Homo sapiens (human)
receptor-mediated endocytosisBeta-2 adrenergic receptor Bos taurus (cattle)
regulation of smooth muscle contractionBeta-2 adrenergic receptor Bos taurus (cattle)
positive regulation of MAPK cascadeBeta-2 adrenergic receptor Bos taurus (cattle)
negative regulation of G protein-coupled receptor signaling pathwayBeta-2 adrenergic receptor Bos taurus (cattle)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-2 adrenergic receptor Bos taurus (cattle)
positive regulation of autophagosome maturationBeta-2 adrenergic receptor Bos taurus (cattle)
positive regulation of lipophagyBeta-2 adrenergic receptor Bos taurus (cattle)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (46)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
amyloid-beta bindingBeta-2 adrenergic receptorHomo sapiens (human)
beta2-adrenergic receptor activityBeta-2 adrenergic receptorHomo sapiens (human)
protein bindingBeta-2 adrenergic receptorHomo sapiens (human)
adenylate cyclase bindingBeta-2 adrenergic receptorHomo sapiens (human)
potassium channel regulator activityBeta-2 adrenergic receptorHomo sapiens (human)
identical protein bindingBeta-2 adrenergic receptorHomo sapiens (human)
protein homodimerization activityBeta-2 adrenergic receptorHomo sapiens (human)
protein-containing complex bindingBeta-2 adrenergic receptorHomo sapiens (human)
norepinephrine bindingBeta-2 adrenergic receptorHomo sapiens (human)
beta-adrenergic receptor activityBeta-1 adrenergic receptorHomo sapiens (human)
beta1-adrenergic receptor activityBeta-1 adrenergic receptorHomo sapiens (human)
protein bindingBeta-1 adrenergic receptorHomo sapiens (human)
PDZ domain bindingBeta-1 adrenergic receptorHomo sapiens (human)
alpha-2A adrenergic receptor bindingBeta-1 adrenergic receptorHomo sapiens (human)
protein heterodimerization activityBeta-1 adrenergic receptorHomo sapiens (human)
G protein-coupled neurotransmitter receptor activity involved in regulation of postsynaptic membrane potentialBeta-1 adrenergic receptorHomo sapiens (human)
norepinephrine bindingBeta-3 adrenergic receptorHomo sapiens (human)
beta-adrenergic receptor activityBeta-3 adrenergic receptorHomo sapiens (human)
protein bindingBeta-3 adrenergic receptorHomo sapiens (human)
beta3-adrenergic receptor activityBeta-3 adrenergic receptorHomo sapiens (human)
beta-3 adrenergic receptor bindingBeta-3 adrenergic receptorHomo sapiens (human)
protein homodimerization activityBeta-3 adrenergic receptorHomo sapiens (human)
epinephrine bindingBeta-3 adrenergic receptorHomo sapiens (human)
protein kinase activityBeta-adrenergic receptor kinase 1Homo sapiens (human)
G protein-coupled receptor kinase activityBeta-adrenergic receptor kinase 1Homo sapiens (human)
protein bindingBeta-adrenergic receptor kinase 1Homo sapiens (human)
ATP bindingBeta-adrenergic receptor kinase 1Homo sapiens (human)
alpha-2A adrenergic receptor bindingBeta-adrenergic receptor kinase 1Homo sapiens (human)
Edg-2 lysophosphatidic acid receptor bindingBeta-adrenergic receptor kinase 1Homo sapiens (human)
beta-adrenergic receptor kinase activityBeta-adrenergic receptor kinase 1Homo sapiens (human)
G protein-coupled receptor bindingBeta-adrenergic receptor kinase 1Homo sapiens (human)
beta2-adrenergic receptor activityBeta-2 adrenergic receptor Bos taurus (cattle)
protein homodimerization activityBeta-2 adrenergic receptor Bos taurus (cattle)
norepinephrine bindingBeta-2 adrenergic receptor Bos taurus (cattle)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (30)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
nucleusBeta-2 adrenergic receptorHomo sapiens (human)
lysosomeBeta-2 adrenergic receptorHomo sapiens (human)
endosomeBeta-2 adrenergic receptorHomo sapiens (human)
early endosomeBeta-2 adrenergic receptorHomo sapiens (human)
Golgi apparatusBeta-2 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-2 adrenergic receptorHomo sapiens (human)
endosome membraneBeta-2 adrenergic receptorHomo sapiens (human)
membraneBeta-2 adrenergic receptorHomo sapiens (human)
apical plasma membraneBeta-2 adrenergic receptorHomo sapiens (human)
clathrin-coated endocytic vesicle membraneBeta-2 adrenergic receptorHomo sapiens (human)
neuronal dense core vesicleBeta-2 adrenergic receptorHomo sapiens (human)
receptor complexBeta-2 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-2 adrenergic receptorHomo sapiens (human)
early endosomeBeta-1 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-1 adrenergic receptorHomo sapiens (human)
Schaffer collateral - CA1 synapseBeta-1 adrenergic receptorHomo sapiens (human)
neuronal dense core vesicleBeta-1 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-1 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-3 adrenergic receptorHomo sapiens (human)
receptor complexBeta-3 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-3 adrenergic receptorHomo sapiens (human)
cytoplasmBeta-adrenergic receptor kinase 1Homo sapiens (human)
cytosolBeta-adrenergic receptor kinase 1Homo sapiens (human)
plasma membraneBeta-adrenergic receptor kinase 1Homo sapiens (human)
ciliumBeta-adrenergic receptor kinase 1Homo sapiens (human)
membraneBeta-adrenergic receptor kinase 1Homo sapiens (human)
presynapseBeta-adrenergic receptor kinase 1Homo sapiens (human)
postsynapseBeta-adrenergic receptor kinase 1Homo sapiens (human)
early endosomeBeta-2 adrenergic receptor Bos taurus (cattle)
Golgi apparatusBeta-2 adrenergic receptor Bos taurus (cattle)
receptor complexBeta-2 adrenergic receptor Bos taurus (cattle)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (177)

Assay IDTitleYearJournalArticle
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID28235Unbound fraction (plasma)2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID40687Apparent binding affinity constant to beta-2 adrenergic receptor determined using [3H]DHA1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Quantitative evaluation of the beta 2-adrenoceptor intrinsic activity of N-tert-butylphenylethanolamines.
AID236916Percentage of mass balance in hexadecane membranes model2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Exploring the role of different drug transport routes in permeability screening.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID310711Clearance in human2007Bioorganic & medicinal chemistry letters, Dec-15, Volume: 17, Issue:24
Design and synthesis of a functionally selective D3 agonist and its in vivo delivery via the intranasal route.
AID76656Compound was tested for effective dose required for 50% of maximum response in guinea pig trachea1981Journal of medicinal chemistry, May, Volume: 24, Issue:5
erythro-5-[1-Hydroxy-2-(isopropylamino)butyl]-7-hydroxycarbostyril, a terbutaline-type derivative of the bronchodilator procaterol.
AID496830Antimicrobial activity against Leishmania major2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496832Antimicrobial activity against Trypanosoma brucei rhodesiense2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID28924Effective permeability (Pe) across a hexadecane membrane (pH 6.8)2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID496824Antimicrobial activity against Toxoplasma gondii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID19419Partition coefficient (logD7.4)1998Journal of medicinal chemistry, Mar-26, Volume: 41, Issue:7
Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID496827Antimicrobial activity against Leishmania amazonensis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID40688Concentration required for maximal (95-100%) beta-2 adrenergic receptor occupancy1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Quantitative evaluation of the beta 2-adrenoceptor intrinsic activity of N-tert-butylphenylethanolamines.
AID24203Distribution coefficient in octanol/water at pH 6.51998Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID218848Change in Gibb's free energy at Low affinity beta-2-adrenoceptor in the Chang living cells1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Mapping of the beta 2-adrenoceptor on Chang liver cells. Differences between high- and low-affinity receptor states.
AID77607Intrinsic activity in guinea pig trachea1981Journal of medicinal chemistry, May, Volume: 24, Issue:5
erythro-5-[1-Hydroxy-2-(isopropylamino)butyl]-7-hydroxycarbostyril, a terbutaline-type derivative of the bronchodilator procaterol.
AID236268Fraction absorbed in human intestine after oral administration compound was measured2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Exploring the role of different drug transport routes in permeability screening.
AID28925Highest effective permeability across hexadecane membrane (pH 4-8)2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID481439Absolute bioavailability in human2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID592681Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
QSAR-based permeability model for drug-like compounds.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID29423HPLC capacity factor (k')2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID24448Partition coefficient value and its ionic species.1998Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach.
AID455986Permeability across human Caco-2 cells2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
AID1873863Displacement of [3H]-CGP12,177 from immobilized Halo tag-fused beta2 adrenoceptor (unknown origin) expressed in Escherichia coli BL21 (DE3)
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID592684Apparent permeability of the compound by PAMPA2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
In vitro characterization of human peptide transporter hPEPT1 interactions and passive permeation studies of short cationic antimicrobial peptides.
AID28234% absorbed in human GI-tract2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID481440Dissociation constant, pKa of the compound2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID24177log(1/ISA) value of the compound1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Quantitative evaluation of the beta 2-adrenoceptor intrinsic activity of N-tert-butylphenylethanolamines.
AID40690Beta-2 adrenergic receptor intrinsic symphaticomimetic activity relative to salbutamol1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Quantitative evaluation of the beta 2-adrenoceptor intrinsic activity of N-tert-butylphenylethanolamines.
AID20050Human absorption A (%)1998Journal of medicinal chemistry, Mar-26, Volume: 41, Issue:7
Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID496823Antimicrobial activity against Trichomonas vaginalis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID497005Antimicrobial activity against Pneumocystis carinii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID26576pKa value of the compound. (extrapolated values)1998Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID156203Binding to POPC/GMI liposomes using biosensor system2000Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11
SPR biosensor studies of the direct interaction between 27 drugs and a liposome surface: correlation with fraction absorbed in humans.
AID1443980Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch2010Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID496825Antimicrobial activity against Leishmania mexicana2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID26304Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1564541Permeability across apical side to basolateral side in human Caco2 cells at 30 uM after 4 hrs by HPLC analysis2019European journal of medicinal chemistry, Nov-01, Volume: 181Identification of potent triazolylpyridine nicotinamide phosphoribosyltransferase (NAMPT) inhibitors bearing a 1,2,3-triazole tail group.
AID236913Permeability Coefficient in Caco-2 cell culture model2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Exploring the role of different drug transport routes in permeability screening.
AID24440Calculated partition coefficient (clogP)1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Quantitative evaluation of the beta 2-adrenoceptor intrinsic activity of N-tert-butylphenylethanolamines.
AID496820Antimicrobial activity against Trypanosoma brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID770362Binding affinity to beta-2 adrenergic receptor (unknown origin) at 1 to 10000 nM2013Bioorganic & medicinal chemistry letters, Oct-01, Volume: 23, Issue:19
β2-Adrenoceptor agonists in the regulation of mitochondrial biogenesis.
AID496818Antimicrobial activity against Trypanosoma brucei brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID77606Intrinsic activity (n=5) in guinea pig trachea1981Journal of medicinal chemistry, May, Volume: 24, Issue:5
erythro-5-[1-Hydroxy-2-(isopropylamino)butyl]-7-hydroxycarbostyril, a terbutaline-type derivative of the bronchodilator procaterol.
AID606104Intrinsic activity at human adrenergic beta2 receptor expressed in H292 cells assessed as intracellular cAMP accumulation after 1 hr relative to formoterol2011Bioorganic & medicinal chemistry letters, Jul-01, Volume: 21, Issue:13
Design driven HtL: The discovery and synthesis of new high efficacy β₂-agonists.
AID29811Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID453204Permeability in human skin after 48 hrs by Franz cell permeability assay2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Development of an in silico model for human skin permeation based on a Franz cell skin permeability assay.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID481446Effective permeability across human jejunum2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID7783Unbound fraction (plasma)2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID781328pKa (acid-base dissociation constant) as determined by Luan ref: Pharm. Res. 20052014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID22293Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID29359Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID606103Agonist activity at human adrenergic beta2 receptor expressed in H292 cells assessed as intracellular cAMP accumulation after 1 hr2011Bioorganic & medicinal chemistry letters, Jul-01, Volume: 21, Issue:13
Design driven HtL: The discovery and synthesis of new high efficacy β₂-agonists.
AID445445Permeability at pH 6.5 by PAMPA method2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID496826Antimicrobial activity against Entamoeba histolytica2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID409956Inhibition of mouse brain MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID26362Ionization constant (pKa)2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID770363Induction of Mitochondrial biogenesis in rabbit RPT cells after 24 hrs by FCCP-OCR assay relative to control2013Bioorganic & medicinal chemistry letters, Oct-01, Volume: 23, Issue:19
β2-Adrenoceptor agonists in the regulation of mitochondrial biogenesis.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID445446Oral bioavailability in human2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
AID156089Binding to POPC (palmitoyl-oleolyl-phosphatidyl-choline) liposomes using biosensor system2000Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11
SPR biosensor studies of the direct interaction between 27 drugs and a liposome surface: correlation with fraction absorbed in humans.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID24420Partition coefficient (logP)1998Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID18849Estimation of fraction absorbed (Fa) in the human intestine using biosensor technology.2000Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11
SPR biosensor studies of the direct interaction between 27 drugs and a liposome surface: correlation with fraction absorbed in humans.
AID496829Antimicrobial activity against Leishmania infantum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID236912Permeability Coefficient in 2/4/A1 cell model2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Exploring the role of different drug transport routes in permeability screening.
AID781325pKa (acid-base dissociation constant) as determined by Liao ref: J Chem Info Model 20092014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID567091Drug absorption in human assessed as human intestinal absorption rate2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID24204Distribution coefficient in octanol/water at pH 7.41998Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach.
AID40686Affinity for cow beta-2 adrenergic receptor by measuring displacement (-)-[3H]dihydroalprenolol (DHA)1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Quantitative evaluation of the beta 2-adrenoceptor affinity of phenoxypropanolamines and phenylethanolamines.
AID453203Lipophilicity, log D of the compound2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Development of an in silico model for human skin permeation based on a Franz cell skin permeability assay.
AID218847Change in Gibb's free energy at High affinity beta2- adrenoceptor in Chang living cells.1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Mapping of the beta 2-adrenoceptor on Chang liver cells. Differences between high- and low-affinity receptor states.
AID28236Unbound fraction (tissues)2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID218845Change in Gibb's free energy at Low affinity beta-2-adrenoceptor in the membranes of bovine skeletal muscle preparation1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Mapping of the beta 2-adrenoceptor on Chang liver cells. Differences between high- and low-affinity receptor states.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID15711Calculated partition coefficient (clogP)1998Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach.
AID481442Transcellular permeability at pH 6.5 calculated from in vitro P app values in Caco-2 and/or MDCK cells2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID8002Observed volume of distribution2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID496821Antimicrobial activity against Leishmania2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID236914Permeability Coefficient in hexadecane membranes model2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Exploring the role of different drug transport routes in permeability screening.
AID74042Compound was tested for effective dose required for 25% of maximum response in guinea pig trachea1981Journal of medicinal chemistry, May, Volume: 24, Issue:5
erythro-5-[1-Hydroxy-2-(isopropylamino)butyl]-7-hydroxycarbostyril, a terbutaline-type derivative of the bronchodilator procaterol.
AID476929Human intestinal absorption in po dosed human2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID29925Volume of distribution in man (IV dose)2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID40695Intrinsic activity was measured as concentration of beta-2 adrenergic receptor agonist required for cAMP production1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Quantitative evaluation of the beta 2-adrenoceptor intrinsic activity of N-tert-butylphenylethanolamines.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID481441Aqueous diffusivity at 37C2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID24202Distribution coefficient in octanol/water at pH 5.51998Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID40694Affinity for cow beta-2 adrenergic receptor by measuring displacement (-)-[3H]dihydroalprenolol (DHA)1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Quantitative evaluation of the beta 2-adrenoceptor affinity of phenoxypropanolamines and phenylethanolamines.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID29337Ionisation constant (pKa)2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID28679Partition coefficient (logD6.8)2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID496817Antimicrobial activity against Trypanosoma cruzi2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID18861GOF value represents multisets of log P data1998Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID426242Binding affinity to human adrenergic beta2 receptor2009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
Synthesis, pharmacological and in silico evaluation of 1-(4-di-hydroxy-3,5-dioxa-4-borabicyclo[4.4.0]deca-7,9,11-trien-9-yl)-2-(tert-butylamino)ethanol, a compound designed to act as a beta2 adrenoceptor agonist.
AID496828Antimicrobial activity against Leishmania donovani2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID28233Fraction ionized (pH 7.4)2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID481444Octanol-water partition coefficient, log P of the compound2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID386623Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID496831Antimicrobial activity against Cryptosporidium parvum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID21264Effective permeability measured in human.1998Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach.
AID17985803H-CGP 12177 Whole Cell Binding Assay from Article 10.1038/sj.bjp.0706048: \\The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.\\2005British journal of pharmacology, Feb, Volume: 144, Issue:3
The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
AID1799821Inhibition Assay from Article : \\Identification of two serine residues involved in agonist activation of the beta-adrenergic receptor.\\1989The Journal of biological chemistry, Aug-15, Volume: 264, Issue:23
Identification of two serine residues involved in agonist activation of the beta-adrenergic receptor.
AID1346250Human beta2-adrenoceptor (Adrenoceptors)2005British journal of pharmacology, Feb, Volume: 144, Issue:3
The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (3,051)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901402 (45.95)18.7374
1990's778 (25.50)18.2507
2000's495 (16.22)29.6817
2010's308 (10.10)24.3611
2020's68 (2.23)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 92.00

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index92.00 (24.57)
Research Supply Index8.31 (2.92)
Research Growth Index4.29 (4.65)
Search Engine Demand Index170.78 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (92.00)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials844 (26.24%)5.53%
Reviews139 (4.32%)6.00%
Case Studies176 (5.47%)4.05%
Observational0 (0.00%)0.25%
Other2,057 (63.96%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (39)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Impact of Anti- Asthmatic Medications on Salivary pH and Dental Caries Pattern in a Group of Egyptian Children With Bronchial Asthma: A Cohort Study [NCT03877874]58 participants (Anticipated)Observational2021-07-31Not yet recruiting
Evaluation of Benefit of Nebulized Bronchodilators at Home in Severe Chronic Obstructive Pulmonary Disease and Very Severe Steady State [NCT02103374]Phase 445 participants (Actual)Interventional2012-01-31Completed
Success of External Cephalic Version With Immediate Spinal Anesthesia Versus Spinal Anesthesia When Attempt Without Anesthesia Has Failed: A Randomized Controlled Trial [NCT03106753]Phase 434 participants (Actual)Interventional2017-04-12Terminated(stopped due to Interim analysis to assess concern for spinal anesthesia and increased cesarean delivery rate.)
Gender-specific Role of the beta2-adrenergic Stimulation With Short- or Long-acting Selective Agonist in Relation to Muscle Remodelling, Function, Performance, and Anti-doping [NCT03565302]72 participants (Anticipated)Interventional2018-06-25Recruiting
The Combination of Terbutaline and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia [NCT04481282]Phase 240 participants (Anticipated)Interventional2020-07-08Recruiting
Hot Flashes and Neurovascular Function in Women [NCT05193968]120 participants (Anticipated)Interventional2022-02-24Recruiting
A Prospective, Blinded, Cross-Over Trial of the Exposure-Response Relationship of Terbutaline Sulfate in Adults With Asthma [NCT04973345]Phase 2/Phase 330 participants (Anticipated)Interventional2023-07-07Recruiting
"A Randomised, Double Blind, Placebo Controlled, Parallel-group Study With Use of Budesonide/Formoterol As-needed, or Terbutaline As-needed or Regular Use of Budesonide + Terbutaline As-needed, in Patients With Mild Intermittent Asthma" [NCT00989833]Phase 266 participants (Actual)Interventional2009-09-30Completed
A Randomized, Open-label, Multicenter Study to Evaluate the Effect of Xolair (Omalizumab) as Add-on Therapy to Inhaled Corticosteroid + Long-Acting Beta Agonist in Fixed or Flexible Dosing Compared to Isolated Inhaled Corticosteroid + Long-Acting Beta Ago [NCT00567476]Phase 4116 participants (Actual)Interventional2007-11-30Completed
Analgesic Effect of Beta 2-mimetics in the Treatment of Neuropathic Pain [NCT01582646]Phase 220 participants (Actual)Interventional2012-01-31Terminated(stopped due to difficulty of recruitment)
As Needed Budesonide/Formoterol Combination Versus Regular Budesonide/Formoterol Combination Plus as Needed Terbutaline in Mild-Moderate Persistent Asthma [NCT00849095]Phase 3860 participants (Actual)Interventional2009-04-30Completed
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs [NCT04278404]5,000 participants (Anticipated)Observational2020-03-05Recruiting
Acute Tocolysis With Terbutaline vs Placebo Prior to Emergency Caesarean Delivery for Suspected Intrauterine Fetal Compromise [NCT05326269]100 participants (Actual)Interventional2017-04-23Completed
[NCT02557581]72 participants (Anticipated)Interventional2015-07-31Recruiting
A Comparison of Tolerability of 10 Inhalations of Symbicort® Turbuhaler® 160/4.5 μg and 10 Inhalations of Terbutaline Turbuhaler® 0.4 mg on Top of Symbicort® Turbuhaler® 160/4.5 μg 1 Inhalation Bid, Randomized, Double-blind, Cross Over, Phase III Study in [NCT00837967]Phase 325 participants (Actual)Interventional2009-01-31Completed
A Pilot Study to Evaluate the Safety of Terbutaline in Children With Type 1 Diabetes [NCT00607503]Phase 19 participants (Actual)Interventional2008-02-29Completed
[NCT02712658]10 participants (Actual)Interventional2015-09-30Completed
Blood and Urinary Concentrations of Terbutaline in Asthmatics and Elite Athletes With Asthma: Comparison Between Inhalation vs. Oral Administration. [NCT00914797]Phase 430 participants (Anticipated)Interventional2009-07-31Not yet recruiting
A Comparison of Symbicort® SMART (160/4.5μg) and Symbicort® Turbuhaler 160/4.5 μg, Plus Terbutaline Turbuhaler 0.4 mg as Needed, for Treatment of Asthma - a 12-month, Randomized, Double-blind, Parallel Group, Active-controlled, Multinational Phase III Stu [NCT00839800]Phase 32,091 participants (Actual)Interventional2009-02-28Completed
β2-agonist Versus Ipratropium Bromide Associated With β2-agonists in Chronic Obstructive Pulmonary Disease Exacerbation [NCT01944033]Phase 3250 participants (Actual)Interventional2013-07-31Completed
A Study to Investigate the Relative Efficacy of Terbutaline Turbuhaler® 0.4 mg and Salbutamol Pressurized Metered Dose Inhaler (pMDI) 200 μg - a Single Blind, Single Dose, Randomized, Crossover, Phase III Study in Japanese Adult Asthma Patients [NCT01096017]Phase 324 participants (Actual)Interventional2010-03-31Completed
A Randomised, Double-blind, Double-dummy, Multi-site, Phase III, Single Dose, 4-way Cross-over Pharmacodynamic Study Evaluating the Efficacy of Bricanyl Turbuhaler M3 Compared to Bricanyl Turbuhaler M2 by Studying the Protective Effect on Methacholine Ind [NCT02322788]Phase 395 participants (Actual)Interventional2015-03-31Completed
Double-blinded Randomized Trial of Terbutaline to Shorten ICU Length of Stay in the Treatment of Status Asthmaticus in Children [NCT00124995]Phase 440 participants Interventional2003-10-31Completed
A Comparison of the Inflammatory Control of Asthma Provided by One Inhalation of Symbicort® Turbuhaler® 160/4.5 µg/Inhalation b.i.d. Plus As-needed Versus One Inhalation of Symbicort® Turbuhaler® 320/9 µg/Inhalation b.i.d. + One Inhalation of Pulmicort® T [NCT00244608]Phase 3100 participants Interventional2005-05-31Completed
The Effects of ß2 Polymorphisms on Beta Selectivity After ß-adrenergic Blockade in Patients With Heart Failure [NCT00214318]25 participants Interventional2005-01-31Completed
Nitroglycerin Versus Terbutaline for Intrapartum Fetal Resuscitation [NCT00185887]110 participants (Actual)Interventional2003-10-31Completed
A Comparison of Symbicort Single Inhaler Therapy (Symbicort Turbuhaler 160/4.5 µg, 1 Inhalation b.i.d. Plus as Needed) and Conventional Best Practice for the Treatment of Persistent Asthma in Adults - a 26-Week, Randomised, Open-Label, Parallel-Group, Mul [NCT00252863]Phase 31,600 participants Interventional2004-12-31Completed
Symbicort and Health Economics in a Real Life Evaluation - SHARE - A Randomised, Open-Label, Parallel-Group, Multicentre Study to Assess the Asthma-Related Health-Care Costs, in Ordinary Clinical Practice During 12 Months [NCT00259766]Phase 31,970 participants Interventional2004-04-30Completed
Comparison of the Efficacy and Safety of Budesonide/Formoterol Turbuhaler® Versus Terbutaline Nebulization as Reliever Therapy in Children With Asthma Presenting at the Emergency Room for Moderate Exacerbation [NCT04705727]Phase 3102 participants (Actual)Interventional2021-08-23Terminated(stopped due to Not enough recruitment in th trial)
A 6-Month, Phase IIIA, Multi-Center,Randomised,Double-Blind, Double-Dummy, Parallel-Group Study of the Efficacy and Safety of Symbicort® Turbuhaler®+ Bricasol® pMDI Compared With Pulmicort® Turbuhaler®+Bricasol® pMDI in Chinese Patients With COPD [NCT00421122]Phase 3315 participants (Actual)Interventional2006-09-30Completed
Intravenous Terbutaline to Facilitate Epidural Catheter Placement for Parturients With Labor Pain [NCT01651962]Phase 4250 participants (Anticipated)Interventional2012-08-31Recruiting
Intravenous Terbutaline Versus Intravenous Nitroglycerine for External Cephalic Version: A Double-Blinded Randomized Controlled Trial in Nulliparous Women [NCT02115256]Phase 2/Phase 36 participants (Actual)Interventional2014-07-31Terminated(stopped due to difficult recruitment)
The Effect of Using Terbutaline or a Reduction in Basal Insulin Infusion as a Therapeutic Agent to Prevent Delayed Nocturnal Hypoglycemia in Children and Adolescents With Type 1 Diabetes [NCT00974051]16 participants (Actual)Interventional2008-03-31Completed
A Multicenter Randomized Trial of Second Line Treatment for Corticosteroid-Resistant or Relapsed Immune Thrombocytopenia: Combined Terbutaline and Danazol Versus Danazol Monotherapy [NCT05494307]Phase 2228 participants (Anticipated)Interventional2022-09-01Not yet recruiting
Assessment of Maternal Blood Gas Changes When Using Atosiban and Terbutaline as Tocolytic Agents, During in Utero Repair of Myelomeningocele [NCT04468568]25 participants (Actual)Observational2017-10-01Completed
Beta-Receptor SELECTivity of Carvedilol and Metoprolol Succinnate in Patients With Heart Failure: A Randomized Dose Ranging Trial (SELECT Trial) [NCT00802230]Phase 425 participants (Actual)Interventional2002-09-30Completed
A Clinical Study Comparing Symbicort 'as Needed' With Pulmicort Twice Daily Plus Terbutaline 'as Needed' in Adult and Adolescent Patients With Asthma [NCT02224157]Phase 34,215 participants (Actual)Interventional2014-11-28Completed
An Open-label, Single-dose, 2-period Cross Over Study in Healthy Volunteers to Assess Relative Bioavailability of Terbutaline Sulphate 1.5 mg After Inhalation Via the M3 Turbuhaler Compared With the M2 Turbuhaler [NCT02178059]Phase 134 participants (Actual)Interventional2014-08-31Completed
A Clinical Study Comparing Symbicort® 'as Needed' With Terbutaline 'as Needed' and With Pulmicort® Twice Daily Plus Terbutaline 'as Needed' in Adult and Adolescent Patients With Asthma. [NCT02149199]Phase 33,850 participants (Actual)Interventional2014-07-07Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00567476 (10) [back to overview]The Mean Change From Baseline to the End of Study in AQLQ Domain Score
NCT00567476 (10) [back to overview]Number of Asthma Exacerbation Episodes Per Participant
NCT00567476 (10) [back to overview]Percentage of Participants With an Increase of More Than 1.5 in AQLQ Overall Score at 20 Weeks
NCT00567476 (10) [back to overview]Percentage of Participants With an Increase of More Than 0.5 in AQLQ Overall Score at Week 20
NCT00567476 (10) [back to overview]Percentage of Participants Using Rescue Medication
NCT00567476 (10) [back to overview]Mean Number of Puffs of Rescue Medication Taken Per Day
NCT00567476 (10) [back to overview]Free Days With no Rescue Medication
NCT00567476 (10) [back to overview]The Mean Change From Baseline to Week 20 in the Overall Asthma Quality of Life Questionnaire (AQLQ)
NCT00567476 (10) [back to overview]Physician's Global Assessment of Treatment Effectiveness
NCT00567476 (10) [back to overview]Patient's Global Assessment of Treatment Effectiveness
NCT00837967 (6) [back to overview]Vital Sign (Pulse Rate)- Average Trapezoidal Area Under the Curve (AUC)
NCT00837967 (6) [back to overview]Vital Sign (Blood Pressure)- Average Trapezoidal Area Under the Curve (AUC)
NCT00837967 (6) [back to overview]Adverse Events
NCT00837967 (6) [back to overview]Blood Glucose - Average Concentration From Trapezoidal Area Under the Curve (AUC)
NCT00837967 (6) [back to overview]Electrocardiogram (ECG)- Average Trapezoidal Area Under the Curve (AUC)
NCT00837967 (6) [back to overview]Serum Potassium - Average Concentration From Trapezoidal Area Under the Curve (AUC)
NCT00839800 (13) [back to overview]Asthma Control Questionnaire (ACQ)
NCT00839800 (13) [back to overview]Asthma Symptom Score
NCT00839800 (13) [back to overview]Evening PEF
NCT00839800 (13) [back to overview]Forced Expiratory Volume in One Second (FEV1)
NCT00839800 (13) [back to overview]Morning Peak Expiratory Flow (PEF)
NCT00839800 (13) [back to overview]The Percentage of Participants Who Had Experienced Asthma Exacerbation(s) at the End of the Study
NCT00839800 (13) [back to overview]Symptom-free Days (no Symptoms and no Awakenings)
NCT00839800 (13) [back to overview]Percentage of Asthma-control Days (no Asthma Symptoms, no Awakenings, and no As-needed Use)
NCT00839800 (13) [back to overview]Percentage of As-needed-free Days
NCT00839800 (13) [back to overview]Number of Asthma Exacerbations
NCT00839800 (13) [back to overview]Nights With Awakening(s) Due to Asthma Symptoms
NCT00839800 (13) [back to overview]Use of As-needed Medication
NCT00839800 (13) [back to overview]The Percentage of Participants Who Had Experienced First Mild Asthma Exacerbations
NCT00974051 (4) [back to overview]Percent of Nighttime Glucose Levels >250 mg/dl
NCT00974051 (4) [back to overview]Blood Glucose Nadir
NCT00974051 (4) [back to overview]Percent of Nighttime Glucose Levels <70
NCT00974051 (4) [back to overview]Percent of Nighttime Glucose Levels <80
NCT00989833 (8) [back to overview]Diary Recording of Asthma Symptoms
NCT00989833 (8) [back to overview]Asthma Control Measured by a 5-item Asthma Control Questionnaire (ACQ5)
NCT00989833 (8) [back to overview]Bronchial Responsiveness to Mannitol
NCT00989833 (8) [back to overview]Concentration of Exhaled Nitric Oxide
NCT00989833 (8) [back to overview]Number of Participants With an Adverse Event During the Study
NCT00989833 (8) [back to overview]Percent Change in Maximum Post-exercise FEV1 Fall After 3 Weeks
NCT00989833 (8) [back to overview]Percent Change in Maximum Post-exercise Forced Expiratory Volume in One Second (FEV1) Fall After 6 Weeks
NCT00989833 (8) [back to overview]Use of as Needed Medication
NCT01096017 (12) [back to overview]Maximum % Change in FEV1 (Forced Expiratory Volume in 1 Second) Within 4 Hours After Drug Inhalation
NCT01096017 (12) [back to overview]Number of Patients With % Change in FEV1 (Forced Expiratory Volume in 1 Second) >15% Within 4 Hours After Drug Inhalation
NCT01096017 (12) [back to overview]Time to Change More Than or Equal to 15% (Time to Onset Response) Within 4 Hours After Drug Inhalation
NCT01096017 (12) [back to overview]FEV1 (Forced Expiratory Volume in 1 Second) Area Under Curve (AUC) 0-4 Hours After Drug Inhalation
NCT01096017 (12) [back to overview]FEV1 (Forced Expiratory Volume in 1 Second) at 120 Minutes After Inhalations of Study Drug as Percentage of Pre-dose
NCT01096017 (12) [back to overview]FEV1 (Forced Expiratory Volume in 1 Second) at 5 Minutes After Inhalations of Study Drug as Percentage of Pre-dose
NCT01096017 (12) [back to overview]FEV1 (Forced Expiratory Volume in 1 Second) at 60 Minutes After Inhalations of Study Drug as Percentage of Pre-dose
NCT01096017 (12) [back to overview]Time to Peak FEV1 (Forced Expiratory Volume in 1 Second) Within 4 Hours After Drug Inhalation
NCT01096017 (12) [back to overview]FEV1 (Forced Expiratory Volume in 1 Second) at 240 Minutes After Inhalations of Study Drug as Percentage of Pre-dose
NCT01096017 (12) [back to overview]FEV1 (Forced Expiratory Volume in 1 Second) at 30 Minutes After Inhalations of Study Drug as Percentage of Pre-dose
NCT01096017 (12) [back to overview]FEV1 (Forced Expiratory Volume in 1 Second) at 180 Minutes After Inhalations of Study Drug as Percentage of Pre-dose
NCT01096017 (12) [back to overview]FEV1 (Forced Expiratory Volume in 1 Second) at 15 Minutes After Inhalations of Study Drug as Percentage of Pre-dose
NCT02115256 (4) [back to overview]Hypotension
NCT02115256 (4) [back to overview]Need for Cesarean Delivery
NCT02115256 (4) [back to overview]Successful Version of the Fetus Into the Vertex Position
NCT02115256 (4) [back to overview]Tachycardia
NCT02149199 (20) [back to overview]Average Change From Baseline in Asthma Symptom Score
NCT02149199 (20) [back to overview]Average Change From Baseline in Asthma Quality of Life Questionnaire; Standard Version (AQLQ(S))
NCT02149199 (20) [back to overview]Average Change From Baseline in Asthma Control Questionnaire (ACQ-5)
NCT02149199 (20) [back to overview]Change From Baseline in the Percentage of Nighttime Awakenings Due to Asthma
NCT02149199 (20) [back to overview]Change From Baseline in Percentage of Asthma Control Days
NCT02149199 (20) [back to overview]Change From Baseline in Percentage of 'As Needed' Free Days
NCT02149199 (20) [back to overview]Average Change From Baseline in Pre-dose Forced Expiratory Volume in 1 Second (FEV1)
NCT02149199 (20) [back to overview]Average Change From Baseline in Number of Inhalations of 'as Needed' Medication.
NCT02149199 (20) [back to overview]Average Change From Baseline in Morning Peak Expiratory Flow (PEF)
NCT02149199 (20) [back to overview]Change From Baseline in Percentage of Symptom-free Days
NCT02149199 (20) [back to overview]Poorly Controlled Asthma Weeks
NCT02149199 (20) [back to overview]Annual Severe Asthma Exacerbation Rate
NCT02149199 (20) [back to overview]Annual Moderate or Severe Asthma Exacerbation Rate
NCT02149199 (20) [back to overview]'Well-controlled Asthma Week' - a Derived Binary Variable (Yes/No)
NCT02149199 (20) [back to overview]Average Change From Baseline in Evening PEF
NCT02149199 (20) [back to overview]Number of Participants Experiencing at Least One Moderate or Severe Asthma Exacerbation
NCT02149199 (20) [back to overview]Number of Participants Experiencing at Least One Occasion With Additional Steroids for Asthma
NCT02149199 (20) [back to overview]Number of Participants Experiencing at Least One Severe Asthma Exacerbation
NCT02149199 (20) [back to overview]Number of Patients With Study Specific Asthma Related Discontinuation
NCT02149199 (20) [back to overview]Percentage of Controller Use Days
NCT02178059 (6) [back to overview]Time to Reach Maximum Observed Plasma Concentration (Tmax)
NCT02178059 (6) [back to overview]Area Under the Plasma Concentration-time Curve From Zero to 36 Hours Postdose [AUC(0-36)]
NCT02178059 (6) [back to overview]Area Under the Plasma Concentration-time Curve From Zero Extrapolated to Infinity (AUC)
NCT02178059 (6) [back to overview]Area Under the Plasma Concentration-time Curve From Zero to the Time of Last Measurable Concentration [AUC(0-t)]
NCT02178059 (6) [back to overview]Maximum Observed Plasma Concentration (Cmax)
NCT02178059 (6) [back to overview]Terminal Half-life (t1/2)
NCT02224157 (10) [back to overview]Average Change From Baseline in Asthma Control Questionnaire (5-item Version) - ACQ-5 Score
NCT02224157 (10) [back to overview]Average Change From Baseline in 'as Needed' Use
NCT02224157 (10) [back to overview]Annual Severe Asthma Exacerbation Rate - Superiority Analysis
NCT02224157 (10) [back to overview]Annual Severe Asthma Exacerbation Rate - Non-inferiority Analysis
NCT02224157 (10) [back to overview]Average Change From Baseline in Pre-bronchodilator FEV1
NCT02224157 (10) [back to overview]Average Change From Baseline in Asthma Quality of Life Questionnaire Standardised Version - AQLQ(S) Score
NCT02224157 (10) [back to overview]Change From Baseline in Percent of 'as Needed' Free Days
NCT02224157 (10) [back to overview]Number of Participants Experiencing at Least One Severe Asthma Exacerbation
NCT02224157 (10) [back to overview]Number of Participants With Study Specific Asthma Related Discontinuation
NCT02224157 (10) [back to overview]Percentage of Controller Use Days
NCT02322788 (1) [back to overview]Provocative Concentration of Methacholine Which Produces a 20% Fall in FEV1 (PC20)
NCT03106753 (10) [back to overview]Numeric Rating Scale (NRS-11)
NCT03106753 (10) [back to overview]Cord pH
NCT03106753 (10) [back to overview]Numeric Rating Scale (NRS-11)
NCT03106753 (10) [back to overview]Number of Participants With Various Mode of Delivery
NCT03106753 (10) [back to overview]Number of Participants With Success Rate of External Cephalic Version to Cephalic Presentation.
NCT03106753 (10) [back to overview]Number of Participants With Newborns With Apgar Score 7 or 9
NCT03106753 (10) [back to overview]Time From Procedure to Delivery.
NCT03106753 (10) [back to overview]Number of NICU Admission
NCT03106753 (10) [back to overview]Newborn Birth Weight
NCT03106753 (10) [back to overview]Number of Adverse Events During Procedure

The Mean Change From Baseline to the End of Study in AQLQ Domain Score

"AQLQ was administered to all patients at Baseline, Week 12 and Week 20, and prior to any clinic visit evaluation and drug administration.~The 32 questions in the AQLQ were divided into four domains: activity limitations, symptoms, emotional function, and environmental stimuli. AQLQ domain scores were calculated by adding the responses to each of the questions in the domain and dividing by the number of questions in the domain. Each domain score was between 1 and 7. Score 7.0 meant that the patient had no impairments due to asthma and score 1.0 indicated severe impairment." (NCT00567476)
Timeframe: Baseline and Week 20

,
InterventionUnits on a scale (Mean)
Activity limitation scoreSymptoms scoreEmotional function scoreEnvironmental stimuli score
Conventional Therapy-0.2-0.20.00.0
Omalizumab + Conventional Therapy1.31.21.31.2

[back to top]

Number of Asthma Exacerbation Episodes Per Participant

For the purpose of evaluating efficacy, a clinically significant asthma exacerbation was defined as a worsening of asthma symptoms as judged clinically by the investigator, requiring doubling the baseline ICS dose for at least 3 days and/or treatment with rescue systemic (oral or IV) corticosteroids. The initiation of the above corticosteroid regimens marked the start of an asthma exacerbation episode and cessation of the additional corticosteroid regimens marked the end of an exacerbation episode. (NCT00567476)
Timeframe: From Baseline through 20 weeks

,
InterventionParticipants (Number)
Patients with 1 episodePatients with 2 episodesPatients with 3 episodesPatients with 4 episodesTotal number of patients with episodes
Conventional Therapy1261120
Omalizumab + Conventional Therapy2553134

[back to top]

Percentage of Participants With an Increase of More Than 1.5 in AQLQ Overall Score at 20 Weeks

The AQLQ was administered to all patients at Baseline, Week 12 and Week 20. The 32 questions in the AQLQ were divided into four domains; activity limitations, symptoms, emotional function, and environmental stimuli. Individual questions are equally weighted. The overall AQLQ score is the mean of the responses to each of the 32 questions and ranges from 1 to 7. A score 7.0 indicates that the patient has no impairments due to asthma and score 1.0 indicates severe impairment. (NCT00567476)
Timeframe: Baseline and Week 20

InterventionPercentage of participants (Number)
Omalizumab + Conventional Therapy40.3
Conventional Therapy2.8

[back to top]

Percentage of Participants With an Increase of More Than 0.5 in AQLQ Overall Score at Week 20

The AQLQ was administered to all patients at Baseline, Week 12 and Week 20. The 32 questions in the AQLQ were divided into four domains; activity limitations, symptoms, emotional function, and environmental stimuli. Individual questions are equally weighted. The overall AQLQ score is the mean of the responses to each of the 32 questions and ranges from 1 to 7. AQLQ of each domain is the mean of the responses to each of the questions within that domain. A score 7.0 indicates that the patient has no impairments due to asthma and score 1.0 indicates severe impairment. (NCT00567476)
Timeframe: Baseline and Week 20

InterventionPercentage of participants (Number)
Omalizumab + Conventional Therapy70.1
Conventional Therapy22.2

[back to top]

Percentage of Participants Using Rescue Medication

When necessary, patients were allowed to take rescue medication using inhaled salbutamol or terbutaline for symptoms of intercurrent bronchospasm. (NCT00567476)
Timeframe: From Baseline through 20 Weeks

InterventionPercentage of participants (Number)
Omalizumab + Conventional Therapy43.6
Conventional Therapy44.7

[back to top]

Mean Number of Puffs of Rescue Medication Taken Per Day

When necessary, patients were allowed to take rescue medication using inhaled salbutamol or terbutaline for symptoms of intercurrent bronchospasm. The number of puffs taken during each 24 hour period was recorded in the patient dairy. The total number of puffs over 20 weeks of treatment was divided by the number of treatment days (140 days) to calculate the mean number of puffs per day. (NCT00567476)
Timeframe: From Baseline through 20 Weeks

InterventionPuffs (Mean)
Omalizumab + Conventional Therapy5.5
Conventional Therapy6.4

[back to top]

Free Days With no Rescue Medication

When necessary, patients were allowed to take rescue medication using inhaled salbutamol or terbutaline for symptoms of intercurrent bronchospasm. Days with no rescue medication intake were the variable of interest for this analysis. (NCT00567476)
Timeframe: From Baseline through 20 weeks (140 days)

InterventionDays (Mean)
Omalizumab + Conventional Therapy73.5
Conventional Therapy74.9

[back to top]

The Mean Change From Baseline to Week 20 in the Overall Asthma Quality of Life Questionnaire (AQLQ)

The AQLQ was administered to all patients at Baseline, Week 12 and Week 20. The 32 questions in the AQLQ were divided into four domains; activity limitations, symptoms, emotional function, and environmental stimuli. Individual questions are equally weighted. The overall AQLQ score is the mean of the responses to each of the 32 questions, and ranges from 1 to 7. A score 7.0 indicates that the patient has no impairments due to asthma and a score of 1.0 indicates severe impairment. (NCT00567476)
Timeframe: Baseline and Week 20

,
InterventionUnits on a scale (Mean)
Baseline (n=77, 37)At Week 20 (n=78, 36)Change from baseline to week 20 (n=77, 36)
Conventional Therapy3.13.0-0.1
Omalizumab + Conventional Therapy3.14.41.2

[back to top]

Physician's Global Assessment of Treatment Effectiveness

At the end of Week 20 a global evaluation of the treatment effectiveness was performed by the investigator using the following scale: Excellent: complete control of asthma; Good: marked improvement of asthma; Moderate: discernible, but limited improvement in asthma; Poor: no appreciable change in asthma; Worsening of asthma (NCT00567476)
Timeframe: 20 Weeks

,
InterventionParticipants (Number)
ExcellentGoodModeratePoorWorsening
Conventional Therapy2411182
Omalizumab + Conventional Therapy22351360

[back to top]

Patient's Global Assessment of Treatment Effectiveness

"At the end of Week 20, a global evaluation of the treatment effectiveness was performed by the patient using the following scale:~Excellent: complete control of asthma; Good: marked improvement of asthma; Moderate: discernible, but limited improvement in asthma; Poor: no appreciable change in asthma; Worsening of asthma" (NCT00567476)
Timeframe: 20 Weeks

,
InterventionParticipants (Number)
ExcellentGoodModeratePoorWorsening
Conventional Therapy3131092
Omalizumab + Conventional Therapy33301030

[back to top]

Vital Sign (Pulse Rate)- Average Trapezoidal Area Under the Curve (AUC)

The mean AUC value was calculated as AUC (calculated using the trapezoidal method) divided by the length of the sampling period. (NCT00837967)
Timeframe: up to 740 min after start dosing for each treatment day

Interventionbeats/min (Mean)
Symbicort70.0
Terbutaline74.1

[back to top]

Vital Sign (Blood Pressure)- Average Trapezoidal Area Under the Curve (AUC)

The mean AUC value was calculated as AUC (calculated using the trapezoidal method) divided by the length of the sampling period. (NCT00837967)
Timeframe: up to 740 min after start dosing for each treatment day

InterventionmmHg (Mean)
Symbicort115.3
Terbutaline114.9

[back to top]

Adverse Events

Total number of adverse events (NCT00837967)
Timeframe: 3 days

Interventionadverse events (Number)
Symbicort14
Terbutaline24

[back to top]

Blood Glucose - Average Concentration From Trapezoidal Area Under the Curve (AUC)

The mean AUC value was calculated as AUC (calculated using the trapezoidal method) divided by the length of the sampling period. (NCT00837967)
Timeframe: up to 140 min after start dosing for each treatment day

Interventionmg/dLiters (Mean)
Symbicort121.1
Terbutaline129.5

[back to top]

Electrocardiogram (ECG)- Average Trapezoidal Area Under the Curve (AUC)

The mean AUC of QTcF (ECG interval measured from the beginning of the Q wave to the end of the T wave, corrected for heart rate using Fridericia's formula)was calculated as AUC (calculated using the trapezoidal method) divided by the length of the sampling period. (NCT00837967)
Timeframe: up to 740 min after start dosing for each treatment day

Interventionms (Mean)
Symbicort411.71
Terbutaline414.33

[back to top]

Serum Potassium - Average Concentration From Trapezoidal Area Under the Curve (AUC)

The mean AUC value was calculated as AUC (calculated using the trapezoidal method) divided by the length of the sampling period. (NCT00837967)
Timeframe: up to 740 min after start dosing for each treatment day

InterventionmEq/L (Mean)
Symbicort4.01
Terbutaline3.88

[back to top]

Asthma Control Questionnaire (ACQ)

The ACQ developed by Juniper and colleagues (Juniper et al 1999) was used without the FEV1 and Beta 2-agonist questions. The Asthma Control Questionnaire has 5 questions that are assessed on a 7-point scale from 0 to 6 where 0 represents good control and 6 represents poor control. The overall score is the mean of the five responses. At least 4 out of the 5 questions must have been answered to provide a value. The mean of the overall score for Weeks 4 to 52 was presented here. (NCT00839800)
Timeframe: 4, 12, 24, 36 and 52 weeks after randomization

Interventionunits on a scale (Mean)
Symbicort SMART1.162
Symbicort+Terbutaline As Needed1.289

[back to top]

Asthma Symptom Score

The mean value from the treatment period for Total Asthma Symptom Score (total score: 0 is best - no asthma symptoms; 6 is worst). (NCT00839800)
Timeframe: 52-week treatment period

Interventionunits on a scale (Mean)
Symbicort SMART1.12
Symbicort+Terbutaline As Needed1.22

[back to top]

Evening PEF

The mean value from a 52-week treatment period. (NCT00839800)
Timeframe: 2-week run-in period (14 - 18 days before randomization - week 0) and a 52-week treatment period

InterventionL/min (Mean)
Symbicort SMART334.2
Symbicort+Terbutaline As Needed327.8

[back to top]

Forced Expiratory Volume in One Second (FEV1)

The mean value for Weeks 4, 12, 24, 36 and 52 was analysed. (NCT00839800)
Timeframe: 4, 12, 24, 36 and 52 weeks after randomization

InterventionLiter (L) (Geometric Mean)
Symbicort SMART2.258
Symbicort+Terbutaline As Needed2.222

[back to top]

Morning Peak Expiratory Flow (PEF)

The mean value from a 52-week treatment period. (NCT00839800)
Timeframe: 52-week treatment period

InterventionLiter/minute (L/min) (Mean)
Symbicort SMART331.8
Symbicort+Terbutaline As Needed324.7

[back to top]

The Percentage of Participants Who Had Experienced Asthma Exacerbation(s) at the End of the Study

Asthma exacerbation was defined as deterioration in asthma leading to oral glucocorticosteroid [GCS] treatment, hospitalization, or emergency room [ER] treatment. (NCT00839800)
Timeframe: week 52

Interventionpercentage of participants (Number)
Symbicort SMART16
Symbicort+Terbutaline As Needed22

[back to top]

Symptom-free Days (no Symptoms and no Awakenings)

A symptom-free day was defined as a day without daytime or night-time symptoms and without night-time awakenings due to asthma symptoms. The mean value was presented here. (NCT00839800)
Timeframe: 52-week treatment period

Interventionsymptom-free days (Mean)
Symbicort SMART45.5
Symbicort+Terbutaline As Needed41.6

[back to top]

Percentage of Asthma-control Days (no Asthma Symptoms, no Awakenings, and no As-needed Use)

An asthma-control day was defined as a a night and day with no asthma symptoms, no awakenings due to asthma symptoms, and no as-needed medication use. The mean value from the treatment period was presented here. (NCT00839800)
Timeframe: 52-week treatment period

Interventionpercentage of asthma-control days (Mean)
Symbicort SMART41.7
Symbicort+Terbutaline As Needed37.9

[back to top]

Percentage of As-needed-free Days

An as-needed-free day is defined as a night and day with no use of as-needed medication. The mean value from the treatment period was presented here. (NCT00839800)
Timeframe: 52-week treatment period

Interventionpercentage of as-needed-free days (Mean)
Symbicort SMART51.4
Symbicort+Terbutaline As Needed47.2

[back to top]

Number of Asthma Exacerbations

Asthma exacerbation was defined as deterioration in asthma leading to oral GCS treatment, hospitalization, or ER treatment. Number of asthma exacerbations during 52 weeks treatment was presented here. (NCT00839800)
Timeframe: up to 52 weeks

InterventionAsthma exacerbations (Number)
Symbicort SMART259
Symbicort+Terbutaline As Needed363

[back to top]

Nights With Awakening(s) Due to Asthma Symptoms

The mean value from the treatment period was presented here. (NCT00839800)
Timeframe: 52-week treatment period

InterventionNights With Awakening(s) (Mean)
Symbicort SMART15.7
Symbicort+Terbutaline As Needed17.5

[back to top]

Use of As-needed Medication

The mean value of total daily number of inhalations from the treatment period for use of as-needed medication (daytime, night-time). (NCT00839800)
Timeframe: 52-week treatment period

Interventioninhalations/day (Mean)
Symbicort SMART1.21
Symbicort+Terbutaline As Needed1.46

[back to top]

The Percentage of Participants Who Had Experienced First Mild Asthma Exacerbations

Mild asthma exacerbation was defined as morning PEF ≥20% below baseline, daily as-needed medication use ≥2 inhalations above baseline, or a night with awakening due to asthma symptoms. The percentage of participants who had experienced mild asthma exacerbation(s) at the end of the study was presented here. (NCT00839800)
Timeframe: up to 52 weeks

Interventionpercentage of participants (Number)
Symbicort SMART71
Symbicort+Terbutaline As Needed80

[back to top]

Percent of Nighttime Glucose Levels >250 mg/dl

(NCT00974051)
Timeframe: 10:00pm to 6:00am

Interventionpercentage of overnght glucose values (Number)
Control Arm30.2
Terbutaline Arm63.5
20% Basal Reduction Arm41.7

[back to top]

Blood Glucose Nadir

BG nadir overnight after intervention (NCT00974051)
Timeframe: overnight hours

Interventionmg/dl (Mean)
Control Arm128
Terbutaline Arm189
20% Basal Reduction Arm162

[back to top]

Percent of Nighttime Glucose Levels <70

(NCT00974051)
Timeframe: 10:00pm to 6:00am

Interventionpercentage of nighttime glucose values (Number)
Control Arm1.7
Terbutaline Arm0
20% Basal Reduction Arm0.3

[back to top]

Percent of Nighttime Glucose Levels <80

(NCT00974051)
Timeframe: 9:00pm to 6:00am

Interventionpercentage of overnight glucose levels (Number)
Control Arm6.6
Terbutaline Arm0
20% Basal Reduction Arm4.9

[back to top]

Diary Recording of Asthma Symptoms

Asthma symptoms during days with exercise (NCT00989833)
Timeframe: 6 weeks

InterventionPercent of exercise days (Mean)
Budesonide/Terbutaline51.1
Terbutaline50.9
Budesonide/Formoterol49.8

[back to top]

Asthma Control Measured by a 5-item Asthma Control Questionnaire (ACQ5)

Change in overall ACQ5. ACQ5 measures asthma control and a lower values shows a better asthma control, a higher value is worse. A decrease in the ACQ5 shows an improvement during the treatment period. Range of ACQ5 is 0-5, with 0 as the best value and 5 as the worst value. Further information at www.qoltech.co.uk. (NCT00989833)
Timeframe: Baseline e and 6 weeks

Interventionunits on a scale (Mean)
Budesonide/Terbutaline-0.3
Terbutaline-0.2
Budesonide/Formoterol-0.4

[back to top]

Bronchial Responsiveness to Mannitol

Change in cumulative Mannitol dose in mg in patients with a positive mannitol provocation test at baseline (PD15) (NCT00989833)
Timeframe: Baseline and 6 weeks

Interventionmg (Mean)
Budesonide/Terbutaline67.26
Terbutaline-6.15
Budesonide/Formoterol151.87

[back to top]

Concentration of Exhaled Nitric Oxide

(NCT00989833)
Timeframe: 6 weeks

Interventionppb (Mean)
Budesonide/Terbutaline25.9
Terbutaline35.5
Budesonide/Formoterol24.4

[back to top]

Number of Participants With an Adverse Event During the Study

(NCT00989833)
Timeframe: 6 weeks

InterventionParticipants (Number)
Budesonide/Terbutaline13
Terbutaline13
Budesonide/Formoterol13

[back to top]

Percent Change in Maximum Post-exercise FEV1 Fall After 3 Weeks

FEV1 (NCT00989833)
Timeframe: Baseline and 3 weeks

InterventionPercent change (Mean)
Budesonide/Terbutaline-4.07
Terbutaline-1.19
Budesonide/Formoterol-3.81

[back to top]

Percent Change in Maximum Post-exercise Forced Expiratory Volume in One Second (FEV1) Fall After 6 Weeks

FEV1 (NCT00989833)
Timeframe: Baseline and Visit 6

InterventionPercent change (Mean)
Budesonide/Terbutaline-5.85
Terbutaline0.61
Budesonide/Formoterol-5.24

[back to top]

Use of as Needed Medication

Mean number of as needed inhalations taken before exercise (NCT00989833)
Timeframe: 6 weeks

Interventionnumber of inhalations per day (Mean)
Budesonide/Terbutaline0.6
Terbutaline0.8
Budesonide/Formoterol0.7

[back to top]

Maximum % Change in FEV1 (Forced Expiratory Volume in 1 Second) Within 4 Hours After Drug Inhalation

percent of pre-dose (ratio) (NCT01096017)
Timeframe: At two visits during a maximum of 15 days

InterventionPercent change (Geometric Mean)
Salbutamol pMDI122.62
Terbutaline Turbuhaler®121.43

[back to top]

Number of Patients With % Change in FEV1 (Forced Expiratory Volume in 1 Second) >15% Within 4 Hours After Drug Inhalation

Number of patients with % change in FEV1 >15% within 4 hours after drug inhalation. (NCT01096017)
Timeframe: At two visits during a maximum of 15 days

InterventionParticipants (Number)
Salbutamol pMDI17
Terbutaline Turbuhaler®16

[back to top]

Time to Change More Than or Equal to 15% (Time to Onset Response) Within 4 Hours After Drug Inhalation

Time to change more than or equal to 15% (time to onset response) within 4 hours after drug inhalation (NCT01096017)
Timeframe: At two visits during a maximum of 15 days

InterventionMinutes (Mean)
Salbutamol pMDI31.36
Terbutaline Turbuhaler®34.32

[back to top]

FEV1 (Forced Expiratory Volume in 1 Second) Area Under Curve (AUC) 0-4 Hours After Drug Inhalation

FEV1 (Forced Expiratory Volume in 1 second) AUC 0-4 hours after drug inhalation (NCT01096017)
Timeframe: At two visits during a maximum of 15 days. FEV1 timepoints: all time points t=5, 15, 30, 60, 120, 180 and 240 minutes.

InterventionmilliLiters x minutes (Geometric Mean)
Salbutamol pMDI617.56
Terbutaline Turbuhaler®634.64

[back to top]

FEV1 (Forced Expiratory Volume in 1 Second) at 120 Minutes After Inhalations of Study Drug as Percentage of Pre-dose

percent of pre-dose (ratio) (NCT01096017)
Timeframe: At two visits during a maximum of 15 days

InterventionPercentage of Pre-Dose FEV1 (Geometric Mean)
Salbutamol pMDI119.54
Terbutaline Turbuhaler®119.79

[back to top]

FEV1 (Forced Expiratory Volume in 1 Second) at 5 Minutes After Inhalations of Study Drug as Percentage of Pre-dose

percent of pre-dose (ratio) (NCT01096017)
Timeframe: At two visits during a maximum of 15 days

InterventionPercentage of Pre-Dose FEV1 (Geometric Mean)
Salbutamol pMDI115.58
Terbutaline Turbuhaler®112.80

[back to top]

FEV1 (Forced Expiratory Volume in 1 Second) at 60 Minutes After Inhalations of Study Drug as Percentage of Pre-dose

percent of pre-dose (ratio) (NCT01096017)
Timeframe: At two visits during a maximum of 15 days

InterventionPercentage of Pre-Dose FEV1 (Geometric Mean)
Salbutamol pMDI120.28
Terbutaline Turbuhaler®118.11

[back to top]

Time to Peak FEV1 (Forced Expiratory Volume in 1 Second) Within 4 Hours After Drug Inhalation

Time to peak measurement of FEV1 (min) (NCT01096017)
Timeframe: At two visits during a maximum of 15 days

InterventionMinutes (Median)
Salbutamol pMDI60.00
Terbutaline Turbuhaler®120.00

[back to top]

FEV1 (Forced Expiratory Volume in 1 Second) at 240 Minutes After Inhalations of Study Drug as Percentage of Pre-dose

percent of pre-dose (ratio) (NCT01096017)
Timeframe: At two visits during a maximum of 15 days

InterventionPercentage of Pre-Dose FEV1 (Geometric Mean)
Salbutamol pMDI113.59
Terbutaline Turbuhaler®117.05

[back to top]

FEV1 (Forced Expiratory Volume in 1 Second) at 30 Minutes After Inhalations of Study Drug as Percentage of Pre-dose

percent of pre-dose (ratio) (NCT01096017)
Timeframe: At two visits during a maximum of 15 days

InterventionPercentage of Pre-Dose FEV1 (Geometric Mean)
Salbutamol pMDI119.42
Terbutaline Turbuhaler®117.02

[back to top]

FEV1 (Forced Expiratory Volume in 1 Second) at 180 Minutes After Inhalations of Study Drug as Percentage of Pre-dose

percent of pre-dose (ratio) (NCT01096017)
Timeframe: At two visits during a maximum of 15 days

InterventionPercentage of Pre-Dose FEV1 (Geometric Mean)
Salbutamol pMDI116.68
Terbutaline Turbuhaler®118.48

[back to top]

FEV1 (Forced Expiratory Volume in 1 Second) at 15 Minutes After Inhalations of Study Drug as Percentage of Pre-dose

percent of pre-dose (ratio) (NCT01096017)
Timeframe: At two visits during a maximum of 15 days

InterventionPercentage of Pre-Dose FEV1 (Geometric Mean)
Salbutamol pMDI118.15
Terbutaline Turbuhaler®115.69

[back to top]

Hypotension

Number of participants with hypotension (NCT02115256)
Timeframe: average of 1 hour

InterventionParticipants (Count of Participants)
Intravenous Terbutaline2
Intravenous Nitroglycerine1

[back to top]

Need for Cesarean Delivery

Number of participants that needed a cesarean delivery (NCT02115256)
Timeframe: average of 1 hour

InterventionParticipants (Count of Participants)
Intravenous Terbutaline0
Intravenous Nitroglycerine0

[back to top]

Successful Version of the Fetus Into the Vertex Position

Number of participants that had successful version of the fetus into the vertex position. (NCT02115256)
Timeframe: average of 1 hour

InterventionParticipants (Count of Participants)
Intravenous Terbutaline3
Intravenous Nitroglycerine0

[back to top]

Tachycardia

Number of participants that had tachycardia (NCT02115256)
Timeframe: average of 1 hour

InterventionParticipants (Count of Participants)
Intravenous Terbutaline2
Intravenous Nitroglycerine0

[back to top]

Average Change From Baseline in Asthma Symptom Score

Asthma symptom score (eDiary) change from baseline during the randomised treatment period. Symptom score is entered morning and evening by the patient on a 4-point scale from 0 to 3 with higher values indicating more severe symptoms. Asthma symptom score is then the sum of the day and night scores, which implies a range of scores from 0 - 6, with higher values indicating more severe symptoms. Baseline is defined as the mean of all non-missing measurements during the last 10 days of the run-in period. (NCT02149199)
Timeframe: up to 52 weeks

Interventionunits on a scale (Least Squares Mean)
Placebo Bid + Symbicort 'as Needed'-0.23
Placebo Bid + Terbutaline 'as Needed'-0.11
Pulmicort Bid + Terbutaline 'as Needed'-0.32

[back to top]

Average Change From Baseline in Asthma Quality of Life Questionnaire; Standard Version (AQLQ(S))

Asthma Quality of Life Questionnaire Standardised Version (AQLQ (S) overall score change from baseline. AQLQ(S) consists of 32 questions in 4 domains. Each question is assessed on a 7-point scale from 1 to 7, with higher values indicating better health-related quality of life. The overall score is calculated as the mean score of all 32 items. (NCT02149199)
Timeframe: Study weeks 0,16,28,40,52

Interventionunits on a scale (Least Squares Mean)
Placebo Bid + Symbicort 'as Needed'0.313
Placebo Bid + Terbutaline 'as Needed'0.186
Pulmicort Bid + Terbutaline 'as Needed'0.415

[back to top]

Average Change From Baseline in Asthma Control Questionnaire (ACQ-5)

Asthma Control Questionnaire 5-item version score change from baseline. ACQ questionnaire contains five questions on patients' symptoms, which are assessed on a 7-point scale from 0 (representing good control) to 6 (representing poor control). The score is the mean score of all questions for which responses are provided. (NCT02149199)
Timeframe: Study weeks 0,4,16,28,40,52

Interventionunits on a scale (Least Squares Mean)
Placebo Bid + Symbicort 'as Needed'-0.33
Placebo Bid + Terbutaline 'as Needed'-0.17
Pulmicort Bid + Terbutaline 'as Needed'-0.48

[back to top]

Change From Baseline in the Percentage of Nighttime Awakenings Due to Asthma

Night-time awakenings (%) due to asthma change from baseline. Variable analysed is the proportion (%) of nights during the relevant period with night-time awakenings. Baseline refers to the last 10 nights of the run-in period. (NCT02149199)
Timeframe: up to 52 weeks

Intervention% of nights (Mean)
Placebo Bid + Symbicort 'as Needed'-7.5
Placebo Bid + Terbutaline 'as Needed'-4.6
Pulmicort Bid + Terbutaline 'as Needed'-9.8

[back to top]

Change From Baseline in Percentage of Asthma Control Days

Asthma control days (%) change from baseline. An asthma control day is defined as the fulfilment of all of the following criteria; a day and night with no asthma symptoms, a night with no awakenings due to asthma symptoms and a day and night with no use of 'as needed' medication. Variable analysed is the proportion (%) of asthma control days during the randomised treatment period. Baseline refers to the last 10 days of the run-in period. (NCT02149199)
Timeframe: up to 52 weeks

Intervention% of days (Mean)
Placebo Bid + Symbicort 'as Needed'13.2
Placebo Bid + Terbutaline 'as Needed'12.8
Pulmicort Bid + Terbutaline 'as Needed'18.5

[back to top]

Change From Baseline in Percentage of 'As Needed' Free Days

'As needed' free days (%) change from baseline during the randomised treatment period. An 'as needed' free day is defined as a day and night with no use of 'as needed' medication. Variable analysed is the proportion (%) of 'as needed' free days during the relevant period. Baseline refers to the last 10 days of the run-in period. (NCT02149199)
Timeframe: up to 52 weeks

Intervention% of days (Mean)
Placebo Bid + Symbicort 'as Needed'44.2
Placebo Bid + Terbutaline 'as Needed'45.0
Pulmicort Bid + Terbutaline 'as Needed'51.7

[back to top]

Average Change From Baseline in Pre-dose Forced Expiratory Volume in 1 Second (FEV1)

Overall estimate of FEV1 (mL) pre-bronchodilator change from baseline. Baseline is the measurement at Visit 3 (prior to first dose of Investigational Product) from MMRM (mixed model repeated measures analysis). (NCT02149199)
Timeframe: Study weeks 0,4,16,28,40,52

InterventionmL (Least Squares Mean)
Placebo Bid + Symbicort 'as Needed'65
Placebo Bid + Terbutaline 'as Needed'11.2
Pulmicort Bid + Terbutaline 'as Needed'119.3

[back to top]

Average Change From Baseline in Number of Inhalations of 'as Needed' Medication.

'As needed' inhalations change from baseline over the randomised treatment period. Baseline is defined as the last 10 days of the run-in period. 'As needed' use was calculated as the cumulative doses of 'as needed' medication over the randomised treatment period divided by the follow-up time (number of days - 1). ie, average number of inhalations per day. (NCT02149199)
Timeframe: up to 52 weeks

InterventionNumber of inhalations per day (Mean)
Placebo Bid + Symbicort 'as Needed'-0.95
Placebo Bid + Terbutaline 'as Needed'-0.82
Pulmicort Bid + Terbutaline 'as Needed'-1.06

[back to top]

Average Change From Baseline in Morning Peak Expiratory Flow (PEF)

Morning peak expiratory flow (eDiary) change from baseline over the randomised treatment period. Baseline is defined as the mean of all non-missing morning measurements during the last 10 days of the run-in period. (NCT02149199)
Timeframe: up to 52 weeks

InterventionL/min (Least Squares Mean)
Placebo Bid + Symbicort 'as Needed'-3.97
Placebo Bid + Terbutaline 'as Needed'-15.92
Pulmicort Bid + Terbutaline 'as Needed'6.01

[back to top]

Change From Baseline in Percentage of Symptom-free Days

Symptom-free days (%) change from baseline during the randomised treatment period.Variable analysed is the proportion (%) of symptom-free days during the relevant period. Baseline refers to the last 10 days of the run-in period. (NCT02149199)
Timeframe: up to 52 weeks

Intervention% of days (Mean)
Placebo Bid + Symbicort 'as Needed'4.2
Placebo Bid + Terbutaline 'as Needed'1.3
Pulmicort Bid + Terbutaline 'as Needed'6.8

[back to top]

Poorly Controlled Asthma Weeks

A poorly-controlled asthma week is defined as a week meeting any one of the following conditions: Two or more consecutive days with awakenings due to asthma on both nights; A recorded use of 'as needed' medication for symptom relief of at least 3 occasions per day, for at least 2 consecutive days; Additional systemic GCS treatment required for severe exacerbation. If there were sufficient data within a week available to confirm the week was not poorly-controlled, the week is labelled as 'does not meet criteria for poorly-controlled'. (NCT02149199)
Timeframe: Weekly for up to 52 weeks

Interventionweeks (Mean)
Placebo Bid + Symbicort 'as Needed'7.7
Placebo Bid + Terbutaline 'as Needed'9.7
Pulmicort Bid + Terbutaline 'as Needed'6.7

[back to top]

Annual Severe Asthma Exacerbation Rate

Severe asthma exacerbations over the randomised treatment period. (NCT02149199)
Timeframe: up to 52 weeks

Interventionexacerbations per year (Least Squares Mean)
Placebo Bid + Symbicort 'as Needed'0.07
Placebo Bid + Terbutaline 'as Needed'0.20
Pulmicort Bid + Terbutaline 'as Needed'0.09

[back to top]

Annual Moderate or Severe Asthma Exacerbation Rate

Moderate or severe asthma exacerbations during the randomised treatment period. (NCT02149199)
Timeframe: up to 52 weeks

Interventionexacerbations per year (Least Squares Mean)
Placebo Bid + Symbicort 'as Needed'0.14
Placebo Bid + Terbutaline 'as Needed'0.36
Pulmicort Bid + Terbutaline 'as Needed'0.15

[back to top]

'Well-controlled Asthma Week' - a Derived Binary Variable (Yes/No)

A well-controlled asthma week is defined as the fulfilment of both conditions A) and B) below: A) Two or more of the following criteria are fulfilled: - No more than 2 days with a daily asthma symptom score >1 - No more than 2 days of 'as needed' medication use, up to a maximum of 4 occasions per week (multiple occasions per day should be regarded as separate occasions) - Morning PEF ≥80% of Predicted Normal every day B) Both of the following criteria are fulfilled: - No nighttime awakenings due to asthma - No additional inhaled and/or systemic glucocorticosteroid treatment due to asthma. The binary variable well-controlled asthma week was derived for each patient and study week. In addition, for each week, the percent of patients with well-controlled asthma week was derived. It is required that the eDiary had to be completed on at least 5 days in a week to be a well-controlled asthma week. (NCT02149199)
Timeframe: Weekly, up to 52 weeks

InterventionPercentage (Mean)
Placebo Bid + Symbicort 'as Needed'34.4
Placebo Bid + Terbutaline 'as Needed'31.1
Pulmicort Bid + Terbutaline 'as Needed'44.4

[back to top]

Average Change From Baseline in Evening PEF

Evening peak expiratory flow (eDiary) change from baseline during the randomised treatment period. Baseline is defined as the mean of all non-missing evening measurements during the last 10 days of the run-in period. (NCT02149199)
Timeframe: up to 52 weeks

InterventionL/min (Least Squares Mean)
Placebo Bid + Symbicort 'as Needed'-11.20
Placebo Bid + Terbutaline 'as Needed'-22.15
Pulmicort Bid + Terbutaline 'as Needed'-4.97

[back to top]

Number of Participants Experiencing at Least One Moderate or Severe Asthma Exacerbation

"A moderate exacerbation is defined as a deterioration of asthma requiring a change in treatment, i.e. initiation of prescribed additional ICS treatment to avoid progression of the worsening of asthma to a severe exacerbation.~A severe exacerbation is defined as a deterioration of asthma requiring any of the following: use of systemic glucocorticosteroids (GCS) for at least 3 days, inpatient hospitalization, or emergency room visit due to asthma that required systemic steroids" (NCT02149199)
Timeframe: Day 1 up to 52 weeks

InterventionParticipants (Number)
Placebo Bid + Symbicort 'as Needed'131
Placebo Bid + Terbutaline 'as Needed'274
Pulmicort Bid + Terbutaline 'as Needed'143

[back to top]

Number of Participants Experiencing at Least One Occasion With Additional Steroids for Asthma

Additional steroids for asthma includes any additional inhaled and/or systemic glucocorticosteroids treatment due to asthma while in the randomised treatment period. (NCT02149199)
Timeframe: Day 1 up to 52 weeks

InterventionParticipants (Number)
Placebo Bid + Symbicort 'as Needed'164
Placebo Bid + Terbutaline 'as Needed'345
Pulmicort Bid + Terbutaline 'as Needed'187

[back to top]

Number of Participants Experiencing at Least One Severe Asthma Exacerbation

A severe exacerbation is defined as a deterioration of asthma requiring any of the following: use of systemic glucocorticosteroids (GCS) for at least 3 days, inpatient hospitalization, or emergency room visit due to asthma that required systemic steroids (NCT02149199)
Timeframe: Day 1 up to 52 weeks

InterventionParticipants (Number)
Placebo Bid + Symbicort 'as Needed'71
Placebo Bid + Terbutaline 'as Needed'152
Pulmicort Bid + Terbutaline 'as Needed'78

[back to top] [back to top]

Percentage of Controller Use Days

ICS controller use days (%) during the randomised treatment period is calculated as the cumulative number of days when any controller medication (containing ICS) was taken including maintenance (Pulmicort bid group) and 'as needed' medication (Symbicort 'as needed' group) and additional prescribed ICS for asthma exacerbations and/or long term poor asthma control (all treatment groups), divided by the number of days in the randomised treatment period. (NCT02149199)
Timeframe: up to 52 weeks

Intervention% of days (Mean)
Placebo Bid + Symbicort 'as Needed'30.8
Placebo Bid + Terbutaline 'as Needed'5.6
Pulmicort Bid + Terbutaline 'as Needed'85.6

[back to top]

Time to Reach Maximum Observed Plasma Concentration (Tmax)

These will be taken at each treatment period (NCT02178059)
Timeframe: Samples will be taken at predose, and at 5, 10, 20, 40, 80, 100 minutes and at 2, 4, 6, 9, 12, 18, 24, 30, and 36 hours postdose

Interventionhour (Median)
Bricanyl Turbuhaler M31.33
Bricanyl Turbuhaler M21.33

[back to top]

Area Under the Plasma Concentration-time Curve From Zero to 36 Hours Postdose [AUC(0-36)]

These will be taken at each treatment period (NCT02178059)
Timeframe: Samples will be taken at predose, and at 5, 10, 20, 40, 80, 100 minutes and at 2, 4, 6, 9, 12, 18, 24, 30, and 36 hours postdose

Interventionnmol*h/L (Geometric Mean)
Bricanyl Turbuhaler M389.0
Bricanyl Turbuhaler M2101

[back to top]

Area Under the Plasma Concentration-time Curve From Zero Extrapolated to Infinity (AUC)

These will be taken at each treatment period (NCT02178059)
Timeframe: Samples will be taken at predose, and at 5, 10, 20, 40, 80, 100 minutes and at 2, 4, 6, 9, 12, 18, 24, 30, and 36 hours postdose

Interventionnmol*h/L (Geometric Mean)
Bricanyl Turbuhaler M396.63
Bricanyl Turbuhaler M2109.7

[back to top]

Area Under the Plasma Concentration-time Curve From Zero to the Time of Last Measurable Concentration [AUC(0-t)]

These will be taken at each treatment period (NCT02178059)
Timeframe: Samples will be taken at predose, and at 5, 10, 20, 40, 80, 100 minutes and at 2, 4, 6, 9, 12, 18, 24, 30, and 36 hours postdose

Interventionnmol*h/L (Geometric Mean)
Bricanyl Turbuhaler M389.04
Bricanyl Turbuhaler M2100.9

[back to top]

Maximum Observed Plasma Concentration (Cmax)

These will be taken at each treatment period (NCT02178059)
Timeframe: Samples will be taken at predose, and at 5, 10, 20, 40, 80, 100 minutes and at 2, 4, 6, 9, 12, 18, 24, 30, and 36 hours postdose

Interventionnmol/L (Geometric Mean)
Bricanyl Turbuhaler M312.00
Bricanyl Turbuhaler M213.12

[back to top]

Terminal Half-life (t1/2)

These will be taken at each treatment period (NCT02178059)
Timeframe: Samples will be taken at predose, and at 5, 10, 20, 40, 80, 100 minutes and at 2, 4, 6, 9, 12, 18, 24, 30, and 36 hours postdose

Interventionhour (Geometric Mean)
Bricanyl Turbuhaler M311.7
Bricanyl Turbuhaler M211.8

[back to top]

Average Change From Baseline in Asthma Control Questionnaire (5-item Version) - ACQ-5 Score

ACQ questionnaire contains five questions on patients' symptoms, which are assessed on a 7-point scale from 0 (representing good control) to 6 (representing poor control). The score is the mean score of all questions for which responses are provided. The average change from baseline to treatment period average in ACQ-5 was derived by computing a contrast for the mean across all post-randomisation visits (week 17, 34, 52) from the MMRM (mixed model repeated measures) analysis. (NCT02224157)
Timeframe: Study weeks 0, 17, 34, 52

InterventionScore (Least Squares Mean)
Placebo Bid + Symbicort 'as Needed' (Experimental)-0.35
Pulmicort Bid + Terbutaline 'as Needed' (Active Comparator)-0.46

[back to top]

Average Change From Baseline in 'as Needed' Use

'As-needed' use change from baseline over the randomised treatment period. Baseline was defined as the last 10 days of the run-in period. 'As needed' use was calculated as the cumulative doses of 'as-needed' medication over the randomised treatment period divided by the follow-up time (number of days - 1). ie, average number of inhalations per day. (NCT02224157)
Timeframe: Week 0 up to 52 weeks

InterventionNumber of inhalations per day (Least Squares Mean)
Placebo Bid + Symbicort 'as Needed' (Experimental)-0.84
Pulmicort Bid + Terbutaline 'as Needed' (Active Comparator)-0.87

[back to top]

Annual Severe Asthma Exacerbation Rate - Superiority Analysis

Severe asthma exacerbations over the randomised treatment period, negative binomial model for superiority test evaluation (NCT02224157)
Timeframe: up to 52 weeks

Interventionexacerbations per participant year (Least Squares Mean)
Placebo Bid + Symbicort 'as Needed' (Experimental)0.11
Pulmicort Bid + Terbutaline 'as Needed' (Active Comparator)0.12

[back to top]

Annual Severe Asthma Exacerbation Rate - Non-inferiority Analysis

Severe asthma exacerbations over the randomised treatment period, negative binomial model for non-inferiority test evaluation (NCT02224157)
Timeframe: up to 52 weeks

Interventionexacerbations per participant year (Least Squares Mean)
Placebo Bid + Symbicort 'as Needed' (Experimental)0.11
Pulmicort Bid + Terbutaline 'as Needed' (Active Comparator)0.12

[back to top]

Average Change From Baseline in Pre-bronchodilator FEV1

The average change from baseline (baseline defined by measurement at week 0, prior to first dose of IP) to the treatment period average assessed over the entire treatment period in pre-bronchodilator FEV1 was derived by computing a contrast for the mean across the post-randomisation visits (week 17, 34, 52) from the MMRM (mixed model repeated measures) analysis. (NCT02224157)
Timeframe: Study weeks 0,17, 34, 52

InterventionmL (Least Squares Mean)
Placebo Bid + Symbicort 'as Needed' (Experimental)104.0
Pulmicort Bid + Terbutaline 'as Needed' (Active Comparator)136.6

[back to top]

Average Change From Baseline in Asthma Quality of Life Questionnaire Standardised Version - AQLQ(S) Score

AQLQ(S) consists of 32 questions in 4 domains. Each question is assessed on a 7-point scale from 1 to 7, with higher values indicating better health-related quality of life. The overall score is calculated as the mean score of all 32 items. The average change from baseline to treatment period average in AQLQ(S) overall score was derived by computing a contrast for the mean across all post-randomisation visits (week 17, 34, 52) from the MMRM (mixed model repeated measures) analysis. (NCT02224157)
Timeframe: Study weeks 0,17, 34, 52

InterventionAQLQ(S) overall score (Least Squares Mean)
Placebo Bid + Symbicort 'as Needed' (Experimental)0.335
Pulmicort Bid + Terbutaline 'as Needed' (Active Comparator)0.431

[back to top]

Change From Baseline in Percent of 'as Needed' Free Days

'As needed' free days (%) change from baseline during randomised treatment period. An 'as-needed' free day was defined as a day and night with no use of 'as needed' medication. Variable analysed is the percentage (%) of 'as-needed' free days during the randomised treatment period. Baseline is defined by the last 10 days of the run-in period. (NCT02224157)
Timeframe: Week 0 up to 52 weeks

InterventionPercentage of 'as needed' free days (Least Squares Mean)
Placebo Bid + Symbicort 'as Needed' (Experimental)41.01
Pulmicort Bid + Terbutaline 'as Needed' (Active Comparator)47.86

[back to top]

Number of Participants Experiencing at Least One Severe Asthma Exacerbation

A severe exacerbation is defined as a deterioration of asthma requiring any of the following: use of systemic glucocorticosteroids (GCS) for at least 3 days, inpatient hospitalization, or emergency room visit due to asthma that required systemic steroids. (NCT02224157)
Timeframe: Day 1 up to 52 weeks

InterventionParticipants (Number)
Placebo Bid + Symbicort 'as Needed' (Experimental)177
Pulmicort Bid + Terbutaline 'as Needed' (Active Comparator)184

[back to top] [back to top]

Percentage of Controller Use Days

ICS controller use days (%) during the randomised treatment period is calculated as the cumulative days when any controller medication (containing ICS) was taken including maintenance (Pulmicort bid group) and 'as needed' medication (Symbicort 'as needed' group) and additional prescribed ICS for asthma (all treatment groups), divided by the number of days in the randomised treatment period. (NCT02224157)
Timeframe: Week 0 up to 52 weeks

InterventionPercentage of days (Least Squares Mean)
Placebo Bid + Symbicort 'as Needed' (Experimental)30.45
Pulmicort Bid + Terbutaline 'as Needed' (Active Comparator)67.92

[back to top]

Provocative Concentration of Methacholine Which Produces a 20% Fall in FEV1 (PC20)

(NCT02322788)
Timeframe: 4 cross-over treatments (<1 day each) with 2-10 days between treatment washout periods

Interventionmg/mL (Least Squares Mean)
M3 1.5 mg17.70
M3 0.5 mg9.88
M2 1.5 mg20.10
M2 0.5 mg10.78

[back to top]

Numeric Rating Scale (NRS-11)

Patient discomfort rated with NRS-11. Total scale from 0-10, with higher score indicating more pain. (NCT03106753)
Timeframe: Day 1

Interventionscore on a scale (Mean)
First procedure
Spinal Anesthesia Immediately for ECV.2.0

[back to top]

Cord pH

Arterial cord pH level (NCT03106753)
Timeframe: Day 1

InterventionpH (Mean)
Spinal Anesthesia Immediately for ECV.7.2
Spinal Anesthesia if no Intervention Fails for ECV.7.2

[back to top]

Numeric Rating Scale (NRS-11)

Patient discomfort rated with NRS-11. Total scale from 0-10, with higher score indicating more pain. (NCT03106753)
Timeframe: Day 1

Interventionscore on a scale (Mean)
First procedureSecond procedure
Spinal Anesthesia if no Intervention Fails for ECV.6.12.2

[back to top]

Number of Participants With Various Mode of Delivery

Mode of delivery as incidence of spontaneous vaginal delivery, operative vaginal delivery, or cesarean section. (NCT03106753)
Timeframe: up to day 42

,
InterventionParticipants (Count of Participants)
Spontaneous Vaginal DeliveryOperative Vaginal DeliveryCesarean Section
Spinal Anesthesia if no Intervention Fails for ECV.619
Spinal Anesthesia Immediately for ECV.6011

[back to top]

Number of Participants With Success Rate of External Cephalic Version to Cephalic Presentation.

Success rate will be measured by comparing the percentage of successful external cephalic versions in each group. (NCT03106753)
Timeframe: Day 1

,
InterventionParticipants (Count of Participants)
NulliparousMultiparous
Spinal Anesthesia if no Intervention Fails for ECV.53
Spinal Anesthesia Immediately for ECV.43

[back to top]

Number of Participants With Newborns With Apgar Score 7 or 9

Newborns with Apgar Score 7 or 9 at 5 minutes after delivery. The Apgar score is based on a total score of 1 to 10. The higher the score, the better the baby is doing after birth. A score of 7, 8, or 9 is normal and is a sign that the newborn is in good health. (NCT03106753)
Timeframe: 7 minutes and 9 minutes after delivery

,
InterventionParticipants (Count of Participants)
79
Spinal Anesthesia if no Intervention Fails for ECV.115
Spinal Anesthesia Immediately for ECV.116

[back to top]

Time From Procedure to Delivery.

Number of days from procedure to delivery. (NCT03106753)
Timeframe: up to day 42

Interventionhours (Mean)
Spinal Anesthesia Immediately for ECV.12.6
Spinal Anesthesia if no Intervention Fails for ECV.11.3

[back to top]

Number of NICU Admission

Number of patients whose neonate was admitted to the NICU in each group. (NCT03106753)
Timeframe: Day 1

InterventionParticipants (Count of Participants)
Spinal Anesthesia Immediately for ECV.1
Spinal Anesthesia if no Intervention Fails for ECV.1

[back to top]

Newborn Birth Weight

Newborn birth weight in grams. (NCT03106753)
Timeframe: Day 1 of delivery

Interventiongrams (Mean)
Spinal Anesthesia Immediately for ECV.3321.6
Spinal Anesthesia if no Intervention Fails for ECV.3257.7

[back to top]

Number of Adverse Events During Procedure

Number of total specific adverse events such as: fetal bradycardia, emergent cesarean section, or abruption. (NCT03106753)
Timeframe: Day 1

Interventionevents (Number)
Spinal Anesthesia Immediately for ECV.11
Spinal Anesthesia if no Intervention Fails for ECV.5

[back to top]